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I. Abstract 
Background: Previous research has shown that spasticity negatively affects physical 
functioning and health status, however information on its impact on overall quality of 
life (QOL) in multiple sclerosis (MS) is limited. Furthermore, qualitative studies indicate 
that spasticity may affect a number of MS-associated conditions such as fatigue, 
depression, anxiety, pain and sleep. However these relationships have not been 
examined in the quantitative studies.  
Objectives: 1) To determine the effect of spasticity on overall QOL. 2) To investigate 
the relationships between spasticity and other neurological impairments associated with 
MS.  
Methods: Demographic details were obtained and a questionnaire pack containing the 
World Health Organization Quality Of Life-BREF (WHOQOL-BREF), Leeds MS QOL scale 
(LMSQOL), World Health Organization Disability Assessment Schedule (WHODAS), 
Multiple Sclerosis Spasticity Scale-88 (MSSS-88), Numerical Rating Scale (NRS 0-10) for 
spasticity, Neurological Fatigue Index - MS (NFI-MS), Hospital Anxiety and Depression 
Scale (HADS), SF-Qualiveen for bladder dysfunction and Neuropathic Pain Scale (NPS) 
was given to patients at three UK neuroscience centres. 
Results: 260 patients completed the questionnaire pack. 84.8% reported spasticity. 
56.1% had moderate (NRS 4-6) or severe (NRS 7-10) spasticity. Patients with spasticity 
were more likely to be disabled, suffer from depression, have higher levels of fatigue 
and report more pain, bladder and sleep problems (p<0.001). An association between 
anxiety and spasticity was weak (rho=0.2, p<0.05). Older age, progressive type of MS, 
higher Extended Disability Status Scale (EDSS) score, unemployment were associated 
with increased severity of spasticity. Spasticity was found to be a significant predictor of 
WHOQOL-BREF physical health after adjusting for sociodemographic variables, anxiety, 
depression, fatigue, bladder dysfunction and pain. WHOQOL-BREF psychological health, 
social relationships, environment and LMSQOL were not predicted by spasticity after 
controlling for the same factors (p>0.05). Depression and fatigue were the strongest 
predictors of poor QOL, which is consistent with current literature. 
Conclusions: Spasticity is very common in MS and is often severe and disabling. There 
is a strong association between spasticity and fatigue, depression, pain, sleep and 
bladder problems. The findings suggest that spasticity might directly and indirectly 
influence overall QOL.  
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VI. Overview of the thesis 
 
Chapter 1 
An introductory chapter consists of three sections. In the first section, pathophysiology 
and measurement of spasticity is discussed. In the second section, a brief overview of 
multiple sclerosis is given with particular focus on spasticity in MS. In the third section, 
basic concepts and measurement issues of quality of life (QOL) are presented.   
Chapter2  
The second chapter of this thesis explores literature regarding the relationship between 
spasticity and QOL. Systematic review of the studies is presented here. Hypothesis and 
aims of the thesis are included as well.  
Chapter 3 
Methodology of the study is presented in chapter 3. Discussion of the recruitment 
process, inclusion and exclusion criteria and the rationale for the outcome measures is 
given. Description of the statistical analysis is also provided. 
Chapter 4 
Results are presented in chapter 4. Response rates, demographic characteristics and 
results from univariate and multiple regression analyses are presented.  
Chapter 5 
The last chapter discusses the findings of the study and revisits relevant literature. 
Limitations and strengths are discussed as well. The chapter ends the thesis with 
directions for future research.  
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Chapter 1- Introduction 
1.1. Spasticity 
1.1.1. Definition of Spasticity 
Spasticity is a common neurological impairment (classified under 'Impairments' 
according to the International Classification of Functioning, Disability and Health (ICF)) 
in many chronic neurological disorders such as stroke, multiple sclerosis and spinal 
conditions (WHO, 2001). Despite it being a common problem it remains poorly defined 
(Malhotra, Pandyan, Day, Jones, & Hermens, 2009). This has been increasingly 
recognised as a major problem in research on spasticity (Pandyan et al., 2005). The lack 
of a precise definition hinders the development of valid measures of spasticity, which 
are fundamental for investigating pathophysiological mechanisms and assessing 
treatment outcomes (Pandyan et al., 2005). Due to its complex pathophysiology and 
diverse clinical features, defining spasticity has challenged researchers and clinicians for 
many years. The first attempts to define spasticity were made by Lance in 1980 (Lance, 
1980). Lance defined spasticity as ‘“a motor disorder characterized by a velocity-
dependent increase in tonic stretch reflexes (muscle tone) with exaggerated tendon 
jerks, resulting from hyperexcitability of the stretch reflex, as one component of the 
UMN syndrome”. 
However, over the years it has been recognised that Lance’s definition is too 
narrow to encompass a wide range of spasticity-associated phenomena (Burridge et al., 
2005; Pandyan et al., 2005; Stevenson, 2010). A review by Pandyan et al. (2005) 
presented four arguments for why Lance's definition of spasticity may not be accurate: 
(1) There is insufficient evidence to suggest that spasticity results exclusively from 
increased tonic stretch reflex, and that other mechanisms such as alpha motor neurone 
hyperexcitability, increased transcortical reflexes and hyperactivity of group II spindle 
afferents may be involved, (2) Velocity dependency is not an exclusive property of 
spasticity, but can also be characteristic of visco-elastic structures (muscle, tendon, 
ligaments) (3) There is no evidence to suggest that phasic stretch reflex is related to 
increased resistance of passive muscle movement (4) Lastly, spasticity is no longer 
18 
 
considered to be purely motor disorder, as afferent input from cutaneous receptors and 
proprioreceptors contribute to muscle activity (Pandyan et al., 2005). In addition, 
Burridge et al. suggested that Lance’s definition made no reference to the way 
spasticity manifests during active function, which may be more relevant to a patient 
experiencing it (Burridge et al., 2005). As a result, the Support Programme for Assembly 
of a database for Spasticity Measurement (SPASM) group proposed the most recent 
definition of spasticity describing it as 'disordered sensori-motor control, resulting from 
an upper motor neurone lesion, presenting as intermittent or sustained involuntary 
activation of muscles’ (Pandyan et al., 2005). 
Despite the efforts of SPASM group to introduce a standardised classification 
system of spasticity measurement, a systematic review by Malhotra et al. found that 
researchers continue to use different definitions of spasticity indicating that there is a 
widespread disagreement about the current understanding of spasticity and its 
measurement (Malhotra et al., 2009). In order to conceptualise what constitutes a 
meaningful measurement of spasticity, it is important to be familiar with the principles 
of normal muscle tone control and the pathophysiological mechanisms responsible for 
the development of spasticity.  
1.1.2. Control of Muscle Tone 
Pioneering work on control of muscle tone was carried out by Sherrington at the 
end of the 19th century (Sherrington, 1898, 1910). He discovered that muscle spindles, 
the small proprioceptive stretch receptors of the muscles, transmit information to the 
spinal cord regarding muscle length and rate of change of muscle length. The muscle 
spindles activate alpha motor neurones, via a monosynaptic reflex, which cause muscle 
contraction, a phenomenon known as a (myotatic) stretch reflex.                  
Two types of afferent fibres are responsible for relaying information from the 
muscle spindles to the spinal cord (Davidoff, 1992). When a muscle is stretched at a 
rapid rate, a short-latency reflex is initiated by the activation of Ia afferent sensory 
fibres. This type of reflex is velocity-dependent and is under control of gamma efferent 
fibres (fusimotor fibres) (Sheean & McGuire, 2009). In order to ensure smooth and 
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controlled muscle contraction, antagonist muscles are inhibited as a result of the stretch 
reflex arc, a process called reciprocal inhibition. Type II afferent fibres become activated 
independent of stretch velocity and are responsible for providing information regarding 
static muscle length and position (Dietz & Sinkjaer, 2007).  
Another important component of muscle tone control is Golgi tendon organs. 
Located in the musculotendinous junction, Golgi tendon organs convey information via 
Ib afferent fibres to the spinal cord regarding the tension exerted by the muscle. Fine 
interplay between muscle spindles and Golgi tendons organs is responsible for normal 
muscle tone (Davidoff, 1992).  
However, it is important to appreciate that both muscle stretch and Golgi tendon 
reflex arcs are under complex supraspinal and collateral neurone control, despite being 
simplistically described as mono- or oligosynaptic reflex systems (Davidoff, 1992). One 
group of specialised neurones are Renshaw cells, located in close proximity to anterior 
horn cells (AHCs). It has been shown that Renshaw cells become activated by collateral 
AHC branches and cause inhibition of AHCs and its synergists in order to limit and 
stabilise discharge frequency (recurrent inhibition) (Maltenfort, Heckman, & Rymer, 
1998). In addition, inhibitory interneurons connected to Ia sensory fibre terminals exert, 
with the help of supraspinal stimulation, a constant inhibitory effect on AHCs. In reality, 
the interplay between these reflex arcs is extremely complex, hence current 
understanding of muscle tone control is still in the early stages.  
1.1.3. Clinical features and pathophysiological correlates of spasticity 
The upper motor neurone (UMN) syndrome is a collection of signs and symptoms 
that occurs as a result of an insult to UMNs anywhere along their course. Classically, the 
manifestations of UMNS are divided into positive and negative phenomena (table 1) 
(Sheean, 2002). Negative features of UMN damage include: motor weakness, fatigability, 
loss of dexterity and selective motor control and slowed movements. These features 
often precede the development of positive phenomena which are characterised by 
muscle overactivity. This manifests as tendon hyper-reflexia, clonus, the clasp-knife 
phenomenon, flexor and extensor spasms, the Babinski sign, spastic dystonia and 
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velocity-dependent hypertonia. Traditionally, only the latter was considered to be 
spasticity (Decq, Filipetti, & Lefaucheur, 2004; Stevenson, 2010).  
 
Table 1. Classification of UMN-associated 
phenomena (Pandyan et al., 2005) 
Positive features Negative Features 
Hyper-reflexia Muscle weakness 
Clonus Loss of dexterity 
Positive Babinski sign Fatigability 
Spasticity  
Flexor spasm  
Extensor spasm  
Mass reflex  
Co-contraction  
Spastic dystonia  
 
However, as these signs and symptoms usually occur together and are caused by 
the same insult to the UMN, the revised definition of spasticity proposed by SPASM 
consider all of the positive phenomena to represent different aspects of spasticity 
(Burridge et al., 2005; Pandyan et al., 2005). Although the pathophysiological 
mechanisms behind each of the aspects of spasticity may differ it has been recognised 
that this has little clinical relevance (Burridge et al., 2005).  
Different features of spasticity can be grouped into three categories based on the 
pathophysiology and clinical manifestations (Sheean, 2002) (Table 2). A major factor 
contributing to the development of spasticity is an abnormal processing of the afferent 
inputs from the periphery such as muscle stretch, pain or cutaneous stimulation (Dietz 
& Sinkjaer, 2007). Clinical manifestation involves both the development of new reflexes 
and exaggeration of the existing ones. In a patient with spasticity, passive muscle 
stretching induces muscle contraction, called a tonic reflex, which constitutes a new 
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reflex (Sheean & McGuire, 2009).  It is a velocity- (faster stretching causes more 
powerful contraction) and length (the shorter the muscle the easier to elicit contraction) 
dependent reflex. By definition, muscle hypertonicity should disappear once movement 
is stopped (Decq et al., 2004). This is an important feature which distinguishes 
spasticity from other disorders causing hypertonicity, such Parkinson's disease, where 
the limb stays rigid even after termination of movement. Intrinsic phasic spasticity 
encapsulates symptoms such as tendon hyper-reflexia and clonus, and is due to 
exaggeration of the phasic component of stretch reflex. The repetitive movement of the 
foot, as seen in clonus, is a result of the alternate stretching and unloading of the 
muscle spindles, which trigger a continuous phasic reflex (Stevenson, 2010).  An 
exaggerated withdrawal reflex causes flexor and extensor spasms that are commonly 
observed in response to noxious cutaneous stimuli. In severe cases, a triple flexion 
reflex may occur, which is characterised by the simultaneous flexion of the hip, knee 
and ankle (Decq et al., 2004).  A release of primitive cutaneous reflex, famously known 
as positive Babinski sign, often occurs and is the hallmark sign of a UMN lesion. 
 
Table 2. Classification of clinical features and corresponding pathophysiological 
mechanisms of spasticity (Sheean, 2002) 
Spinal reflexes Efferent drive Disordered control of muscle 
movements 
Stretch Spastic dystonia Co-contraction 
Nociceptive   
Cutaneous   
 
 
 The second mechanism responsible for spastic dystonia is a continuous efferent 
discharge causing prolonged increase in muscle tone (Sheean, 2002). There is a 
sustained muscle contraction driven by efferent stimulation which is not dependent on 
sensory feedback. Clinically, this can be seen in patients with hemiparesis, who display 
flexion of the elbow and extension of the leg. 
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 The third aspect of spasticity is a disordered voluntary motor control, known as 
co-contraction. Normally, contraction of the agonist muscle will simultaneously cause 
relaxation of the antagonist, this is known as a reciprocal inhibition. If UMNs are 
damaged, this reflex is dysfunctional which leads to simultaneous contraction of 
agonistic and antagonistic muscle groups. This is commonly seen in patients who 
experience spasms, characteristically occurring in response to body movements (Sheean 
& McGuire, 2009).   
The manifestations of spasticity described above result from the damage to UMNs 
either at the spinal or supraspinal levels. UMNs exert inhibitory and excitatory effects on 
spinal reflexes, producing balanced control of muscle tone. Hence, if there is a loss of 
predominantly inhibitory fibres, a patient will develop more positive features of UMN 
syndrome and vice versa. Interestingly, in contrary to the previous understanding which 
supported that spasticity is predominantly caused by corticospinal tract dysfunction, it 
has been shown in animal models that pure corticospinal lesions produce weakness and 
loss of dexterity, but little spasticity (Mukherjee & Chakravarty, 2010). In contrast, 
dysfunction of the parapyramidal fibers, mainly the medial reticulospinal tract (MRT) 
and the dorsal reticulospinal tract (DRT), are critical in the development of spasticity 
(Mukherjee & Chakravarty, 2010; Sheean & McGuire, 2009). The DRT predominantly 
exerts an inhibitory effect on anterior horn cells and is under cortical control, whereas 
the MRT exerts excitatory effects and is independent from cortical activity. These tracts 
run in close proximity with the pyramidal tracts, hence lesions in the spinal cord may 
produce positive and negative phenomena depending on which tracts are affected. For 
instance, patients with complete spinal cord injuries exhibit markedly lower degrees of 
spasticity compared to patients with incomplete transection. This is likely to be a result 
of the incomplete damage primarily affecting the inhibitory tracts and sparing the 
excitatory ones (Sheean, 2002). 
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However, this only explains the pathophysiology of spasticity occurring secondary 
to the lesions affecting the spinal cord, but not the brainstem or the brain, such as in 
cases of stroke or traumatic brain injury. It has been observed that spasticity caused by 
lesions in UMNs at the supraspinal level is less prominent compared to spinal spasticity. 
This is explained by loss of cortical stimulation of the DRT causing unopposed excitatory 
stimulation of AHCs by the MRT (Sheean, 2002). As a result, lesions in the cortex or 
internal capsule will produce spasticity. 
Clinical manifestations of spasticity, such as stiffness and reduced range of 
movement, are not necessarily a consequence of increased muscle tone secondary to 
increased muscle stretch reflex. Following an UMN lesion, changes in the visco-elastic 
properties of the muscle, soft tissues and tendons frequently occur in patients with 
spasticity (O'Dwyer & Ada, 1996). Accumulation of connective tissue, loss of sarcomeres 
and muscle atrophy may lead to reduced muscle compliance and contractures (Gracies, 
2005). As a result, patients may develop increasing levels of stiffness and physical 
disability secondary to biomechanical changes and not solely due to alterations in the 
neural networks controlling muscle tone.    
1.1.4. Mechanisms responsible for spasticity 
Several mechanisms for development of spasticity have been suggested, however 
the pathophysiology remains to be incompletely understood. As previously mentioned, 
loss of supraspinal control which is mainly from the DRT is associated with increased 
sensitivity of AHCs. Other important changes include decreased Ib fibre inhibition and 
Renshaw cell inhibition (Gracies, 2005; Mayer, 1997; Mukherjee & Chakravarty, 2010; 
Sheean & McGuire, 2009). Although several studies attempted to show that muscle 
spindle sensitivity is up-regulated due to the increased gamma efferent drive, the 
results have not supported this (Burke, Gillies, & Lance, 1970; Mayer, 1997; Tardieu, 
Tardieu, Colbeau-Justin, & Bret, 1982). Disynaptic Ib inhibition has been found to be 
depressed with lesions in the brain, but not in the spinal cord (Decq et al., 2004). The 
H' response recruitment curves, also known as recurrent inhibition, are depressed in 
spasticity, however in up to 40% of patients the curve is identical to that of healthy 
24 
 
controls (Decq et al., 2004). Finally, intrinsic changes in the motor neurone also develop 
over time, characterised by abnormally prolonged plateau-like potentials that cause 
increased muscle contraction in response to synaptic inputs (Kiehn & Eken, 1997).  
1.1.5. Measurement of spasticity 
It is evident that spasticity is not a single entity, but has various manifestations 
with poorly understood underlying mechanisms. This explains why defining spasticity 
has been and still remains a challenge for many. While some may argue that defining 
spasticity may be of academic interest only, a meaningful measurement of spasticity is 
of great importance in clinical practice. Measurement of spasticity has proved equally 
difficult which is not surprising as the lack of a precise definition precludes any attempt 
of meaningful measurement. 
There is a myriad of measures for spasticity that have been reported in the 
literature, reflecting the problematic nature of spasticity measurement (Burridge et al., 
2005; Platz, Eickhof, Nuyens, & Vuadens, 2005; Priebe, Sherwood, Thornby, Kharas, & 
Markowski, 1996) (table 3). Since many of the tools to measure spasticity have been 
developed using Lance’s definition there has been a focus on the assessment of muscle 
tone and passive range of movement (Burridge et al., 2005). However, it has been 
increasingly recognised that spasticity is a multidimensional problem and a measure of 
a single aspect of spasticity is not appropriate (Priebe et al., 1996). 
 
 
 
 
 
 
 
 
 
25 
 
Table 3. Classification of commonly used measurement tools for spasticity 
Clinical  Biomechanical Electrophysiological 
Patient-reported measures 
   Visual Analogue Scale 
   Numerical Rating Scale 
   Penn Spasm Frequency Scale      
   Spinal Cord Injury-Spasticity      
   Evaluation Tool         
   Patient-Reported Impact of  
   Spasticity Measure 
   Multiple Sclerosis Spasticity    
   Scale - 88 
Goniometry assessment of range 
of motion 
Wartenburg pendulum test 
Electromyography 
  H reflex 
  T reflex 
  H max/M max ratio 
  
   Self-Reported Scale for   
   spasticity 
  
Clinician-administered measures   
   Ashworth and Modified        
Ashworth Scales 
 Tardieu Scale 
National Institute of Neurological 
Disorders and Stroke reflex scale 
Spinal Cord Assessment Tool 
Clonus Score 
  
 
Despite the variability in the methods for measuring spasticity, they can be 
generally grouped into three categories: clinical, biomechanical and electrophysiological 
(table 3). While clinical measures have high utility and are widely used in the clinical 
setting, the latter two require complicated equipment, hence their use is usually 
restricted to research purposes. It is beyond the scope of this chapter to review all of 
the methods for measuring spasticity, instead a brief overview of commonly used 
methods within each group is presented below. 
 
1.1.5.1. Clinical methods 
Clinical measures are the most commonly used methods in the assessment of 
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spasticity. They can be divided into clinician-rated and patient-rated. Research on 
functional movement in recent years has indicated that clinical signs of spasticity have 
little correlation with the functional aspects of spasticity (Dietz & Sinkjaer, 2007). For 
example, it has been shown that exaggerated tendon reflexes have little effect on active 
movement in patients with spasticity (Dietz & Sinkjaer, 2007). It is important to consider 
active function when assessing spasticity, since purely clinical signs and muscle 
resistance to passive stretch can be misleading when deciding on antispasticity therapy. 
For instance, without development of spastic muscle some patients with stroke would 
not be able to walk (Dietz & Sinkjaer, 2007).  
 It has been increasingly recognised that clinician-administered measures for 
spasticity are often inadequate and inappropriate. For example, the Ashworth scale, 
despite being the most widely used measure for spasticity, has been recently 
questioned due to concerns over its validity, reliability and responsiveness (Fleuren et al., 
2010; Pandyan et al., 1999; Pandyan, Price, Barnes, & Johnson, 2003; Platz et al., 
2005). Moreover, studies have shown that findings on examination performed by a 
clinician do not always correlate with the severity and even location of spasticity 
reported by the patients (Lechner, Frotzler, & Eser, 2006; Priebe et al., 1996; Skold, Levi, 
& Seiger, 1999). Because the Ashworth scale only measures muscle resistance to 
passive stretch, it has been suggested that it does not measure other aspects of 
spasticity that are important to a patient (Burridge et al., 2005; Lechner et al., 2006; 
Platz et al., 2005; Priebe et al., 1996). For example, it is not possible to assess 
spasticity-related spasms, pain or interference with active function using the Ashworth 
scale alone.  
It has been argued that spasticity is a complex and multidimensional problem and 
only the person experiencing spasticity can reliably judge its severity (Kirshblum, 1999; 
Priebe et al., 1996; Skold, 2000). As a result, recently there has been a growing interest 
in developing tools that measure spasticity from the patient’s perspective across a 
variety of neurological conditions, so as to help clinicians understand and adequately 
treat spasticity-related symptoms. The use of patient-reported measures for spasticity is 
also becoming a standard practice in randomised controlled trials evaluating anti-
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spasticity therapies, as shown by several recent studies (Adams & Hicks, 2011; Boviatsis, 
Kouyialis, Korfias, & Sakas, 2005; Schyns, Paul, Finlay, Ferguson, & Noble, 2009). 
Despite the considerable number of studies investigating self-reported measures of 
spasticity, little agreement exists on their place in current clinical practice and research. 
Numerous systematic reviews have evaluated various tools for spasticity assessment 
including biomechanical, electrophysiological and clinician assessed, however patient-
reported measures for spasticity have received little attention (Burridge et al., 2005; 
Hinderer & Gupta, 1996; Hsieh, Wolfe, Miller, & Curt, 2008; Platz et al., 2005) 
 A systematic literature review identified seven self-reported spasticity scales. The 
scales can be grouped into those measuring severity of spasticity: Visual Analogue Scale 
(VAS)/ Numerical Rating Scale (NRS) and Penn Spasm Frequency Scale (PSFS); those 
measuring impact of spasticity: Spinal Cord Injury-Spasticity Evaluation Tool (SCI-SET), 
Performance Scales Spasticity (PSS), Patient-Reported Impact of Spasticity Measure 
(PRISM) and Self-Reported Scale for Spasticity (SRSS); or both: Multiple Sclerosis 
Spasticity Scale - 88 (MSSS-88). In the paragraphs below, a description of the scales 
and their psychometric properties such as utility, validity and reliability are discussed.   
1.1.5.1.1. Patient-reported measures for spasticity 
              1.1.5.1.1.1. Visual Analogue Scale (VAS) and Numerical Rating Scale (NRS) 
Even though the Visual Analogue Scale (VAS) and Numerical Rating Scale (NRS) 
have been introduced to grade spasticity fairly recently (Farrar, Troxel, Stott, Duncombe, 
& Jensen, 2008; Lechner et al., 2006; Skold et al., 1999),  they have been widely used 
in the studies on pain, patient satisfaction and quality of life (Farrar, Berlin, & Strom, 
2003; Farrar, Young, LaMoreaux, Werth, & Poole, 2001). VAS is a simple way of 
assessing spasticity by asking the patient to rate the degree of spasticity on a 100mm 
graphical scale which is normally graded from 0 (no spasticity) to 100 (worst possible 
spasticity) in reference to a certain time frame (present, previous hour, 24 hours etc.) or 
activity i.e. post-intervention. NRS is slightly different in the sense that it is an 11-point 
numerical response scale (range 0-10). 
 Several studies have shown that VAS/NRS has robust psychometric properties 
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(Anwar & Barnes, 2009; Farrar et al., 2008; Skold et al., 1999). Evidence on test-retest 
reliability and construct validity of NRS was presented in a study by Anwar et al. (n=35) 
(Anwar & Barnes, 2009). NRS was found to have little variability between two 
sequential visits and correlated moderately with the Ashworth scale (r=0.46) and to a 
lesser but significant degree with Tardieu scale (r=0.4).  
VAS and NRS have also been shown to have high responsiveness (Farrar et al., 
2008; Skold et al., 1999). Skold et al. in a study on SCI patients demonstrated that VAS 
was more likely to detect a change after intervention compared to clinical assessment 
using the Ashworth scales (Skold et al., 1999). Similarly, Farrah et al. in a post hoc 
analysis of a randomised controlled trial on MS patients found that NRS had higher 
responsiveness than the Ashworth scale and PSFS (Farrar et al., 2008). The authors 
anchored NRS scores on patients’ global impression of change (PGIC) and defined 
clinically important difference (CID) and minimal clinically important difference (MCID) 
for NRS spasticity as 29.5% and 18% respectively. 
VAS/NRS has high clinical utility due to its simplicity and ease of administration. 
Validation of VAS/NRS across different neurological conditions could provide a simple 
and convenient comparison measure. It is noteworthy that VAS/NRS intends to measure 
the severity of spasticity, however it cannot differentiate between the underlying 
disease mechanisms. This is important since biomechanical changes in the muscle can 
mimic neurogenic spasticity, but these would not respond to antispasticity therapies. 
Unfortunately, this is a common flaw of most clinical measures for spasticity. In addition, 
other symptoms such as pain occurring simultaneously with spasticity might influence 
the VAS score thus confounding the result (Farrar et al., 2008). However, spasticity 
related pain is often the most troubling symptom reported by patients, therefore 
measuring sensory symptoms associated with spasticity might be considered equally 
important (Lechner et al., 2006; Skold et al., 1999).  
1.1.5.1.1.2. Penn Spasm Frequency Scale (PSFS) 
PSFS is a five point scale which is used by the patient to rate frequency of 
spasms. 0 represents ‘no spasms’ and 4 represents ‘spontaneous spasms occurring 
29 
 
more than ten times per hour’ (Penn et al., 1989). The scale was later modified by 
Priebe et al. who added a second component to assess severity of spasms and 
interference with function (Priebe et al., 1996). The second component is completed 
only if a respondent affirms the first part. PSFS measure is simple, quick and easy to 
complete for a patient and does not require specialised equipment. 
 Although it was initially developed for patients with spinal spasticity resulting 
from MS or SCI, PSFS has also been used in studies on stroke and traumatic brain injury 
(Meythaler, Guin-Renfroe, Brunner, & Hadley, 2001). Despite this widespread use little is 
known about the psychometric properties of PSFS (Hsieh et al., 2008). Two studies that 
evaluated the correlation between PSFS and clinical methods (patellar tap, ankle clonus, 
Achilles reflex) and the Ashworth scale showed poor to moderate correlation (Lechner 
et al., 2006; Priebe et al., 1996). Consequently, Priebe et al. questioned whether PSFS is 
a poor tool that inadequately measures spasticity or whether the Ashworth scale does 
not represent the elements of spasticity that are important to a patient (Priebe et al., 
1996). A similar study by Lechner et al. (n=47) investigated the validity of PSFS and 
found that if a patient is asked to rate their spasticity at 'present', PSFS scores correlate 
with the Ashworth scale much more strongly than the scores of 'general' spasticity 
reported by a patient (Lechner et al., 2006). The authors suggested that the PSFS and 
clinical examination represent different dimensions of spasticity and that severity of 
general spasticity cannot be adequately assessed with clinician administered methods 
alone. Moreover, spasticity fluctuates greatly over time and a single clinical measure can 
only produce a point-in-time estimate of its severity (Skold, 2000). 
Lastly, Benz et al. in a study on Spinal Cord Assessment Tool (SCAT) compared 
PSFS and SCAT scores showing that only presence of clonus strongly correlated with 
self-reported spasms, while flexor and extensor spasms did not, indicating that clonus 
might play an important role in a patient's perception of severity of the spasms (Benz, 
Hornby, Bode, Scheidt, & Schmit, 2005). 
Despite its prevalent use in clinical practice, no studies have established its 
reliability. In addition, PSFS has been shown to be less responsive than NRS by Farrah 
et al. (Farrar et al., 2008). As discussed above, in terms of content validity, PSFS only 
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measures one aspect of spasticity, thus it should not be used as a sole measurement of 
spasticity. Moreover, it is crucial to specify the timeframe since spasms vary throughout 
the day and change in frequency and intensity in response to activities. Although Priebe 
et al. reported the preliminary use of interference with function subscale, no further 
validation has been found in the literature (Priebe et al., 1996). 
1.1.5.1.1.3. Spinal Cord Injury Spasticity Evaluation Tool (SCI-SET) 
The complex effects of spasticity on the function may not be captured by scales 
measuring severity of spasticity such as VAS or frequency of spasms (PSFS) (Hsieh et al., 
2008; Skold et al., 1999). As a result, Adams et al. developed a Spinal Cord Injury 
Spasticity Evaluation Tool (SCI-SET), a 35-item, 7-day recall questionnaire which aims 
to assess the impact of spasticity in patients with chronic SCI (Adams, Ginis, & Hicks, 
2007). The tool covers various aspects of daily life that may be affected by spasticity 
ranging from mobility to social functioning. Since spasticity may also have positive 
effects on mobility and posture, the authors employed a bidirectional response scale (-3 
– extremely problematic, +3-extremely helpful) (Mahoney et al., 2007). This feature of 
the tool allows the identification of aspects of spasticity that are positive and negative. 
The SCI-SET was shown to have excellent internal consistency (alpha=0.9), test-retest 
reliability (ICC=0.91) and construct validity as measured by self-reported severity, self-
reported spasticity impact and PSFS. 
Three interventional studies were performed that administered the SCI-SET as 
an outcome measure of spasticity, however only one study by Kumru et al. showed 
significant improvement in scores on SCI-SET after repetitive transcranial magnetic 
stimulation in patients with SCI (Adams & Hicks, 2011; Boutilier, Sawatzky, Grant, 
Wiefelspuett, & Finlayson, 2012; Kumru et al., 2010).The designers of the SCI-SET 
reported that a 7-day recall period might lead to inability of the tool to capture short 
term effects of an intervention, thus responsiveness still remains to be elucidated. 
Another limitation of the tool is that some patients might attribute difficulty to perform 
certain tasks to unrelated physical impairment, and not necessarily spasticity. 
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1.1.5.1.1.4. Patient-Reported Impact of Spasticity Measure (PRISM) 
 Another tool that measures the impact of spasticity was developed by Cook et 
al. in war veterans with SCI (Cook et al., 2007). It is a multidimensional construct 
containing 41-items that represent seven subscales which include: ‘Social 
Avoidance/Anxiety, Psychological Agitation, Daily Activities, Need for 
Assistance/Positioning, Need for Intervention, and Social Embarrassment'. To take into 
account varied effects of spasticity on patient’s life the PRISM scale also includes one 
item which refers to how much positively or negatively patients feel they are affected by 
spasticity. 
 The tool demonstrates good reliability in terms of internal consistency 
(Cronbach’s α =0.74. to 0.96) and reproducibility (intra-class correlation co-efficient = 
0.82 to 0.91). Construct validity has only been partially validated by comparing PRISM 
scores with self-reports of severity of the spasms and interference with function. It is 
noteworthy, that only ‘daily activities’ and ‘need for intervention’ subscales of PRISM 
significantly correlated with PSFS interference with function scale. To date no studies 
compared PRISM with clinical methods since authors argued that the scale measures 
the impact of spasticity rather than the symptom itself. Westerkam et al. showed 
significant negative correlations of 3 PRISM subscales (daily activities, positive impact 
and need for assistance/positioning) with Life Situation Questionnaire-Revised 
(Westerkam, Saunders, & Krause, 2011). Since PRISM was developed in a highly 
specific population of war veterans, applicability in a different population affected by 
SCI is uncertain.  
1.1.5.1.1.5. Multiple Sclerosis Spasticity Scale – 88 (MSSS-88) 
Although studies report that spasticity affects around 85% of MS patients very 
few tools have been developed to target spasticity assessment in MS patients (Berger, 
2013). This niche in clinical research on outcome measures in MS was filled by the 
development of MSSS-88 by Hobart et al. (Hobart et al., 2006). MSSS-88 is a patient-
reported, interval-level outcome measure for spasticity in MS that is based on Rasch 
measurement principles (Hobart et al., 2006). It is an 88-item scale that covers 8 
components which address symptoms and the physical and psychosocial impact of 
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spasticity. Each of the eight scales showed good fit statistics and high person separation 
index (>0.92) supporting good reliability and validity. Moderate correlations with MS 
Impact Scale - 29, SF-36, Functional Assessment of MS and self-report of spasticity 
confirmed convergent validity of the MSSS-88.  
The three physical subscales were reported to have larger floor effects than 
other scales indicating the need to expand the content of these subscales. The major 
advantage of MSSS-88 over existing spasticity scales is its interval properties compared 
to ordinal scales like SCI-SET or PRISM. Three clinical trials employed MSSS-88 as an 
outcome measure in addition to clinical methods (Mori et al., 2011; Schyns et al., 2009; 
Sosnoff, Motl, Snook, & Wynn, 2009). Two out of three trials demonstrated better 
responsiveness of the scale compared to Ashworth. Schyns et al. found that vibration 
therapy resulted in reduced scores on the spasm subscale on MSSS-88 with no change 
in the Ashworth scale (Schyns et al., 2009). Similarly, significant reductions on MSSS-88 
walking and pain/discomfort subscales were noted in response to 4-week unloaded 
exercise, while there was no improvement on the Ashworth scale (Sosnoff et al., 2009).  
1.1.5.1.1.6. Performance Scales Spasticity subscale 
Performance scales have been developed and used by the North American 
Research Committee for Multiple sclerosis (NARCOMS) to assess disability in MS based 
on patient self-reports (Marrie & Goldman, 2007; Schwartz, Vollmer, & Lee, 1999). The 
scale covers eight domains, one of which is spasticity. The subscale for spasticity is a 
single item 6-point response scale that measures the impact of spasticity on the daily 
activities: 0=’normal’ (no symptoms of spasticity), 5=’total’ (everyday, spasticity 
problems prevent me from doing many of my daily activities). Schwartz et al. reported 
high test-retest reliability for the spasticity subscale (0.76) and internal consistency for 
overall PS (alpha=0.89) (Schwartz, Bode, & Vollmer, 2012). Convergent validity has only 
been partially validated by Marie et al. against Timed 25 Foot Walk (0.78) (Marrie & 
Goldman, 2007). Additional evidence of validity of the scale was obtained in a study by 
Rizzo et al. where the scale was shown to closely correlate with SF-36, Patient-
Determined Disease Steps (PDDS) and the remaining Performance scales (Rizzo, 
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Hadjimichael, Preiningerova, & Vollmer, 2004). In the same study patients receiving 
intrathecal baclofen reported less spasticity compared to oral antispasticity drugs.  
1.1.5.1.1.7. Self-Report Spasticity Scale (SRSS) 
SRSS was recently developed by Barker et al. in stroke patients to assess the 
severity of spasticity (Barker, Horton, Kent, & Tennant, 2013). The authors aimed to 
develop a tool that is simple, quick and acceptable to use in everyday clinical practice 
and community follow-up. SRSS consists of 8 items representing 6 domains of spasticity: 
pain, spasms, fatigue, restricted movement, loss of balance and altered appearance. 
The scale was subjected to Rasch analysis which showed absence of multidimensionality, 
good fit to the model and high reliability (r=0.701). Circumferential evidence on the 
convergent validity was achieved from comparisons with Barthel Index (r=-0.652) and 
London Handicap Scale (r=-0.658), however no other tools for assessing spasticity were 
employed.  Currently, SFSS has been validated only in stroke patients and more 
research is needed to determine whether the scale could be adopted in other conditions. 
There is some concern whether the scale measures spasticity or other phenomena such 
as paresis or arthritis. If further research proves it is a valid tool for spasticity, SRSS can 
be widely used as a quick and easy-to-administer tool in clinical practice. 
 
            1.1.5.1.2. Clinician-administered measures for spasticity 
            1.1.5.1.2.1. Tonic Spasticity 
The Ashworth Scale (AS) is the most widely used measure for spasticity and was 
originally developed as an outcome measure for antispasticity treatment in multiple 
sclerosis (Ashworth, 1964). The AS measures muscle resistance to passive stretch on a 
5-point scale (0-no increase in tone, 4-a limb is rigid in flexion or extension). The 
Modified Ashworth Scale (MAS) was designed by Bohanon and Smith to increase 
sensitivity to change by adding 1+ as most of the patients were rated at the lower end 
(Bohannon & Smith, 1987). 
        Despite being the most commonly used measure for spasticity, the AS has many 
flaws. As far as face validity is concerned, the AS measures muscle tone to passive 
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stretch, which is only one aspect of the current spasticity definition. Indeed, Skold et al. 
found that only 60% of patients reporting spasticity are detected to have spasticity 
based on clinical methods alone (Skold et al., 1999). This is not surprising since the AS 
measures spasticity only in the flexors and extensors of the limbs and the rest of the 
body areas such as thorax, neck and jaw are not examined (Lechner et al., 2006; Skold, 
2000). Furthermore, Burridge et al. on behalf of the SPASM group argued that AS 
should not be considered as a valid and gold standard tool since AS measures spasticity 
during passive motion, while in fact problems during active motion are more relevant to 
the patient (Burridge et al., 2005).  The Ashworth Scale correlates poorly with other 
clinical manifestations of spasticity such as hypereflexia and clonus, which begs the 
question whether the Ashworth scale can measure the reflexogenic nature of spasticity 
(Platz et al., 2005). Lastly, a number of studies reported low inter-rater and intra-rater 
reliability, hence discouraging its use in assessment of spasticity (Fleuren et al., 2010; 
Pandyan et al., 1999). Despite the flaws of AS, the tool has high clinical utility, as it is 
quick and easy to administer and does not require specialised equipment. 
Another method to assess muscle tone is by using the Tardieu Scale (TS). The TS 
differs from the AS since the examiner applies three different velocities of passive 
stretch (Tardieu, Shentoub, & Delarue, 1954). The quality of the muscle reaction at 
specified velocities and the angle at which the muscle reaction occurs was shown to 
differentiate between neurogenic and biomechanical muscle resistance (Patrick & Ada, 
2006). Due to the scarcity of research on TS, a review by Haugh et al. concluded that 
validity and reliability of the scale has not been determined so far (Haugh, Pandyan, & 
Johnson, 2006). 
1.1.5.1.2.2. Phasic spasticity 
Several grading systems have been proposed to quantify reflex responses. The 
National Institute of Neurological Disorders and Stroke (NINDS) myotatic reflex scale, 
which uses a grading system ranging from 0-absent reflex to 4-enhanced reflex plus 
clonus has been shown to have moderate to substantial inter-rater reliability (Litvan et 
al., 1996). The Spinal Cord Assessment Tool (SCAT), developed by Benz et al. in spinal 
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cord patients, assesses reflexes, clonus and flexor and extensor spasms (Benz et al., 
2005). It was shown to have good concurrent reliability when compared to EMG, 
however no studies have evaluated the reliability so far (Platz et al., 2005). 
 1.1.5.2. Biomechanical and Electrophysiological methods 
Alternatives to subjective clinical measurements of spasticity are objective 
laboratory methods, namely biomechanical and electrophysiological. Although they may 
provide important information for research purposes, these methods are costly, time 
consuming and require specialised equipment and training (Burridge et al., 2005). In 
addition, these measures have been shown to correlate poorly with clinical methods 
such as PSFS and VAS (Voerman et al., 2009; Voerman, Gregoric, & Hermens, 2005). 
Biomechanical methods offer an objective way of quantifying velocity-dependent 
muscle resistance to passive stretch by use of dynamometer or pendulum tests 
(Biering-Sorensen, Nielsen, & Klinge, 2006). Both methods require electro-goniometers 
or computerised software, which hinders their widespread use. The advantage of 
biomechanical methods is that they can distinguish between neurogenic and visco-
elastic causes of spasticity and objectively assess the degree of resistance, which 
eliminates measurer’s bias (Biering-Sorensen et al., 2006).  
Electromyography (EMG) has been used either in conjunction with biomechanical 
methods or alone in the assessment of spasticity (Biering-Sorensen et al., 2006). It is 
noteworthy that spasticity assessment with EMG has to be undertaken with some 
stimulation, either electrical (H-reflex) or mechanical (tendon tap (T-reflex)). 
Spontaneous EMG activity is only seen during muscle spasm (Biering-Sorensen et al., 
2006). Hyper-excitability of the stretch reflex in spasticity is characterised by an 
increase in the H max/ M max ratio, because of exaggerated response of the H reflex 
and the absence of inhibition associated with relaxation (Decq et al., 2004). EMG has 
been an invaluable tool in studying the pathophysiology of spasticity, however its use as 
a measurement for spasticity has some important limitations (Voerman et al., 2005). 
Firstly, the size of responses heavily depends on muscle mass, subcutaneous fat and 
skin resistance, hence it is not possible to reliably compare the readings across patients 
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(Biering-Sorensen et al., 2006). Secondly, EMG responses such as H-reflex or T-reflex 
vary greatly across healthy individuals. Lastly, no correlation has been observed 
between MAS and EMG in patients with spasticity, however this could also be due to the 
flaws of clinical measurement (Voerman et al., 2009; Voerman et al., 2005)  
1.1.6. Conclusions 
The literature on the definition of spasticity and its measurement remains 
conflicting. Inconsistent and sometimes completely opposite findings and views among 
researchers and clinicians highlight the ongoing interest in this subject and this is 
unlikely to end in the near future. In the words of Stokic, editor of Clinical 
Neurophysiology: 'the truth [about spasticity] is still in the eye of the beholder' (Stokic, 
2010).  
Whatever the underlying pathophysiology of spasticity might be, it is a serious 
complication of UMN damage that carries a significant burden for patients and their 
carers. Spasticity is a recognised impairment in a number of adult conditions which 
affect the central nervous system including stroke, multiple sclerosis, spinal cord injury, 
motor neurone disease and traumatic brain injury. Spasticity is a particularly common 
and troublesome impairment in patients with multiple sclerosis (MS), affecting up to 
84% of patients (Rizzo et al., 2004). In the next section, a general overview of MS is 
presented with a particular emphasis on MS-related spasticity.  
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1.2. Multiple Sclerosis 
1.2.1. Overview 
Multiple Sclerosis (MS) is a neurodegenerative disease characterised by chronic 
inflammation, demyelination and degeneration of the central nervous system (Olek, 
2002). At the initial stage of the disease neuroinflammation is transient producing 
paroxysmal attacks followed by remyelination and recovery, hence the relapsing-
remitting nature of MS (Compston & Coles, 2008). However, in the majority of patients 
remyelination is not durable and progressive fibrosis and degeneration of the central 
nervous system occurs (Weinshenker et al., 1989).  In the last couple of decades, there 
has been a rapid increase in the development of disease-modifying therapies (DMTs) 
with a view to control the course of the disease. Although the DMTs have been shown 
to be effective in reducing relapses, their effectiveness in preventing disability and 
delaying transition to secondary progressive disease is limited (Derwenskus, 2011; 
Goodin et al., 2002). As the disease progresses neurological impairments and disability 
become increasingly common, affecting patient functioning, ability to perform activities 
of daily living (ADL) and quality of life (QOL) (Zwibel, 2009). Consequently, in order to 
minimise the impact of MS on QOL a regular comprehensive assessment and 
management of consequences of the disease remains central to the care of MS patients. 
1.2.2. Historical perspective 
The first descriptions of a demyelinating disorder were documented by the 
famous French neurologist Jean Martin Charcot in 1868 (Charcot, 1868a). He described 
the correlation between clinical and pathological features of the illness in patients with 
intermittent neurological symptoms. At histological examination he noted the presence 
of plaques, axonal demyelination and inflammatory cell infiltration and suggested the 
term ‘sclérose en plaques disseminée,” (Charcot, 1868b). Since then, a number of 
discoveries have been made which greatly contributed to better understanding of the 
pathophysiology of MS. The utilisation of experimental autoimmune encephalomyelitis 
has led to the widely accepted notion of an autoimmune basis of MS (Rivers, Sprunt, & 
Berry, 1933). This was later supported by Elvin Kabat, who discovered oligonoclonal 
bands (Kabat, Glusman, & Knaub, 1948). Following this, findings from twin studies and 
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viral infections associated with development of MS led to the hypothesis that MS occurs 
in genetically susceptible individuals after exposure to an environmental agent (Kurtzke, 
1993; Levin et al., 2003; Myrianthopoulos & Mackay, 1960). Lastly, in more recent years 
advancements in biotechnology and neuroimaging have led to the discovery of a 
number of disease modifying therapies and successful application of MRI in the 
diagnosis and management of MS. 
1.2.3. Epidemiology and aetiological factors 
MS is the most common demyelinating disease of the central nervous system 
affecting 126 669 people (203 in 100000) in the United Kingdom (Mackenzie, Morant, 
Bloomfield, MacDonald, & O'Riordan, 2014). The peak age of onset for MS is 40 in 
women and 45 in men (Mackenzie et al., 2014).  Relapsing remitting MS has an earlier 
age of onset (25-29) compared to primary progressive (35-39). Female to male ratio is 
2:1, which is also characteristic of other autoimmune disorders (Olek, 2002). 
Incidence and prevalence of MS varies greatly geographically. Highest prevalence 
is seen in countries with temperate climates such as North America, Northern Europe, 
New Zealand and South Eastern Australia (Kurtzke, 1993). The geographical variation 
may be explained by environmental factors, latitude and racial differences with white 
races being more commonly affected than Asian and African (Elian, Nightingale, & Dean, 
1990; Marrie, 2004). MS prevalence appears to increase going south to north in the 
northern hemisphere, and the reverse is true for the southern hemisphere (Hammond 
et al., 1987; Simpson, Blizzard, Otahal, Van der Mei, & Taylor, 2011). To exemplify such 
a distinct trend, MS prevalence is higher in Scotland compared to England (Mackenzie et 
al., 2014).  
A number of environmental exposures have been postulated, however no single 
agent has been identified to be causative so far (Marrie, 2004). Infection, vaccinations, 
occupational exposures, stress, smoking and sunlight have been reported to be 
associated, however the evidence is contradicting (Ascherio & Munger, 2007; Ebers, 
2008; Marrie, 2004).  Reduced sunlight exposure has the strongest supporting evidence 
(Ascherio & Munger, 2007). It was speculated that the geographical variation of MS may 
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be explained by vitamin D deficiency, which is common in countries with a temperate 
climate (Ascherio & Munger, 2007; Marrie, 2004). In addition, vitamin D has been 
shown to have antinflammatory properties (Krishnan & Feldman, 2011). Findings from 
migration studies also support the hypothesis of environmental agents triggering MS 
(Alter et al., 1962; Hammond, English, & McLeod, 2000). It has been found that 
migration from a low incidence area to a high incidence area before puberty leads to 
the individual adopting the higher risk for MS of the new area, but this seems not to be 
true if migration occurs after puberty (Hammond et al., 2000). 
 1.2.4. Pathogenesis 
 The aetiology of MS is unknown, however it is believed that the disease 
develops in genetically susceptible individuals in the presence of environmental triggers 
(Compston & Coles, 2008).  There is a 1-5% risk of developing MS if a parent or a 
sibling has the disease, with 25% concordance among monozygotic twins (Robertson, 
Clayton, Fraser, Deans, & Compston, 1996). Genetic studies have identified HLA alleles 
on chromosome 6, namely DR15 and DQ6, which were shown to be associated with 
increased risk of MS, particularly in northern Europeans (Marrosu et al., 1992; Olerup & 
Hillert, 1991). The HLA genes have been suggested to play an important role in 
determining whether T cells recognise antigenicity towards myelin proteins (Mohme et 
al., 2013). 
  Studies on experimental encephalomyelitis have established a central role of T 
cells in the pathogenesis of inflammation, demyelination and plaque formation (Fletcher, 
Lalor, Sweeney, Tubridy, & Mills, 2010). It is known that CD4 T cells are activated by 
local glial and dendritic cells presenting autoantigens via MHC class II system (Fletcher 
et al., 2010). Subsequently, CD4 T cells transform into Th1 cells. Activated Th1 cells 
disrupt the myelin, release other antigens, attract nonspecific inflammatory cells and 
antimyelin-forming B cells by secreting various cytokines such as interferon-gamma and 
TNF-a (Hafler, 2004). The presence of oligoclonal bands points towards B cell 
involvement in the pathogenesis of MS. The reasons for CD4 T cell reactivity to antigens 
in the central nervous system are not known, however environmental triggers have 
40 
 
been suggested (Ebers, 2008; Marrie, 2004). Epstein-Barr virus has been implicated to 
activate CD4 T cells via molecular mimicry (Lang et al., 2002). Lang et al. identified that 
basic myelin protein is identical to proteins found on Epstein-Barr virus (EBV) (Lang et 
al., 2002). In addition, B cells found in demyelinating plaques have been shown to be 
EBV positive (Serafini et al., 2007). 
The pathologic hallmarks of MS are demyelinating plaques within the white 
matter containing inflammatory infiltrates (Inglese, 2006). The recurrent attacks of 
inflammation eventually lead to scarring and gliosis. Repeated attempts at remyelination 
cause oligodendrocyte loss contributing to the progressive impairment (Hafler, 2004). 
Aside from demyelination, neuroaxonal damage is thought to be central in causing 
permanent neurological deficits (Trapp, Ransohoff, & Rudick, 1999). Various 
mechanisms involving inflammation, free radicals and nitric oxide have been implicated 
in axonal loss (Bjartmar, Wujek, & Trapp, 2003).  
1.2.5. Clinical features 
Depending on the location of inflammation within the CNS, presentation in MS 
can vary greatly. The majority of patients present with a clinically isolated syndrome 
(CIS) characterised by acute or subacute onset of neurological deficit lasting for a few 
weeks and followed by complete or near complete recovery (D. H. Miller, Chard, & 
Ciccarelli, 2012). The resolution of symptoms appears to be a result of decreasing 
inflammation and oedema, rather than remyelination, which might not occur despite the 
absence of symptoms (Achiron & Barak, 2000). McAlpine reported that the most 
common presenting symptoms were limb weakness (40%), optic neuritis (22%), 
paraesthesia (21%), diplopia (12%), vertigo (5%) and disturbance of bladder control 
(5%) (McAlpine, 1972). Very few symptoms are specific to MS, which include 
Lhermitte’s symptom (an electrical feeling running down the spine triggered by neck 
flexion) and Uthoff’s phenomena (temporary worsening of the symptoms with an 
increase of core body temperature). As the disease advances, symptoms of fatigue, 
depression, spasticity and cognitive dysfunction predominate the clinical picture and 
substantially contribute to MS-related disability (Zwibel, 2009).  
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 1.2.6. Diagnosis 
 Due to the variable nature of presentation, diagnosis of MS can be challenging. 
To aid this the McDonald diagnostic criteria for MS have been developed, with the most 
recent corrections made in 2010 (Polman et al., 2011) (table 4). According to the 
McDonald criteria the diagnosis requires objective evidence of lesions disseminated in 
time and space, i.e. more than one clinical attack with more than one area of CNS 
affected. In the majority of cases diagnosis can be made on clinical grounds alone, 
however when diagnosis is ambiguous MRI imaging may help to identify the lesions in 
space and time. MS-characteristic lesions include periventricular, juxtacortical, 
infratentorial and within the spinal cord on T2 MRI scan which may or may not be 
gadolinium-enhancing. Occurrence of new lesions on T2 sequence at any point in time 
during follow-up constitutes dissemination in time. Supportive investigations include CSF 
for oligonoclonal bands and visual evoked potentials, usually performed in the less 
common cases of insidious neurological progression. MRI identifies abnormality in the 
brain or spinal cord in over 95% of patients with MS, however presence of MRI lesions 
alone (radiologically isolated syndrome) should not lead to a diagnosis of MS, as non-
specific changes in the brain are common, particularly in patients over 50. 
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Table 4. The 2010 McDonald criteria for diagnosis of MS (Polman et al., 2011) 
Clinical presentation Additional data needed for MS diagnosis 
≥2 attacks; objective clinical evidence 
of ≥2 lesions or 1 lesion with 
reasonable history of a prior attack 
none 
≥2 attacks; objective clinical evidence 
of 1 lesion 
Dissemination in space: 
-≥1 T2 lesion in at least 2 of 4 MS-typical regions of the CNS 
(periventricular, juxtacortical, infratentorial, or spinal cord); or 
await for another clinical attack implicating a different CNS 
location 
1 attack; objective clinical evidence of 
≥2 lesions 
Dissemination in time: 
simultaneous presence of asymptomatic gadolinium enhancing 
and non-enhancing lesions; or a new T2 and/or gadolinium 
enhancing lesion at any point of follow up; or await for a second 
clinical attack 
1 attack; objective clinical evidence of 
1 (clinically isolated syndrome) 
Requires evidence on  dissemination in both space and time(as 
above) 
Insidious neurological progression 
(suggestive of PPMS) 
1 year of disease progression (retrospectively or prospectively 
determined) plus 2 of 3 of the following: 
1. ≥1 T2 lesions in MS-typical regions of CNS 
2. ≥2 lesions in the spinal cord 
3. Positive CSF (oligonoclonal bands and/or elevated IgG index) 
 
1.2.7. Clinical Course 
No biochemical or radiological markers have been identified so far to classify 
different types of MS, hence clinical course remains the only way of defining the disease 
type. There are four main distinct stages of MS: clinically isolated syndrome (CIS), 
relapsing-remitting MS (RRMS), secondary progressive MS (SPMS) and primary 
progressive MS (PPMS). The likelihood of having a second attack after CIS, hence 
diagnosis of MS, increases substantially in the presence of MRI lesions at the first 
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presentation (D. H. Miller et al., 2012). Estimated risk of MS if MRI is abnormal is as 
high as 80%, while only less than 20% of patients with normal MRI will develop MS. 
Other factors associated with a decreased risk of developing MS are optic neuritis, 
sensory symptoms and negative oligonoclonal bands (D. H. Miller et al., 2012). Of those 
who develop MS, 85% experience relapsing-remitting disease with recurrent attacks of 
neurological deficits followed by complete or near complete recovery over the course of 
a few weeks. A relapse by definition is a neurological deterioration or a new symptom 
occurrence lasting for more than 24 hours and is preceded by a relapse free period of 
30 days in the absence of fever or other systemic disease, which would otherwise 
unmask subclinical features of MS (Inglese, 2006). Although the relapses occur 
erratically, they usually do not exceed 1.5 occurrences per year (Inusah et al., 2010) . 
However, after 25 years of disease activity the majority of patients eventually convert to 
SPMS, which is characterised by incomplete recovery and progressive, accumulative 
neurological impairment (Confavreux, Vukusic, Moreau, & Adeleine, 2000). 
A substantial minority (approximately 15%) of patients present with primary 
progressive MS, characterised by progressive insidious neurological impairment with 
predominant spinal involvement (Thompson et al., 1997). It often presents a diagnostic 
challenge to the clinicians and requires extensive investigations including neuroimaging 
and CSF laboratory studies. PPMS is associated with later age of onset, equal male to 
female ration, lower lesion load and fewer gadolinium-enhancing lesions (D. H. Miller & 
Leary, 2007). Since PPMS is thought to be driven by neurodegenerative processes, 
rather than inflammatory, patients with PPMS typically do not respond to disease 
modifying drugs and rapidly progress to high levels of disability (D. H. Miller & Leary, 
2007). In less than 5%, patients present with features of primary progressive MS with 
superimposed relapses, a type known as progressive-relapsing MS (Tullman, Oshinsky, 
Lublin, & Cutter, 2004).  
Other less common types are benign and malignant MS. The use of term ‘benign 
MS’ has been somewhat controversial and misleading. It is defined as minimal or no 
disability, equivalent of EDSS ≤ 3, 10 years after disease onset (Glad, Nyland, & Myhr, 
2006). However, it is has been increasingly recognised that patients with a benign form 
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of MS, although not physically disabled, often suffer from fatigue, depression and 
cognitive impairment, which can negatively affect QOL and employment status (Glad, 
Aarseth, Nyland, Riise, & Myhr, 2010). Rarely, MS may follow a malignant course 
causing severe disability in multiple neurological systems or death within a short period 
of time (Lublin & Reingold, 1996). 
     1.2.8. Prognosis 
The course of MS is variable. Although MS is rarely fatal, as the disease 
progresses it is almost invariably associated with increased levels of disability and 
reduced quality of life (Wynia, van Wijlen, Middel, Reijneveld, & Meilof, 2012). Fifty 
percent of patients will require a walking aid within 15 years of disease activity 
(Tremlett, Zhao, Rieckmann, & Hutchinson, 2010). Death ensues approximately after 30 
years of disease and is a result of increased risk of skin, chest and bladder infections 
secondary to severe neurological disability (Compston & Coles, 2008). Factors 
associated with disease progression are: male, older age, motor symptoms, frequent 
relapse and incomplete remissions (Tremlett et al., 2010) . 
1.2.9. Spasticity in multiple sclerosis  
Data regarding prevalence and impact of MS-related spasticity is scarce. Several 
patient surveys estimated that spasticity affects approximately 64% -84% of the MS 
population (MS Society Symptom Management Survey, 1997; Rizzo et al., 2004). 
However, a survey exploring opinions of healthcare professionals regarding MS-related 
spasticity showed that neurologists believe that less than a half of their patients have 
spasticity (Collongues & Vermersch, 2013). The NARCOMs survey involving more than 
20000 participants found that 16% of the respondents had no spasticity, 31% minimal, 
19% mild (occasional), 17% moderate (frequently affects activities), 13% severe (need 
to modify daily activities) and 4% total (prevents daily activities) (Rizzo et al., 2004). 
The data from the MS Symptom Management Survey showed that muscle spasms and 
muscle stiffness are among the most troublesome and common symptoms together 
with fatigue, pain and bladder problems (MS Society Symptom Management Survey, 
1997). 
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Spasticity may cause pain, reduce ability to walk and interfere with personal 
hygiene (Paisley, Beard, Hunn, & Wight, 2002; Stevenson, 2010; Thompson, Jarrett, 
Lockley, Marsden, & Stevenson, 2005). Indeed it is spasticity, not weakness, that has 
been shown to be associated with increased levels of disability in MS patients (Barnes, 
Kent, Semlyen, & McMullen, 2003).  
Several studies investigated the costs and societal burden of MS-related 
spasticity (Arroyo, Vila, & Clissold, 2011; Oreja-Guevara, 2011; Svensson, Borg, & 
Nilsson, 2014). Svensson et al. reported results from a patient survey on costs related 
to MS spasticity in a Swedish population (Svensson et al., 2014). Total annual cost per 
patient was estimated to be 114393 Euros. Interestingly, direct medical costs accounted 
only for 7% of this total and direct non-medical costs related to personal assistance, 
housing and informal care accounted for more than 60%. In addition, health care costs 
in patients with severe spasticity were found to be 2.4 times higher compared to those 
with mild spasticity. It is noteworthy that the costs of antispasticity therapy and 
rehabilitation services were minimal, accounting for only 3% of direct medical costs 
while disease-modifying therapies were responsible for 56%. The review by Berger et al. 
on the current management practices of MS related spasticity indicated that more effort 
should be made to improve the provision of adequate antispasticity treatment (Berger, 
2013). 
 A large cross-sectional '6E' study in Spain (n=2029) found that a significantly 
larger proportion of patients with MS spasticity compared to those without spasticity 
required carer support (16.3% vs. 4%), used rehabilitation services (10.6% vs. 40.8%) 
and required special MS disability subsidies (59.6% vs. 26.5%) (Oreja-Guevara, 2011). 
A Spanish twin study '5E' retrospectively reviewed medical records of up to 3 years of 
patients with MS spasticity resistant to two or more medications in order to determine 
the natural evolution of spasticity in this patient cohort (Arroyo et al., 2011). The study 
showed that patients with resistant spasticity continued to progress to more severe 
stages in the period of 2.1 years despite treatment with antispasticity medication. More 
than a third of patients were wheelchair-bound and only 18% were in employment.  
These data suggest that spasticity is associated with a significant health care burden, 
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primarily through reduced capacity to work, use of social services and reliance on 
informal care from family and friends. 
1.2.9.1. Spasticity and its relationship with other MS impairments 
There is limited evidence regarding the relationship between spasticity and other 
clinical features commonly associated with MS such as pain, fatigue, sleep problems, 
urinary dysfunction, anxiety, depression etc. Based on the data from the healthcare 
professionals survey regarding spasticity management in MS, neurologists felt that 
mobility impairment, rigidity, pain, bladder dysfunction, spasms and sleep disorders 
were the most disabling symptoms associated with spasticity (Collongues & Vermersch, 
2013). 
Similar preliminary findings were reported from the patient survey in Spain 
(Oreja-Guevara, 2011). Oreja – Guevara et al. in the '5E' study (n=2029) found that 
patients with spasticity had significantly more sleep problems (50.9% p<0.001) than 
patients without spasticity (26.1%). However authors did not indicate what measures 
were used to quantify sleep disturbance, nor was a definition for patients with or 
without spasticity provided. In the same study urinary disturbance was found to be 
more common in patients with spasticity (70%) compared to those without (29.2%, 
p<0.05). In a cross-sectional German study MOVE 1 (n=414) around half of the MS 
patients with spasticity reported symptoms of pain, bladder dysfunction and fatigue 
(Flachenecker, Henze, & Zettl, 2014). No symptom-specific scales were used, except for 
fatigue, which was assessed using Wurzburg Fatigue inventory in MS (WEIMus). 
However authors did not compare fatigue levels across the groups of increasing 
spasticity, hence limited information can be derived from this study.  
The findings from the above studies suggest that there might be an association 
between spasticity and other factors, however studies failed to administer appropriate 
measures for spasticity and other neurological impairments. There is insufficient data to 
assume that relationships existing between spasticity and other clinical features are 
causal.  It is possible that unrelated symptoms occur with an increasing incidence as MS 
progresses, and spasticity might represent a marker of the severity of the disease. 
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 1.2.9.2. Management of spasticity 
 Adequate management of spasticity is fundamental in order to maximise 
mobility and avoid associated complications. Early treatment measures are important in 
preventing a self-perpetuating cycle of worsening spasticity, which affects mobility and 
increases pain, which in turn can amplify spasticity (Stevenson, 2010). Spasticity may 
lead to very serious, but preventable complications such as contractures, pressure 
ulcers and spinal deformities that can have a significant impact on patient's life (Kheder 
& Nair, 2012). 
A wide variety of antispasticity therapies have been described in the literature, 
ranging  from oral medication used in the early stages of the disease to botulinum toxin 
injections and surgical techniques in patients who are severely affected. However 
overall effectiveness of antispasticity therapies remains limited (Paisley et al., 2002). A 
Cochrane systematic review of oral antispasticity agents in MS concluded that clinical 
benefit of these agents is small and the tolerability is low (e.g. muscle weakness, 
drowsiness, nausea and liver toxicity) (Shakespeare, Boggild, & Young, 2003). Hence, 
despite a wide array of antispasticity medications available on the market, spasticity 
remains a challenge for many healthcare professionals. 
 The management of spasticity is problematic requiring close co-operation 
between the physicians and patients in order to achieve the best results (Thompson et 
al., 2005). However, this is often difficult, with evidence from large patient surveys in 
North America and Europe indicating low satisfaction with antispasticity treatment both 
from patient and healthcare professional perspectives (Flachenecker et al., 2014; Rizzo 
et al., 2004). In a German study (MOVE1) 41.3% of patients were not satisfied or 
partially dissatisfied with the treatment. In addition, patients with more severe 
spasticity were more likely to be dissatisfied with the treatment than patients with mild 
spasticity (Flachenecker et al., 2014). Equally, more than 40% healthcare professionals 
feel dissatisfied with antispasticity interventions in MS (Collongues & Vermersch, 2013). 
 There is also some evidence to suggest that management practices vary greatly 
and are often suboptimal. In a study by Barnes et al. (n=68) the investigators 
evaluated the adequacy of MS spasticity management in a random sample of MS in 
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Newcastle Upon Tyne (Barnes et al., 2003). The study confirmed that spasticity is 
poorly managed as more than half of the sample had moderate to severe spasticity. In 
addition, the authors also reported that in more than 50% of the patients dose 
adjustments of oral antispasticity agents needed to be made. This is in line with 
findings of MOVE1 study, which reported that 61%, 37% and 16% of patients with mild, 
moderate and severe spasticity respectively did not receive antispasticity therapy 
(Flachenecker et al., 2014). In addition, a healthcare professional survey revealed that a 
quarter of neurologists do not regularly monitor spasticity symptoms (Collongues & 
Vermersch, 2013). Similar findings were obtained from the MS Society survey on 
spasticity management indicating that spasticity management in the UK needs 
improvements in order to meet patient needs (MS Society Symptom Management 
Survey, 1997). 56% of the patients claimed they had never seen a rehabilitation 
specialist and 60% had never been seen by an MS specialist nurse. 
The first step in the management of spasticity is setting goals which should be 
agreed between a patient and management team. Goal attainment scale is commonly 
used to measure the success of an intervention (Kheder & Nair, 2012). Examples of 
spasticity management goals are the relief of discomfort, improved sitting, standing and 
walking, facilitated activities of daily living, reduced burden of care, improved body 
image and self-esteem and prevention of complications mentioned earlier (Stevenson, 
2010). On the other hand, not every patient with spasticity requires aggressive 
treatment, especially when spasticity is not associated with functional limitations or pain 
and discomfort (Dietz & Sinkjaer, 2007). Spasticity can be beneficial for posture and 
transfers and may reduce leg dependent oedema and risk of deep vein thrombosis 
(Haselkorn et al., 2005). The following paragraphs describe the management options of 
spasticity. 
1.2.9.2.1. Identification of triggers 
A number of triggers for spasticity have been reported by patients (Phadke, 
Balasubramanian, Ismail, & Boulias, 2013). Common factors exacerbating spasticity 
include: urinary infection, pain, pressure ulcers, infection, ingrown toenail, constipation 
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and urinary calculi. Patient and carer education about how to recognise and report 
these aggravating factors is an important part of spasticity management (Kheder & Nair, 
2012). 
1.2.9.2.2. Non-pharmacological interventions 
Rehabilitation is the backbone of spasticity management and should always be 
employed alongside other therapies (Kesselring & Beer, 2005). However, a recent 
Cochrane review reported that there is limited evidence on efficacy of non-
pharmacological interventions to treat MS-related spasticity (Amatya, Khan, La Mantia, 
Demetrios, & Wade, 2013). Passive muscle stretching may help prevent and treat 
contractures, improve mobility and posture, however its benefit is of questionable 
importance (Katalinic, Harvey, & Herbert, 2011). Exercise, particularly cycling and using 
a treadmill, is suggested to improve overall strength and function in patients with 
spasticity, however its effect on directly reducing spasticity is not well established (Ada, 
Dorsch, & Canning, 2006). Correct posture is crucial in preventing secondary 
complications; standing exercises and proper positioning can prevent the occurrence of 
contractures, reduce spasticity, and improve bladder function, bowel function and 
overall well-being (Stevenson, 2010). Whole body vibration therapy, transcranial 
magnetic stimulation, transcutaneous electrical nerve stimulation and electromagnetic 
therapy have been reported but remain only experimental (Amatya et al., 2013).    
1.2.9.2.3. Antispasticity agents 
A variety of medications exist to treat spasticity, however their effectiveness is 
low and side effects are common. Several systematic reviews emphasised conceptual 
difficulties with measurement of spasticity, hence assessing the effectiveness of 
antispasticity agents remains a serious issue in clinical trials (Paisley et al., 2002; 
Shakespeare et al., 2003). Although there is some evidence to suggest that 
antispasticity agents reduce muscle tone as measured by the Ashworth Scale, their 
effect on physical functioning is questionable (Paisley et al., 2002). 
Every effort should be made to identify the most effective drug on an individual 
basis (Kheder & Nair, 2012). Multiple medications should be attempted if a single agent 
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therapy fails. Centrally acting agents include gamma-aminobutyric acid-B (GABA-B) 
receptor agonists (baclofen, diazepam), a2-receptor agonists (tinazidine) and 
cannabinoids. Drugs acting peripherally are botulinum toxin and dantrolene. Most 
commonly used agents according to the Spanish patient survey '5E' are baclofen 
(75.5%), tizanidine (37.3%), benzodiazepines (31.9%), gabapentin (15.7%), botulinum 
toxin (12.7%), cannabinoids (11.3%) and others (4.4%) (Oreja-Guevara, 2011).   
Baclofen is the most widely used oral antispasticity agent. It reduces motor 
neurone activity by stimulating GABA-B receptors. Baclofen has been shown to be 
effective in reducing spasticity compared to placebo, however side effects are common 
which include weakness, dizziness and drowsiness. Previous reviews have not found any 
difference between baclofen and diazepam in relieving spasticity, however diazepam 
was associated with a worse side effect profile (Paisley et al., 2002; Shakespeare et al., 
2003). 
Another class of antispasticity agents acting as GABA-B agonists are 
benzodiazepines. Benzodiazepines can be effective in treating spasticity, particularly if 
sleep problems are prominent, however its use is limited for day time symptoms due to 
drowsiness and sensorimotor slowing. 
GABAergic agents, such as gabapentin and pregabalin, have been shown to have 
some effectiveness in reducing spasticity (L. J. Bradley & Kirker, 2008). Although initially 
developed as anti-convulsants, serendipitous observations have shown that they might 
reduce spasticity in MS patients. Both drugs are less effective in reducing spasticity 
compared to baclofen and diazepam, however they can be useful if pain and discomfort 
associated with spasticity are the prominent symptoms. 
Tizanidine is a centrally acting a2-receptor agonist which inhibits excitatory spinal 
neurones and reduces muscle tone. Careful tapering of tinazidine should be performed 
as it can precipitate adrenergic crisis. There is strong evidence in favour of tizanidine 
over placebo in the short term reduction of spasticity, however its long term effects are 
less clear (Eyssette, Rohmer, Serratrice, Warter, & Boisson, 1988; C. Smith, Birnbaum, 
Carter, Greenstein, & Lublin, 1994). 
There is growing evidence to support the use of cannabinoids in treating 
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spasticity and other symptoms of MS (Leussink et al., 2012); the mechanism of action 
by which cannabinoids reduce spasticity is currently unknown. A meta-analysis of three 
randomised controlled trials investigated the effects of nabiximols (cannabinoid agent) 
as an add-on therapy in patients who failed on standard oral antispasticy agents (Wade, 
Collin, Stott, & Duncombe, 2010). The authors concluded that nabiximols produces 
significant benefit compared to placebo and is well tolerated. However, the use of 
cannabinoids is limited due to concerns over their long term cognitive and behavioural 
effects. 
Botulinum toxin, which blocks acetylcholine release, is particularly useful for 
managing focal spasticity, such as adduction spasticity of the legs (Kesselring & Beer, 
2005). Injections of botulinum toxin into the selected muscle with the help of EMG or 
ultrasound can achieve relief of spasticity for 3-4 months. Post injection physiotherapy 
and splinting can maximise the effects of botulinum toxin injections. 
1.2.9.2.4. Surgical therapies  
Oral baclofen has very low bioavailability, hence its effects on the central nervous 
system are minimal. Intrathecal baclofen (ITB) bypasses this problem by delivering high 
doses of baclofen directly into the central nervous system without causing baclofen-
associated side effects. ITB should be considered in patients who fail on two oral 
antispasticity agents and those with predominant lower limb spasticity (Erwin et al., 
2011). A successful trial of ITB warrants pump implantation in such patients (Kheder & 
Nair, 2012). Regular follow up appointments are needed to refill the pump and to detect 
pump-related complications such a failure, infection and cerebrospinal fluid leakage. 
Surgical peripheral neurectomy and chemical neurolysis using phenol injections 
are useful in cases where spasticity affects large, powerful muscles groups such as 
thigh adductors. This technique may achieve relief for many months, however spasticity 
may recur as a result of sprouting of new nerve endings. 
A radical surgical technique which can be used to treat spasticity is selective 
dorsal rhizotomy. Transection of sensory nerves decreases Ib sensory gamma afferent 
input to the spinal cord which in turn reduces motor neurone excitation. However, the 
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invasive nature of dorsal rhizotomy limits its use to only few selected cases.  
1.2.10. Conclusions 
Multiple sclerosis is a demyelinating disorder of the CNS, which is associated with 
severe disability and a number of neurological symptoms. Spasticity is one of the most 
commonly occurring impairments in MS and has been shown to be associated with 
significant disease burden. Management of spasticity is difficult, since current therapies 
have limited effectiveness. Because of the chronic nature of the disease and the 
widespread impact MS can have on patients’ lives, there has been a growing interest in 
understanding quality of life (QOL) in MS. In the following section of this chapter, an 
overview of the concepts and measurement of QOL is presented with the focus on QOL 
determinants in MS. 
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1.3. Quality of Life 
1.3.1. Overview and Historical Perspective 
Quality of life (QOL) is a relatively new concept in the health care setting, 
which has been extensively studied only in the last three decades. However, the roots of 
QOL concepts date back as far as ancient Greece. Aristotle described 'happiness' as 'a 
certain kind of virtuous activity of the soul, happiness was a God-given blessing, 
therefore a happy man lives well and does well' (Zhan, 1992).  
It was not until mid-20th century before measurement of QOL was introduced 
into medical practice. As one of the pioneers of QOL assessment, Karnofsky devised a 
scale with the emphasis on physical function and performance status of the patient 
(Karnofsky & Burchenal, 1949).  Karnofsky's Performance Status scale was an 
innovative measure of disease outcome compared to the conventional focus on 
prognosis and disease progression (Zhan, 1992). Later, Katz et al. developed an Index 
of Activities of Daily Living which not only assessed physical function, but also 
addressed the implications of physical function on everyday activities (Katz, Ford, 
Moskowitz, Jackson, & Jaffe, 1963). It is evident that the first attempts to measure 
patients’ QOL were primarily focused on physical aspects of life. Over the years it was 
recognised that this biomedical model of QOL is far from sufficient to explain its 
complex underpinning concepts, and that social and mental aspects are equally 
important contributors to QOL (1995). 
QOL is recognised to be a fundamental part of current health care across the 
world and is relevant to everyone at all stages of life (Bakas et al., 2012). Albrecht and 
Fitzpatrick have identified four uses of QOL assessment in health care (Albrecht GL, 
1994). It is used (1) for planning and assessment of care for individual patients (2) as 
an outcome measure in clinical trials and medical research (3) for health needs 
assessment of populations (4) for resource allocation.  Currently, the US Food and Drug 
Agency and European Medicines Agency strongly encourage the utilisation of QOL 
measures in the assessment of new therapies (Baumstarck et al., 2013b). And this 
trend is also observed in MS research: 118 clinical trials have reported the use of QOL 
measures by the end of 2012 (Baumstarck et al., 2013b). QOL research has however 
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been challenged with a number of issues despite its widespread use in clinical practice, 
health care assessment and policy making. These issues range from basic conceptual 
frameworks to practicalities of measurement and their clinical application (Ferrans, 2007; 
Ferrans et al., 2005; Rapkin & Schwartz, 2004; 1996). This section presents an overview 
of the basic concepts of QOL, issues in QOL measurement and its relevance to MS. 
 1.3.2. Definitions and concepts 
QOL is a complex and multidimensional construct for which many definitions have 
been proposed (table 5) (Carr & Higginson, 2001). It is also not uncommon to find 
authors of scientific articles avoiding defining QOL; this has been illustrated by a 
systematic review which found that 16 out of 68 papers on QOL models failed to 
provide a definition (Taillefer, Dupuis, Roberge, & LeMay, 2003). The lack of a 
universally agreed definition presents serious methodological concerns in QOL research.   
At the basic level of understanding, QOL could be conceptualised as a combination of all 
sources of satisfaction (including positive anticipation) minus threats (including negative 
anticipation) (Mitchell, Benito-León, González, & Rivera-Navarro, 2005). The World 
Health Organisation defines QOL as 'The perception by individuals of their position in 
life, in the context of the culture and value systems in which they live and in relation to 
their goals, expectations, standards, and concerns.' (WHO, 1996). Three core 
prerequisites are embedded in the WHO definition: (1) assessment of QOL is subjective 
and individualised, (2) QOL is a multidimensional construct, (3) involves individuals’ 
perception of both negative and positive dimensions. 
 
 
Despite increasing efforts to reach a consensus on a standard definition of QOL, a 
Table 5. Definitions of QOL (Carr & Higginson, 2001) 
‘The extent to which hopes and ambitions are marched by experience’ 
‘The perception by individuals of their position in life, in the context of the culture and value systems in which  
they live and in relation to their goals, expectations, standards, and concerns’ 
‘Appraisal of one’s current state against some ideal’ 
‘The things people regard as important in their lives’ 
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number of other terms have been used interchangeably which adds additional confusion 
to the literature concerning QOL research. The most cited examples include life 
satisfaction, well-being, happiness, health status and living conditions (Haas, 1999). 
Health-related QOL (HRQOL) is a particularly commonly used term and although used 
interchangeably with QOL it connotes a different meaning. QOL is determined by 
health-related factors (physical, functional and mental well-being) and non-health-
related factors (social support, environment, jobs, family, spirituality, etc.) (Ferrans et al., 
2005). In contrast, HRQOL is a narrower concept viewed generally from the medical 
perspective (Rudick & Miller, 2008). It is concerned with aspects of QOL that are directly 
related or affected by the presence of disease or treatment. As Schipper suggests 
'HRQOL is the functional effect of an illness and its consequent therapy upon a patient 
as perceived by the patient' (Schipper, Clinch, & Olweny, 1996). Despite these apparent 
differences, the distinction between HRQOL, health status and QOL is often blurred and 
the terms are used interchangeably in the literature (C. Bradley, 2001). 
 1.3.3. QOL domains 
Although there is a belief that QOL is unidimensional, by far a greater number of 
advocates support the idea that QOL is a multidimensional construct, requiring 
assessment of multiple domains (Guyatt, Veldhuyzen Van Zanten, Feeny, & Patrick, 
1989; Pagano & Gotay, 2006; Rejeski & Mihalko, 2001; Torrance, 1986). Again, as there 
is no consensus on the definition of QOL, it is also not clear which domains should be 
included in the assessment of QOL. In the early 1990s, Ferrans suggested the 
taxonomy of the conceptualisations of QOL and grouped it into 6 domains:(1) normal 
life, (2) social utility, (3) happiness/affect, (4) satisfaction with life, (5) achievement of 
personal goals, and (6) natural capacities (Ferrans, 1990). A number of different QOL 
domains such as work, civic rights, personal development have been since reported to 
be important aspects of QOL (Cummins, 1996; Meeberg, 1993; Shalock, 1996; Wilson & 
Cleary, 1995). In 1995, WHO QOL group set out to develop a cross-culturally valid QOL 
measure based on the data from 15 centres around the world (WHO, 1995). The group 
developed two measures, WHOQOL-100 and WHOQOL-BREF (26 item version), which 
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assess QOL across 6 dimensions: physical, environment, social relationships, 
psychological, spiritual, and level of independence. The WHOQOL-100 has been shown 
to be a valid measure across different countries and cultures in a number of conditions 
(WHO, 1998b). However, despite extensive collaboration of a large number of experts, 
WHO QOL Assessment has been criticised for having no justification of the choice of 
domains and omitting some of the domains such as material well-being or 
productivity/employment (Hagerty et al., 2001).   
No single list of QOL domains is exhaustive due to the individual nature of QOL.  
As a result, individualised QOL models have been suggested as exemplified by the 
Schedule for the Evaluation of Individualised Quality of Life (SEIQOL) (McGee, O'Boyle, 
Hickey, O'Malley, & Joyce, 1991). The patient is asked to identify five areas of their life 
and rate them using visual analogue scales. In the direct weighting version, the patient 
also rates the relative importance of each domain in the context of overall QOL. This 
gives a unique insight into how the important aspects of QOL, as determined by a 
patient, are affected by a disease or treatment. However, the use of individualised QOL 
instruments has been limited due to lack of standardisation and concerns that it 
measures individual domains of QOL rather than overall QOL (Moons, Marquet, Budts, & 
De Geest, 2004). 
1.3.4. Models of QOL 
The multidimensional nature and varied use of terms of QOL has led to the 
development of a great number of conceptual models of QOL (Bakas et al., 2012). A 
model, also referred to as a conceptual framework, is a schematic representation of 
theory explaining underlying phenomena and in this case QOL is represented by 
depicting interrelationships among concepts. A systematic review in 2004 identified 
three most commonly used models of QOL in the literature: Wilson and Cleary, Ferrans 
and colleagues, and World Health Organization International Classification of 
Functioning, Disability, and Health (WHO ICF) (Bakas et al., 2012). All of the models 
(described below) have a similar notion in that they are based on biomedical and 
psychosocial grounds. 
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1.3.4.1. Wilson and Cleary QOL model 
One of the first taxonomies of conceptualisations of QOL was proposed by 
Wilson and Cleary in 1995 (Wilson & Cleary, 1995). The model served as a basis for the 
majority of QOL models that were developed in a number of conditions. Wilson and 
Cleary structured the outcomes moving along the continuum of increasing complexity 
starting with biological parameters to symptomatology, functionality, general health 
perceptions and finally overall QOL. Authors suggested that each domain is related to 
the others and may also have reciprocal relationships. In addition, individual and 
environmental factors may influence the outcomes at any stage, affecting overall QOL, 
however authors did not define these two factors.  Health status and QOL were used 
interchangeably in the model, which are now accepted to be conceptually distinct. 
1.3.4.2. Ferrans QOL model 
Wilson and Cleary’s work formed the basis of the model devised by Ferrans 
and colleagues (Ferrans et al., 2005). The authors retained the five major domains, but 
simplified the model by removing the non-medical factors and the labels in arrows 
depicting the relationships (figure 3). Precise definitions for individual and 
environmental factors were suggested in the model. The authors further improved the 
theoretical background regarding the main concepts of the model. Ferrans et al. 
suggested examples of measurement tools and indicated that causal and reciprocal 
relationships may exist between the domains, but did not specify. In a systematic 
review of HRQOL models, Bakas et al. recommended the use of Ferrans and colleagues’ 
model as a guide for researchers formulating and testing hypothesis due to its clarity, 
improved definitions and sound theoretical basis (Bakas et al., 2012). 
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1.3.4.3. World Health Organisation health/QOL model 
World Health Organization International Classification of Functioning, Disability, 
and Health (WHO ICF) developed a universal model of health and health states for use 
across different cultures and disciplines (2001). The primary focus of WHO ICF is on 
health and related psychosocial aspects, which contrasts to an earlier WHO model 
proposed in 1980 focusing on impairment, disability and handicap (1980). WHO ICF 
conceptualised HRQOL as a person’s perception of health and health-related domains of 
well-being, hence the model focuses on health rather than overall QOL. It was 
suggested that WHO ICF serves more as a classification framework of health, disease 
and functioning, rather than a guide for hypothesis generation in QOL research (Bakas 
et al., 2012). 
1.3.5. QOL and response shift 
     Another important property of QOL is that it is a dynamic concept rather than a 
static phenomena (Rapkin & Schwartz, 2004); a patient's experience of a disease 
changes their expectations, hence their QOL changes too. The term 'response shift' has 
been introduced to describe the idea that the reference, by which people judge their 
QOL, changes as the disease progresses (Carr, Gibson, & Robinson, 2001). As a result, 
QOL constantly changes over time and is under the influence of a number of factors 
Figure 1. Ferrans QOL model(Ferrans, Zerwic, Wilbur, & Larson, 2005) 
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(Carr et al., 2001). For example, even in the clinical trial where QOL is measured at 
equal intervals, differences in patient's responses are very likely to be observed since 
the study participants follow individual disease trajectories (Rapkin & Schwartz, 2004). 
Hence QOL response shift could be understood as epiphenomenon: individual's rating of 
QOL can respond to treatment, disease progression and other life events in an atypical 
way, i.e. statistically different from the expected value hypothesised by an observer. The 
following driving forces of response shift are: (1) catalyst (e.g. diagnosis of disease), (2) 
antecedents (i.e. personal characteristics of the individual such as personality and 
expectations, (3) mechanisms (i.e. means of dealing with the impact of the disease, 
such as coping and adaptation abilities) (Burns, Graham, Rose, & Simmons, 2012). The 
implication of 'response shift' is particularly relevant in assessment of an intervention. 
The concern is that because of the 'response shift' it might be impossible to ascertain 
whether QOL instrument measures the attribute of interest (i.e. QOL) or the change of 
internal standards (Burns et al., 2012). 
1.3.6. QOL in MS 
QOL has been extensively studied in patients with MS (Baumstarck et al., 
2013b; Benito-Leon, Morales, Rivera-Navarro, & Mitchell, 2003; D. M. Miller & Allen, 
2010; Mitchell et al., 2005). Although QOL research is a relatively new field in MS with 
first papers appearing in the literature in the early 1990s, it has been a subject of 
intense scientific research ever since (Rudick, Miller, Clough, Gragg, & Farmer, 1992; 
Solari, 2005). This exponentially increasing interest is not without justification (figure 4). 
Due to the progressive and disabling nature of the disease, QOL in MS can be 
substantially reduced. Indeed, studies that compared QOL across a number of chronic 
conditions found that QOL in MS was worse than in inflammatory bowel disease, 
rheumatoid arthritis, psychotic disorders, epilepsy and diabetes (Chopra, Herrman, & 
Kennedy, 2008; Hermann et al., 1996; Rudick et al., 1992).  Benito-Leon et al.’s review 
on QOL in MS suggested five reasons why MS patients have particularly poor QOL: (1) 
MS causes a myriad of disabling neurological and neuropsychiatric impairments, which 
can have detrimental effect on virtually all aspects of daily living (2) patients with MS 
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are diagnosed at a young age, thus MS impacts the most productive years and is a 
source of anticipation of future disability (3) MS course is unpredictable and patients 
lose sense of control over their lives (4) there is currently no cure for MS (5) established 
treatments show little success, carry risks and are often inaccessible due to health 
inequalities (Benito-Leon et al., 2003).  In the absence of curative therapies, maximising 
QOL is the ultimate goal in the management of MS patients. In order to achieve this, it 
is important to understand what factors are influential to QOL in MS.   
Figure 2.  A number of publications per year on quality of life in multiple 
sclerosis in the Pubmed database. 
 
 
            1.3.6.1. Determinants of QOL in MS 
           Research has found that agreement is poor between patients and clinicians 
upon which factors influence QOL (Janse et al., 2004). Health care professionals often 
focus on physical aspects of patient care while patients prioritise psychological and 
social aspects (Rothwell, McDowell, Wong, & Dorman, 1997). This is also supported by 
findings in studies showing poor concordance between physical functioning and overall 
QOL (Ford, Gerry, Johnson, & Tennant, 2001; Rothwell et al., 1997). For example, in a 
study on progressive MS patients (n=29) O'Connor et al. found no correlations between 
overall QOL and EDSS, Multiple Sclerosis Functional Composite score and MRI lesion 
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load (O'Connor, Lee, Ng, Narayana, & Wolinsky, 2001).  These observations have led to 
the belief that factors other than physical ones must heavily influence overall QOL.  
              1.3.6.1.1. Neuropsychiatric dysfunction and mental health 
  Psychiatric disturbances have consistently been found to be one of the 
strongest predictors of QOL in MS (Mitchell et al., 2005). In a study by O'Connor et al. 
mentioned above, while no correlation was found between physical measures and QOL, 
emotional well-being and mental health were strongly related to overall QOL scores 
(O'Connor et al., 2001). Depression affects around half of patients with MS and has 
been found to negatively influence QOL (Amato, Ponziani, Rossi, et al., 2001; Chwastiak 
et al., 2002; Goksel Karatepe et al., 2011; Jones et al., 2012). Mitchell et al. suggested 
several ways by which depression affects QOL: (1) depression diminishes motivation, 
interest and concordance thus retarding physical performance, (2) depression occurs 
when all of the coping resources have been exhausted, thus is a good marker of deeper 
underlying problems, (3) patients with depression have a ‘distorted’ view of the world, 
thus their appraisal of QOL might make it look worse than it actually is (Mitchell et al., 
2005).  
Anxiety has also been identified as a risk factor for reduced QOL (Fruehwald, 
Loeffler-Stastka, Eher, Saletu, & Baumhackl, 2001). High levels of anxiety and 
psychological distress have been found to affect up to 40% of newly diagnosed patients 
(Janssens, van Doorn, de Boer, van der Meche, et al., 2003). A particularly troubling 
aspect of anxiety are fears of disease progression and disability (Mitchell et al., 2005). 
Kern et al. demonstrated that sub-syndromal psychiatric disturbances such as 
interpersonal sensitivity, paranoid ideation and obsessive-compulsiveness are 
particularly common and are associated with lower QOL irrespective of disability (Kern 
et al., 2009). In addition, psychiatric symptoms may also influence the way patients 
perceive the impact of neurological dysfunction. Janssens et al. found that depression 
and anxiety are important mediators of the impact of disability on QOL (Janssens, van 
Doorn, de Boer, Kalkers, et al., 2003). The study found that EDSS scores were 
significantly associated with reduced mental and physical domains of SF-36, however 
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after adjustment for anxiety and depression disability was not found to be a significant 
predictor for mental health and general health scales. 
Cognitive dysfunction is becoming an increasingly recognised complication of 
MS and has been linked to reduced QOL. The estimated prevalence of cognitive 
impairment in the MS population is 45-65% (Amato, Ponziani, Siracusa, & Sorbi, 2001; 
Rao, Leo, Bernardin, & Unverzagt, 1991). Cutajar et al. reported significant correlation 
between memory impairment, executive function and QOL (Cutajar et al., 2000). 
Benedict et al. showed that cognitive impairment is a significant predictor of QOL even 
after controlling for depression (Benito-Leon, Morales, & Rivera-Navarro, 2002). 
However, the relationship between QOL and cognitive impairment is not linear. Kenealy 
et al. demonstrated that patients with severe cognition dysfunction and 
autobiographical memory impairment have significantly better QOL than less severely 
affected individuals (Kenealy, Beaumont, Lintern, & Murrell, 2000). The authors 
suggested that the lack of insight is the most likely explanation for such observations. 
1.3.6.1.2. Psychosocial factors 
Factors that may be less clinically evident, such as coping and self-efficacy, 
have also been identified to be playing important roles in determining patient’s 
perception of their QOL (McCabe, Stokes, & McDonald, 2009; Motl, McAuley, Snook, & 
Gliottoni, 2009). Self-efficacy is a concept that describes an individual's belief in their 
ability to overcome challenges using innate abilities. Chronic progressive disorders such 
as MS pose an increasing number of challenges as the disease worsens, hence 
maintaining high levels of self-efficacy is crucially important. Self-efficacious individuals 
show greater improvements on physical and mental domains of QOL in response to 
treatment (Motl et al., 2009). Similarly, different coping styles have been shown to be 
important predictors of QOL (McCabe et al., 2009). For example, wishful thinking has 
been shown to be a strong predictor of poor QOL (McCabe & McKern, 2002). From the 
clinical perspective, identifying coping strategies and subjecting patients to 
psychological interventions, such as group therapy, can have positive effects on overall 
QOL (Tesar, Baumhackl, Kopp, & Gunther, 2003). 
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A person's abilities to cope and maintain high levels of self-efficacy are 
constantly under the influence of their environment, family, friends, health professionals 
etc. Hence, social support is a vital mediator of many of the factors that influence QOL 
(Fong, Finlayson, & Peacock, 2006). Indeed, an individual may enter a self-perpetuating 
cycle of poor social support leading to loss of coping and self-efficacy abilities, which in 
turn can increase social isolation and stigma. As a result, maintaining social networks 
through employment, education and hobbies is an imperative aspect of good QOL in 
patients with MS (Mitchell et al., 2005). 
1.3.6.1.3. Neurological impairments 
Physical symptoms and disability have been shown to reduce QOL in MS, but 
are weaker predictors of QOL compared to the neuropsychiatric and psychosocial 
factors described in the paragraphs above (Amato, Ponziani, Rossi, et al., 2001; 
Janssens, van Doorn, de Boer, Kalkers, et al., 2003). The most commonly reported 
symptoms in a population survey (n=2265) included: fatigue (96%), balance and 
dizziness (92%), loss of mobility (91%), sensory problems (88%), bladder problems 
(87%), loss of memory and concentration  (87%), spasticity (85%), vision problems 
(82%), pain (81%), bowel problems (74%), sexual dysfunction (70%), tremor (68%), 
speech and swallowing problems (68%) (Hemmett, Holmes, Barnes, & Russell, 2004). 
Despite the high prevalence of these symptoms and impairments, little is known about 
their effects on QOL. Since the majority of these symptoms coexist and are related to 
advancing levels of disability, it is difficult to ascertain their individual contribution in 
determining QOL. A common limitation of a number of studies is that only one or two 
impairments are accounted for in the regression analyses with QOL as a dependent 
factor, hence not addressing all of the possible contributors (Wynia, Middel, van Dijk, De 
Keyser, & Reijneveld, 2008).  
A number of studies have identified fatigue to be a significant predictive factor 
for a wide range of QOL domains after adjusting for confounders, such as disability and 
depression (Zwibel, 2009). Sleep disturbance has been found to be twice as common in 
patients with MS compared to the general population (62% vs. 32%) and have been 
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shown to be an independent predictor of QOL as measured by SF-36 (Lobentanz et al., 
2004). Pain is another important symptom of MS. MS-related pain can be 
musculoskeletal or central neuropathic in origin or may be related to spasms and 
trigeminal neuralgia (Khan & Pallant, 2007). Presence of pain has been linked to lower 
QOL, depression, sleep disturbance and work problems (Kalia & O'Connor, 2005). 
 Nortvedt et al. also reported that bowel, bladder and sexual dysfunction are 
associated with lower QOL (Nortvedt et al., 2001). Importantly, the authors emphasised 
that these problems are very common even at lower levels of disability (53%, n=6, 
EDSS<4).   
Although physical symptoms and impairments are less predictive of overall QOL 
compared to other factors such as coping, self-efficacy and depression, they are an 
important part of the MS patient's life due to their high prevalence and interference with 
function (Zwibel, 2009). In the absence of curative treatment, symptomatic 
management forms the basis of care for patients with MS. Finally, both physical and 
psychosocial factors influence QOL and may interact with each other, hence a 
biopsychosocial approach in the management of patients with MS should be employed. 
1.3.7. Effect of disease-modifying therapies on QOL in MS 
A number of clinical trials have evaluated disease-modifying therapies (DMT) 
using QOL measures (Benito-Leon et al., 2003). Until recent years, QOL instruments 
were either not employed in clinical trials or used only as secondary outcome measures 
(Benito-Leon et al., 2002). This has changed with the arrival of costly new therapies. 
QOL measures have played an important part in proving the cost-effectiveness of DMTs, 
this provides essential evidence for healthcare-related agencies such as the National 
Institute of Health and Clinical Excellence (NICE) in approving the use of new therapies. 
The results from studies investigating the effect of DMTs on QOL have been 
conflicting. A systematic review by Rudick et al. (2008) concluded that because of the 
differences in methodologies, rigor, interventions and study samples, drawing 
conclusions about the effect of DMTs on QOL was not possible (Rudick & Miller, 2008). 
Overall, the studies have reported improvement in QOL scores, however not always 
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with statistical significance. The strongest evidence for improving QOL in MS has been 
found in studies assessing the effectiveness of natalizumab. Two randomised placebo 
controlled trials (Natalizumab Safety and Efficacy in Relapsing-Remitting MS (AFFIRM) 
and Safety and Efficacy of Natalizumab in Comnination with Interferon-β-1 in Patients 
with Relapsing Remitting MS (SENTINEL)) showed significant improvements in physical 
and mental components on SF-36 irrespective of disease activity (Polman et al., 2006; 
Rudick et al., 2006). 
Less conclusive results have been reported in studies on interferon-β and 
glatiramer acetate therapies. The outcomes of these studies were greatly varied 
reporting significant improvements, no improvement at all, and even negative effects 
on QOL (Rudick & Miller, 2008). 
 1.3.8. Measuring QOL in MS 
'When you can measure what you are speaking about and express it in 
numbers, you know something about it – but when you cannot measure it in numbers 
your knowledge is of a meagre and unsatisfactory kind – it may be the beginning of 
knowledge but you have scarcely, in your thought, advanced to the stage of science 
whatever the matter may be' (Lord Kevin) 
Until recently, the mainstay outcome measures in MS research and clinical 
practice were based on laboratory tests, imaging, neurological examination and 
disability scores such as EDSS. Although these measures provide important information 
concerning patients’ disability status, disease activity and the likelihood of disease 
progression, limited information regarding impact of the disease on QOL can be obtain 
using these measures alone. For example, the EDSS is heavily weighted towards 
mobility and walking ability, but does not reflect many other important aspects of 
disease severity such as pain or vitality (Hemmett et al., 2004). Indeed, studies have 
shown that severity of disease is a poor predictor of QOL (Nortvedt, Riise, Myhr, & 
Nyland, 1999; O'Connor et al., 2001). Norveldt et al. compared SF-36 scores with EDSS 
and found that only physical functioning, social functioning and general health showed 
significant correlations, while the other QOL domains did not (Nortvedt et al., 1999).  In 
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addition to this, QOL measures may also help predict the rate of progression to 
disability irrespective of EDSS scores and MRI lesion load at baseline (Nortvedt, Riise, 
Myhr, & Nyland, 2000). Hence, QOL measures not only provide invaluable information 
about the impact of MS in a way that neurological examination and disability measures 
do not, but they may also serve as a predictor of disease progression. 
There are two general approaches to HRQOL assessment: health profiles and 
utility assessment (D. M. Miller & Allen, 2010). Health profiles, also known as health 
status measures, are multidimensional constructs, which consist of several subscales 
and are based on psychometric techniques. These are self-reported measures that are 
commonly used in clinical trials and clinical practice. Examples include SF-36 and MS 
Impact Scale-29 (MSIS-29). In comparison, utility measures are generic tools that are 
based on economic and decision theory and are reported as a summary score. EuroQol 
tools are examples of utility measures. They are useful in policy making and health care 
provision in assessing the costs and benefits of a medical intervention (Kattan, 2003). 
At the individual level they aid patients in making choices between treatments in light of 
profound costs and side effects.   
As a result of the wealth of research on QOL in MS a wide range of QOL 
measures have been developed. Two broad types of QOL measures exist: generic and 
specific. Generic tools refer to QOL measures that have been designed to assess QOL in 
any disease. They are useful in making standardised comparisons across conditions 
which can provide important information for developing health policies and service 
provision. Disease-specific QOL measures by definition are designed for use in a 
specific condition. They are intended to capture more subtle disease-specific aspects of 
QOL, which otherwise might not be reflected in generic tools. Disease-specific tools 
may be more reliable than generic tools, particularly when assessing clinical 
interventions which target specific aspects of the disease (Baumstarck et al., 2013a; 
Benito-Leon et al., 2003; D. M. Miller & Allen, 2010; Rudick & Miller, 2008). 
Table 6 contains the list of commonly used generic and disease-specific QOL 
tools in MS. By far the most widely used generic tool in the MS population is Short Form 
– 36 (SF-36). It is considered to be a measure of health status, rather than overall QOL 
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and has been validated in a number of conditions (Ware & Sherbourne, 1992). Several 
limitations of using SF-36 in MS have been reported, which include poor responsiveness, 
large floor and ceiling effects and problems with using summary scores (Hobart, 
Freeman, Lamping, Fitzpatrick, & Thompson, 2001). To address the weakness of the 
generic measures, a number of MS-specific QOL tools have been developed (table 6). 
One such example is MSQOL-54, which contains 18 MS-specific items added to SF-36 
(Vickrey, Hays, Harooni, Myers, & Ellison, 1995). More detailed description of QOL 
measures in MS is given in chapter 2.  
 
Table 6. Generic and MS-specific QOL instruments (Benito-Leon et al., 2003) 
Generic  MS-Specific 
Nottingham Health Profile  MSQOL-54 
Sickness Impact Profile Disability and Impact Profile 
SF-36/SF-12 Functional Assessment of MS 
Farmer Quality of Life Index Hamburg QOL Questionnaire in MS 
EuroQoL Leeds MS QOL 
Functional Status Questionnaire MS Impact Scale 
 QOL Index -MS version 
 Performance Scales 
 
            1.3.9. Psychometric properties of QOL assessment 
Validity refers to what extent a tool measures what it intends to measure. 
Hence, for a QOL measure to be valid it should be grounded on a sound conceptual 
basis and meet the robustness of the following psychometric criteria: reliability, internal 
and external validity and responsiveness.   
Reliability or internal consistency refers to what extent the set of items from the 
same domain are consistent in measuring the trait. The reliability coefficient is 
expressed as Cronbach's alpha, which should be higher than 0.7 in order for a measure 
to have sufficient reliability (Reynaldo & Santos, 1999). Test-retest reliability is another 
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property of the measure, which refers to what extent the responses of the scores 
remain consistent over a period of time. This requires a collection of data at baseline 
and usually after 2-4 weeks in order to calculate the degree to which the scores 
correlate, using Spearman's rho or Pearson's correlation coefficients.  
There are two properties of internal validity that should be taken into account 
when evaluating the validity of a measure. First, content validity is a non-statistical 
assessment of a measure involving critical analysis of the questionnaire contents. It 
addresses issues such as whether all of the themes of the domain are measured by the 
items and whether the items represent correct themes. Second, construct validity is a 
statistical analysis which examines the extent to which the theoretical framework of the 
questionnaire measures what it proposes to measure. Although there are many 
different statistical methods to investigate this, the underlying notion is the same which 
involves analysis of the relationships between responses to different items (Baumstarck 
et al., 2013a). Examples include exploratory and confirmatory factor analyses, Rasch 
method and computation of correlation coefficients. 
The extent to which two measures show agreement is called external validity.  
Convergent (also concurrent) validity refers to the relationship between different 
domains of the measure or other previously validated measure. When the questionnaire 
scores are compared with established 'gold standard' measures, such as clinical 
parameters, it is referred to as criterion validity. However, very often in QOL research 
there is no established 'gold standard' measure. 
Lastly, the responsiveness refers to measure’s ability in detecting a change of a 
trait under investigation, in this case person’s QOL. This is particularly important in 
clinical trials evaluating therapeutic efficacy. Despite the abundance of QOL measures in 
MS there is limited data on responsiveness of these measures (Baumstarck et al., 
2013a).  
1.3.10. Practical Considerations and Barriers of QOL assessments 
Despite the fact that patient-reported outcome measures of QOL provide 
invaluable information when assessing treatment effectiveness and disease impact, a 
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significant proportion of clinicians are reluctant to employ QOL instruments in day-to-
day practice (Solari, 2005). The barriers include: sceptical attitudes of clinicians toward 
QOL measurements, the lack of guidelines on interpreting clinically meaningful change 
and the absence of theoretical consensus regarding the definition of QOL (D. M. Miller 
& Allen, 2010). Practicalities of administering, processing, scoring, storing and retrieving 
data from QOL tools are also significant barriers to their acceptability in the already 
multifaceted clinical care of MS patients (Solari, 2005). While research has shown that 
length of the questionnaires seems not to be a burden for patients with MS, the 
complexities in structure of domains and scoring systems often discourage physicians 
from using them. Indeed, one survey on renal transplant physicians found that 55% 
would be willing to use QOL tools if they were more user-friendly (Lee et al., 2004). 
Despite this, QOL assessment helps clinicians to detect the disease aspects that 
would otherwise go unrecognised, provides a means of evaluating treatment 
effectiveness and facilitates physician-patient co-operation, therefore it is fundamental 
to ensure the widespread use of QOL assessment by improving its acceptability 
(Bandari, Vollmer, Khatri, & Tyry, 2010; Solari, 2005). Recent developments in 
technology and measurement science have led to innovative ways of administering QOL 
tools using computerised adaptive testing (CAT) (D. M. Miller & Allen, 2010). Questions 
of increasing difficulty are posed to respondents based on the item-response theory. 
This allows assessment of QOL with a high degree of precision using a minimum 
number of questions, which scores are automatically computed by the software. It is 
predicted that such developments in patient-reported outcome measures will help to 
incorporate more widely QOL assessment in care of MS patients (D. M. Miller & Allen, 
2010). 
            1.3.11. Conclusions 
In conclusion, QOL research is a rapidly evolving area of health and social 
sciences. QOL measurement plays a vital role in the assessment of health services and 
clinical interventions and guides policy makers in resource allocation. Nevertheless, 
there are a number of challenges that QOL research is faced with. The lack of a precise 
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definition, differences in conceptual frameworks and disagreement on how QOL should 
be assessed may hinder the future progress in QOL research in MS. 
Assessing QOL in patients with MS forms a fundamental part of today's clinical 
practice. QOL measures provide important information about the impact of disease, 
which might otherwise be overlooked using traditional outcome measures such as EDSS. 
QOL assessment is particularly important in MS as there is a considerable body of 
evidence to suggest that MS is associated with significant reduction across a wide range 
of QOL domains. Recognising that both physical and psychosocial factors may affect 
QOL is important in order to address these issues and improve QOL.    
           Spasticity is a common and disabling symptom in MS. Up to 85% of MS patients 
report symptoms of spasticity; management can be extremely challenging for health 
professionals and frustrating for patients. Although much is known about the impact of 
spasticity on disability and physical functioning, little literature exists on its effects on 
QOL despite spasticity being a more prevalent symptom compared to pain, vision, 
bladder, bowel and sexual problems in MS. In this chapter, the importance of QOL 
assessment in health care and understanding what factors influence self-perceived QOL 
was discussed. In the following chapter a systematic review discusses the evidence on 
the relationship between spasticity and QOL.   
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Chapter 2 - Literature Review 
2.1. Introduction  
Previous studies have emphasised that spasticity can adversely affect physical 
functioning in MS (discussed in Chapter 1), however few studies have investigated the 
effects of spasticity on QOL. The aim of this chapter is to systematically review the 
literature concerning the relationship between spasticity and QOL. Any adult 
neurological condition which may be characterised by presence of spasticity will be 
reviewed. Special attention will be paid to MS-related spasticity and its effects on QOL. 
2.2. Methods 
MEDLINE (1950 to 3 December 2013), CINAHL (1981 to 3 December 2013), 
Embase (1980 to December 2013) and PsychINFO (1950 to 3 December 2013) 
databases were searched for papers investigating the effects of spasticity on quality of 
life (see appendix 1 for detailed search strategy). Search terms included 'spast*' and 
'quality of life'. Inclusion criteria restricted selection of articles to those on adults with 
acquired neurological conditions (age>18 years), reporting both spasticity and QOL 
outcome measures and published in English. Studies on patients with infantile onset 
spasticity (less than 2 years), such as cerebral palsy, were excluded. Interventional trials 
investigating the effects of antispasticity agents which employed QOL tools as outcome 
measures were excluded from the review. Finally, the reference lists of the selected 
articles were reviewed to identify additional studies. 
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Studies on infantile onset  
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 Not in English Language 
Full-text articles 
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(n = 27) 
Full-text articles 
excluded, with 
reasons 
(n = 10) 
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No QOL measure (n=2) 
No spasticity measure (=2) 
QOL in carers (n=1) 
Interventional studies (n=3)  
Studies 
included in 
qualitative 
synthesis 
(n = 17) 
Figure 3. Literature search methodology 
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2.3. Results 
The search identified 551 articles. After excluding duplicates and applying 
inclusion criteria, 17 articles were selected for review. Most studies were cross-sectional 
or prospective (table 7). Although any neurological condition of adults met eligibility 
criteria, studies were only found in three chronic neurological conditions, specifically 
multiple sclerosis (MS) (n=5), stroke (n=6), and spinal cord injury (SCI) (n=6).  
 
2.3.1. Spasticity Assessment Tools 
Ashworth and modified Ashworth scales (MAS), which were used in 6 studies 
(35%). Six studies (35%) employed patient reported measures for spasticity. Visual 
analogue scales (VAS) and Numerical Rating Scales (NRS) were used in four studies. 
Westerkam et al. used a self-administered tool for assessing spasticity in patients with 
spinal cord injury called the Patient Reported Impact of Spasticity Measure (PRISM) 
(Westerkam et al., 2011). Two studies concurrently administered MAS and NRS (Arroyo, 
Massana, & Vila, 2013; Flachenecker et al., 2014). Rizzo et al. grouped patients into 
increasing degrees of spasticity severity using the Performance Scale Spasticity Subscale 
(Rizzo et al., 2004). In the remainder of the studies (n=7) spasticity assessment tools 
were not specified and spasticity was reported as present or absent. 
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Table 7. Summary of the studies 
Number of 
studies 
Type of 
study 
Conditions QOL 
measures 
Spasticity 
measures 
Studies that found 
significant effect of 
spasticity on HRQOL 
17 Cross-
sectional (13) 
 
Longitudinal 
(4)  
Stroke (6) 
 
 
MS (5) 
 
 
SCI (6) 
SF-36/12 (8) 
 
EQ-5D – (5) 
 
WHOQOL-
BREF (1) 
 
SIP (1) 
 
NHP (1) 
 
MSQoL-54 
(1) 
 
NRS (2) 
 
VAS (1) 
  
SSQOL (1) 
Ashworth 
scale/MAS (6) 
 
NRS/VAS (4) 
 
PRISM (1) 
 
Performance 
Scales (1) 
 
Unspecified (7) 
Stroke -2 (33%) 
 
 
MS - 5 (100%)  
 
 
SCI -5 (83%) 
 
2.3.2. Quality of Life Assessment tools 
A variety of QOL measures were employed in the studies. Most of the studies 
(n=15, 88.2%) administered health-related quality of life (HRQOL) measures. The three 
most widely used measures of HRQOL were Short Form-36 (SF-36), Short Form-12 (SF-
12) and EuroQol-5D (EQ-5D). SF-36 and SF-12 assess health status across eight 
domains (physical functioning, role-physical, bodily pain, general health, vitality, social 
functioning, role-emotional and mental health) (Ware & Sherbourne, 1992). Each 
dimension is rated between 0 and 100, with higher scores representing better HRQOL. 
Scores below 50 are interpreted as worse HRQOL compared to an age-matched general 
population. Summary scores for physical and mental components are derived from the 
eight domain scores. 
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Five studies administered EQ-5D, a commonly used health utility measure. EQ-
5D is a preference-based questionnaire which consists of a visual analogue scale (VAS) 
and a 5-dimension questionnaire which measures mobility, usual activities, self-care, 
pain/discomfort and anxiety/depression (Rabin & de Charro, 2001). 
The remainder of general QOL tools included the Sickness Impact Profile (SIP), 
Nottingham Health Profile (NHP), numerical rating scale (NRS)/visual analogue scale 
(VAS) and World Health Organisation Quality of Life – BREF (WHOQOL-BREF). The SIP 
assesses functional status across 6 domains which are grouped under physical, mental 
and social dimensions (Bergner, Bobbitt, Carter, & Gilson, 1981). The NHP comprises of 
38 items assessing health status across 6 dimensions: physical mobility, pain, social 
isolation, emotional reactions, energy, and sleep (O'Brien, Banner, Gibson, & Yacoub, 
1988). The WHOQOL-BREF consists of 26 items, which represent four broad domains of 
QOL (physical health, psychological well-being, social relationships and satisfaction with 
environment) (WHO, 1998a). It is considered a more global measure of QOL as it 
addresses the non-health related aspects such as social roles, relationships, spirituality, 
self-perceived well-being and satisfaction with life (Huang, Wu, & Frangakis, 2006). 
Two studies administered disease-specific tools. The Multiple Sclerosis Quality 
of Life-54 (MSQoL-54) questionnaire was developed to measure HRQOL in MS. MSQoL-
54 is based on SF-36 and contains additional MS-specific items on bowel, bladder, 
cognitive function and health distress (Vickrey et al., 1995). The Stroke Specific Quality 
of Life (SSQOL) questionnaire consists of 49 items that examine 12 domains of HRQOL 
including energy, family roles, language, mobility, mood, personality, self-care, social 
roles, thinking, vision, upper-extremity function and work productivity (Williams, 
Weinberger, Harris, Clark, & Biller, 1999). 
2.3.3. Spasticity and Quality of Life in Multiple Sclerosis 
Five cross-sectional studies investigated the relationship between spasticity and 
HRQOL in MS, all of which found spasticity to be associated with lower HRQOL (Table 
8). The two largest studies, conducted in North America, estimated spasticity either 
through patient grading using Performance Scales spasticity subscale or by unspecified 
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questions in a telephone interview and found that patients with spasticity had 
considerably worse scores on physical components measured by SF-36/SF-12 and only 
slightly worse scores on the mental component (Rizzo et al., 2004; Wu, Minden, 
Hoaglin, Hadden, & Frankel, 2007) (table 9). Multicentre cross-sectional studies in 
Europe (Spain, Germany, Sweden) reported that increasing levels of spasticity 
(measured by self-reported NRS) were associated with parallel decrease in scores on 
SF-12, EQ-5D and MSQoL-54 (Arroyo et al., 2013; Flachenecker et al., 2014; Svensson 
et al., 2014). Arroyo et al. (n=419) reported that spasticity, assessed by either MAS and 
NRS, affected certain aspects of HRQOL, namely general health, physical functioning, 
physical role and vitality as measured by SF-36 (Arroyo et al., 2013). 
 
Table 8. Summary of the studies investigating effects of spasticity on QOL in MS. 
Author Design Sample Spasticity 
tool 
QOL 
measure 
Comments 
Rizzo et al. 
(2004), USA 
Cross-
sectional 
n=20969, NARCOMS registry. 4 
groups of patients with increasing 
degrees of spasticity. Demographic 
factors associated with severe 
spasticity were: older age, male, 
education, unemployed, longer 
period since diagnosis.   
Performance 
Scales 
(spasticity 
subscale) 
SF-36 Patients without spasticity 
scored 47.4 on PCS ad 52.1 
on PCS. Patients with severe-
total spasticity scored 28.7 
on PCS and 45.8 on MCS. 
 
Arroyo et al. 
(2013), Spain 
Cross-
sectional 
n=419, multicentre study. Mean age 
46.4 (SD 11), 62.4% female, 71% 
on antispasticty treatment, 43.9 % 
SP, 42.1%RR. Sociodemographic 
factors associated with severe 
spasticity: aged between 45-65, 
longer course of MS, secondary 
progressive, urinary dysfunction, 
living alone. 
NRS – patient 
MAS 
SF-12 Compared to general 
population PCS and MCS 
scores were 31 (9.3) and 
45.4 (12). Correlation 
between spasticity and QOL 
weak to moderate (r=-0.2 to 
-0.5). Patients with lower 
QOL scores were older, no 
education, SP, confined to 
bed, urinary dysfunction 
Flachenecker 
et al. (2013), 
Germany 
Cross-
sectional 
n=414, multicentre. Mean age 48.6 
(9.6), 64.3% female, 44.7% RR, 
44.4% SP, median EDSS score 5.5, 
disability worsened with spasticity 
severity,  
NRS- patient 
NRS- 
physician 
EQ-5D 
MSQoL-
54 
Patients with mild spasticity 
scored 0.6 (0.2) on EQ-5D, 
while patients with severe 
spasticity 0.3 (0.3). Similar 
trends on MSQoL-54. 
Patients with spasticity were 
more disabled, had more 
fatigue, sleep dysfunction 
and pain. 
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Svensson et 
al. (2014), 
Sweden 
Cross-
sectional 
n=105, 68%female, mean age 58 
(11), MS duration  24 (12), 64% SP, 
Average NRS score 4. 
NRS- patient EQ-5D QOL scores expressed as 
QALY and VAS. Patients with 
mild spasticity scored 0.54 
(0.3) and 58.4 (20.6) 
respectively. Patients with 
severe spasticity scored 0.37 
(0.4) and 49.9 (22.3).  
Wu et 
al.(2007), USA 
Cross-
sectional 
n=2109, data collected computer 
assisted telephone interview, 77% 
female, 38% age 45-55 
Unspecified SF-12 PCS scores significantly lower 
in spasticity group 32.10 
(0.29) than without spasticity 
43.01 (0.43). MCS scores are 
lower in spasticity group 
47.85 (0.34) than without 
spasticity 50.56 (0.39). 
 
Several clinical factors were found to increase the likelihood of experiencing 
severe spasticity in MS (Arroyo et al., 2013; Rizzo et al., 2004). These included older 
age, longer duration of MS, secondary progressive type of MS, pain, fatigue, sleep 
problems, urinary dysfunction and increasing disability. However, none of the studies 
accounted for these confounders when comparing HRQOL scores. Only one study by 
Svensson et al. (n=105), assessing the costs and HRQOL in MS-related spasticity, 
reported spasticity to be a significant predictor of EQ-5D scores irrespective of 
Expanded Disability Status Scale (EDSS) scores using linear regression analysis 
(Svensson et al., 2014). 
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Table 9. Effects of spasticity on physical and mental domains in MS. 
 Sample size Condition Cohorts Physical Mental 
Compone
nt 
 
Measure  
Rizzo et al.  20969 MS Severe/Total 
spasticity 
 
 
No spasticity 
 
 
28.7 
 
 
 
47.4 
45.8 
 
 
 
52.1 
SF-36  
Wu et al.  2109 MS Spasticity 
 
No spasticity 
32.1 
 
43.1 
47.85 
 
50.56 
SF-12 
Flacheneck
er et al. 
419 MS Mild  
 
Severe  
54.9 
 
39.5 
59.6 
 
48.7 
MSQoL-54 
 
           2.3.4. Spasticity and Quality of Life in Spinal Cord Injury 
Five cross-sectional studies and one longitudinal prospective study reported the 
effects of spasticity on QOL in adults who have suffered a spinal cord injury (SCI) (table 
10). Spasticity was found to be associated with significantly worse physical 
components, but not always with mental domains. Westgren et al. (n=320) found all of 
the domains on SF-36 to be significantly lower in patients with spasticity compared to 
the rest of the cohort (Westgren & Levi, 1998). However, only patients who rated their 
spasticity as ‘problematic’ were included in the spasticity group (n=33) (Westgren & 
Levi, 1998). Post et al. (n=318) reported that patients with spasms scored significantly 
lower on physical and social, but not mental domains on SIP (Post, de Witte, van 
Asbeck, van Dijk, & Schrijvers, 1998).  Vogel et al. in a study on adults with paediatric-
onset SCI found SF-12 scores to be significantly lower in patients with spasticity (Vogel, 
Krajci, & Anderson, 2002). Singh et al. (n=50) in a study on QOL determinants at 6 
months post-injury found spasticity was associated with significantly lower QOL (VAS) 
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(Singh, Dhankar, & Rohilla, 2008). All of the studies reported that other impairments 
experienced by the patients including bladder, bowel, pain and respiratory problems 
were significantly associated with worse HRQOL.  
Table 10. Summary of the studies investigating effects of spasticity on QOL in SCI.  
Author Design Sample Spasticity 
tool 
QOL 
measure 
Comments 
Westgren et 
al.(1998), 
Sweden 
Cross-
sectional 
n=353, mean 
age 42, 261 
male, 124 
tetraplegic, 176 
paraplegic. 
Unspecified 
 
SF-36 33 patients defined as problematic 
spasticity compared against the rest 
of the cohort. Scores were 
significantly lower in all the domains.  
Younger age at injury unemployment, 
bladder problems , bowel problems 
were associated with significantly 
lower scores.  
Westerkam 
et al. (2011), 
USA 
Cross-
sectional 
n=1549, mean 
age 45.1, 
average age at 
injury 32.5, 
PRISM 
NRS 
Life Situation 
Questionnaire- 
Revised 
NRS QOL 
Regression analysis showed spasticity 
was associated with home, 
vocational, global satisfaction and 
overall QOL.  
Noonan et al. 
(2008), USA 
Cross-
sectional 
n=70, age at 
injury 45(18), 
age at follow up 
51 (18), female 
19% 
Unspecified SF-36 
NRS overall QOL 
(from QLQ-C30) 
Stepwise regression analysis showed 
spasticity is not a significant predictor 
of SF-36 scores after adjusting for 
confounders such as motor 
impairment, bladder, bowel and 
sexual dysfunction.  
Post et al. 
(1998), 
Netherlands 
Cross-
sectional 
n=318, mean 
age 39.4 (12.5), 
mean time after 
injury 3.6 (1.9) 
years,  
Unspecified SIP 
Life Satisfaction 
Questionnaire 
Spasms were associated significantly 
lower physical and social domains 
and life satisfaction, but not 
psychological domain. Other 
significant factors were pain, 
respiratory problems, urinary tract 
infections, but these were not 
accounted.  
Vogel et al. 
(2002), USA 
Cross-
sectional 
n=216, mean 
age 29, mean 
age at injury 14, 
patients with 
paediatric-onset 
SCI 
Unspecified SF-12 
Satisfaction with 
Life Scale 
Spasticity was associated with lower 
SF-12 scores but not with life 
satisfaction.  Pressure sores and UTI 
were associated with lower HRQOL 
and life satisfaction.  
Singh et al. 
(2007), India 
Longitudinal 
prospective (6 
months) 
n=50, mean age 
at injury 
34.23(15), mean 
age 37 (15), 
Male 36% 
Unspecified VAS 60%reported spasticity. It was 
significantly associated with lower 
QOL score. Bowel, urinary problems 
and pain also significantly lowered 
QOL. No adjustments to confounders 
were made.   
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Two studies examined the relationship between spasticity, associated symptoms 
and QOL. In a large study (n=1549) by Westerkam et al. spasticity was a significant 
predictor of overall QOL (measured by NRS) and life satisfaction (home, vocational, 
global satisfaction measured by Life Situation Questionnaire) after adjusting for 
sociodemographic variables (age, sex, marital status, employment and time since 
diagnosis) (Westerkam et al., 2011). In a study by Noonan et al. (n=70), although 
spasticity was a significant predictor of physical component scores (SF-36) after 
adjusting for sociodemographic confounders, spasticity became an insignificant 
predictor once other confounders (bowel, bladder, sexual dysfunction and motor 
impairment) were taken into account (Noonan, Kopec, Zhang, & Dvorak, 2008).  
2.3.5. Spasticity and Quality of Life in Stroke 
Six studies (4 longitudinal, 2 cross-sectional) reported conflicting results on the 
relationship between spasticity and QOL in stroke survivors. In a large study (n=460) by 
Gillard et al., the investigators measured HRQOL at 3 months, 1 year and 2 years after 
stroke using SF-12, EQ-5D, and SSQOL (Gillard, 2005). Gillard et al. reported that 
patients with spasticity scored consistently lower on all the three outcome measures at 
every follow-up. Similar findings were reported in a study of 211 patients by Urban et 
al. (Urban et al., 2010). Patients with spasticity had significantly lower EQ-5D scores 
compared to the cohort without spasticity at 6 months after stroke (Urban et al., 2010). 
In addition, patients with spasticity had worse Barthel Index scores, indicating greater 
problems with activities of daily living.  
Four studies found no significant relationship between spasticity and QOL. 
Wissel et al. (n=103) found that stroke survivors with spasticity (measured with MAS) 
had significantly lower scores on EQ-5D immediately after stroke (6 days), but not at 16 
weeks of follow up (60.3 vs. 80.6, p=0.07), although disability levels measured by 
Barthel Index were significantly worse in the spasticity group at both baseline and 
follow up (Wissel et al., 2010). Welmer et al. (n=66) reported that patients with post-
stroke spasticity (n=13) had significantly worse scores on the physical functioning 
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subscale of SF-36, but not on the remainder of the subscales (Welmer, von Arbin, 
Widen Holmqvist, & Sommerfeld, 2006).  Dajpratham et al. in a multicentre cross-
sectional study (n=327) in Thailand found no difference on WHOQOL-BREF scores 
(Dajpratham, Kuptniratsaikul, Kovindha, Kuptniratsaikul, & Dejnuntarat, 2009). Similarly, 
Ones et al. (n=88) found no significant correlation between NHP scores and spasticity 
(r=-0.12, p>0.05) (Ones, Yilmaz, Cetinkaya, & Caglar, 2005).  
Table 11. Summary of the studies investigating effect of spasticity on QOL in stroke 
Author Design Sample Spasticity 
tool 
QOL tool Comments 
Wissel et al. 
(2010), 
Germany  
Longitudinal 
Prospective (16 
weeks) 
n=103, mean age 69 
(35-96), female 38%, 
86% ischaemic 
stroke  
MAS EQ-5D 24.35% developed spasticity at 
baseline. Patients with spasticity 
scored significantly lower on EQ-5D 
than patients without spasticity. At 
16 weeks 21.4 % had spasticity, no 
significant effect on HRQOL.  
Urban et al. 
(2010), 
Germany 
Longitudinal 
prospective (6 
months) 
n=211, mean age 
68(13), male 62% 
MAS EQ-5D 75 patients developed spasticity. EQ-
5D was significantly lower in patients 
with spasticity compared to cohort 
without spasticity (53.6 vs 
80,p<0.001). Patients with spasticity 
had lower Barthel scores.  
 
Welmer et 
al.(2006), 
Sweden 
Longitudinal 
Prospective (3, 
18 month follow 
up) 
n=66, 13 developed 
spasticity, 
MAS SF-36 Only physical functioning scores were 
significantly lower in spasticity 
cohort. Spasticity group also had 
higher levels of disability measured 
by Barthel. 
Dajpratham et 
al. (2009), 
Thailand 
Cross-sectional n=327, mean age 
62.2 (12), 193 males, 
spasticity 41.6%.  
MAS WHOQOL-
BREF 
No difference across QOL scores was 
found between patients with 
spasticity and without spasticity.  
Gillard et 
al.(2012), USA 
Longitudinal 
prospective (3 
months, 1year 
and 2 years) 
n=460, mean age 
66, 49% female, 
Unspecified SF-12 
EQ-5D 
SSQOL 
Significantly lower scores in all 3 QOL 
measures in 54 patients with 
spasticity compared to controls.  
Ones et al. 
(2005), 
Turkey 
Cross-sectional n=88, mean age 
62.9(11.4), male 
56.8%, proportion of 
patients with 
spasticity not 
reported 
Ashworth 
scale 
NHP No correlation was found between 
spasticity and QOL (r=-0.12, p>0.05) 
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              2.4. Discussion 
This review presented the current evidence on the relationship between 
spasticity and QOL in three neurological conditions: MS, SCI and stroke. Although 
generalisation of the results should be interpreted with caution due to different 
methodologies, study designs, outcome measures and participants, it appears that 
spasticity is associated with lower HRQOL. 
Physical components of HRQOL were more affected by increasing levels of 
spasticity compared to mental components.  This is in keeping with previous studies on 
spasticity and its effects on physical functioning and disability, and supports the 
contention that these HRQOL measures reflect health status (Arroyo et al., 2011; Oreja-
Guevara, 2011; Sommerfeld, Eek, Svensson, Holmqvist, & von Arbin, 2004). Several 
studies reported mental components of SF-12 and SF-36 to be negatively correlated 
with spasticity, which illustrates a relationship between increasing spasticity and 
worsened psychological well-being (Gillard, 2005; Post et al., 1998; Wu et al., 2007).  
Wider implications of spasticity on family, work and social functioning are less 
clear. Studies that administered more global measures of QOL such as WHOQOL-BREF, 
rather than measures of health status, found no significant relationship between 
spasticity and QOL (Dajpratham et al., 2009; Noonan et al., 2008). In a qualitative study 
on SCI patients with spasticity, Mahoney et al. found that subjects adjust to having 
spasticity and learn how to control it (Mahoney et al., 2007). Some subjects utilised 
spasticity to counteract the weakness and improve posture and transfers. These 
observations may explain a lack of impact of spasticity on overall QOL in the selected 
studies. However, the results from two qualitative studies on spasticity in MS indicated 
that spasticity has detrimental effects on a variety of aspects of life, and not exclusively 
physical health (Morley, Tod, Cramp, & Mawson, 2013; Nicolson & Anderson, 2001). 
Morley et al. performed semi-structured interviews with 12 patients with MS-related 
spasticity and found that spasticity adversely affected not only physical aspects of 
health, but also relationships, self-esteem, employment, goal-setting and future 
planning. Some subjects reported that spasticity contributed to anxiety and depression. 
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Unpredictability of spasticity was found to cause embarrassment and loss of sense of 
control of subjects' lives. Similar observations were reported by Nicolson et al. in a 
qualitative study, which involved three focus groups consisting of patients with MS-
related spasticity. The authors confirmed that spasticity can have deleterious effects on 
patients' social roles, mental health and physical function. Future studies are needed to 
investigate broader effects of spasticity in multiple sclerosis using quantitative methods 
to test hypotheses generated in the qualitative studies. 
The relationship between spasticity and HRQOL appears to be weakest in the 
stroke population, with only two out of six studies reporting significant difference 
(Gillard, 2005; Urban et al., 2010). Although the results should be interpreted with 
caution due to variable methodology and sample sizes, it could be hypothesised that 
spasticity does not have a major impact on HRQOL in stroke patients, and other factors 
may play a more important role.  
2.4.1. Weaknesses of the studies 
The major limitation of the studies is the failure to control for confounding 
factors. Studies on  MS reported that spasticity is commonly associated with various 
sociodemographic variables (age, employment status, education, living alone) and 
disease-related variables (longer course of duration, secondary progressive MS, higher 
EDSS score, pain, bladder dysfunction, sleep problems, fatigue) (Arroyo et al., 2013; 
Flachenecker et al., 2014; Rizzo et al., 2004). Unfortunately, only one study accounted 
for EDSS score, and found that spasticity is a significant predictor of HRQOL irrespective 
of the levels of disability (Svensson et al., 2014). 
Two studies on SCI patients found that spasticity was a predictor of HRQOL 
after accounting for sociodemographic variables and time since injury (Noonan et al., 
2008; Westerkam et al., 2011). However, once other SCI-associated conditions were 
taken into account (pain, bowel, sexual dysfunction and motor impairment), spasticity 
was found to be an insignificant predictor of HRQOL. Although the authors concluded 
that spasticity is not a significant determinant of HRQOL, it may be that spasticity might 
indirectly influence HRQOL as it may worsen symptoms of pain, interfere with sexual 
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function and cause more disability. In addition, the authors did not administer specific 
measures for these variables, but used dichotomous values instead (presence/absence 
of a symptom). The interrelationships between different variables would need further 
confirmation using appropriate measures by employing more sophisticated statistical 
techniques such as structural equation modelling. 
          2.4.2. Conceptual issues in QOL assessment 
          Fifteen out of seventeen studies in this review used health status measures 
including SF-12, SF-36, SIP and utility measure EQ-5D, all of which are heavily weighted 
towards physical functioning. Not surprisingly, all of these measures correlated closely 
with spasticity as expected from the data on studies investigating the effects of 
spasticity on disability (Arroyo et al., 2011; Lundstrom, Terent, & Borg, 2008; 
Sommerfeld et al., 2004). 
It is important to make a distinction between HRQOL and overall QOL, a subject 
briefly discussed in Chapter 1, Quality of Life section. HRQOL is a narrower entity of 
global QOL, which only encompasses the domains that are directly affected by disease 
or treatment (Schipper et al., 1996). As a result, HRQOL excludes other aspects of life 
such as cultural, political or societal (Ferrans et al., 2005). However, Ferrans et al. 
argued that in patients with chronic conditions virtually every aspect of life can be 
affected, hence the concept of HRQOL is insufficient to address all potential effects of a 
condition (Ferrans, 2007; Ferrans et al., 2005). 
 It is noteworthy that measures such as SF-36 and SIP, although employed to 
measure QOL in the selected studies, have been shown to measure different constructs 
of QOL (Huang et al., 2006; K. W. Smith, Avis, & Assmann, 1999). For example, a large 
study (n=11,440) by Huang et al. investigated the psychometric properties of the SF-36 
and WHOQOL-BREF and concluded that the SF-36 measures HRQOL whereas WHOQOL-
BREF measures global QOL (Huang et al., 2006).  The findings are consistent with 
widely accepted models of QOL, such as Wilson and Cleary and Ferrans, in which SF-36 
is a measure of health perception and not overall QOL (Ferrans et al., 2005; Wilson & 
Cleary, 1995). To avoid the conceptual confusion, the authors of the proposed models 
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urged researchers to clearly define their study outcomes, however the terms QOL and 
HRQOL were used interchangeably in the published studies and none of the studies 
explicitly provided the definition of QOL. 
As discussed in Chapter 1, the relationship between self-perceived QOL and health 
status is not straightforward, i.e. a person with poor health might not necessarily report 
poor QOL, and equally not all persons with excellent health have good QOL. In a study 
of 493 patients with cancer, Covinsky et al. found that 43% of the most severely 
disabled rated their global QOL as good or better, while a significant 15% of those with 
the best physical function rated their QOL as fair or poor (Covinsky et al., 1999). Smith 
et al. performed path analysis on 12 studies that employed health status and overall 
QOL measures and found that health status is influenced more by physical functioning, 
while overall QOL by emotional well-being (K. W. Smith et al., 1999). It is evident that 
measures of health status and overall QOL are distinct and measure different 
constructs.   
Ferrans et al. argued that the dis-concordance between health perception and 
overall QOL is explained by the interaction of life satisfaction and individual and 
environmental factors (Ferrans, 2007). Since a person's evaluation of QOL is based on 
the system of internal standards which are under the influence of individual and 
environmental factors, self-perception of QOL might differ independently from health 
status. However, from the studies reviewed here it is impossible to conclude how 
spasticity affects overall QOL, since health status measures, rather than overall QOL 
tools, were employed.  
Only two studies employed a disease-specific measure of HRQOL (Stroke 
Specific Quality of Life and MSQoL-54). Generic QOL instruments are useful for 
comparing QOL across different conditions, but they might be insensitive to minor 
changes in specific conditions (Baumstarck et al., 2012; Benito-Leon et al., 2003). For 
example, there is some evidence to suggest that SF-36 might not be appropriate in the 
MS population, due to its significant floor and ceiling effect (Hobart et al., 2001).  
Disease specific measures of QOL are generally accepted as more advantageous 
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because they enable researchers to capture subtle and unique effects of a particular 
condition on QOL, which otherwise might be overlooked by generic measures (Benito-
Leon et al., 2003). There is a possibility that some of the studies failed to find a 
correlation between spasticity and QOL because of the limitations of using generic 
scales rather than disease specific scales. 
2.4.3. Problems with spasticity assessment 
Seven studies did not specify the measures of spasticity, and reported only its 
presence or absence. Clearly, there is a wide spectrum of severity of spasticity, hence 
dichotomous categorisation of spasticity might not be valid. For instance, Westgren et 
al. classed patients to have spasticity only if they reported it to be ‘problematic’, which 
only comprised 10% of the subjects, while estimated prevalence of spasticity in SCI is 
~50% (Singh et al., 2008; Westgren & Levi, 1998). 
The Ashworth scale was the most commonly employed measure for spasticity (6 
studies). However, as discussed in Chapter 1 there is a growing body of evidence to 
disregard it as a valid tool for assessment of spasticity (Burridge et al., 2005; Fleuren et 
al., 2010; Pandyan et al., 1999). Hence, the relationship between spasticity and QOL 
needs to be re-examined using appropriate measures for spasticity. 
2.4.4. Limitations of the review 
The main limitation of this review is that only observational studies, mostly 
cross-sectional in nature, were included. Consequently, it is impossible to determine a 
causal relationship between spasticity and QOL. In addition, outcome measures for 
spasticity and QOL reported in the studies were frequently inadequate as both of these 
concepts are complex and multifaceted. 
               Another limitation of the review is that only limited data could be extracted 
from the studies. For instance, only three out of seven studies that used SF-36 reported 
the individual domain scores. For future work, reporting individual subscale scores 
would provide better insight into which areas of QOL are most affected by spasticity. 
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Lastly, a meta-analysis was not possible for this review because of different 
methodologies, participants and outcome measures. 
2.5. Conclusions 
Spasticity appears to be an important factor in determining HRQOL in MS and 
SCI, but is less significant in the stroke population. Physical components are more 
affected by spasticity than mental domains. It is currently not known whether spasticity 
affects QOL directly or mediates via associated conditions such as fatigue, depression, 
anxiety, pain etc.  Based on the findings of the studies, no clear conclusions could be 
made regarding effects of spasticity on overall QOL, since the studies employed health 
status measures. In conclusion, due to the methodological flaws regarding both 
spasticity and QOL assessment, the relationship between spasticity and QOL requires 
further investigation.  
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Chapter 3 - Methodology 
3.1. Hypotheses 
1.  Spasticity is associated with worse overall QOL.  
2. There is a positive relationship between spasticity and the following MS-associated 
conditions: pain, bladder, sleep, fatigue, disability, anxiety and depression.  
3.2. Aims 
To achieve the answers to the above hypotheses, this thesis aims to: 
1. To investigate the relationship between spasticity and overall QOL using patient-
reported outcome measures for spasticity (MS Spasticity Scale-88) and two QOL 
measures: overall QOL measure (WHOQOL-BREF) and MS-specific measure (Leeds 
MS QoL Scale) 
 
2.  To determine whether spasticity is an independent predictor of QOL after 
adjusting for confounding factors using multiple linear regression model. 
 
3.  To investigate the relationship between spasticity and pain, bladder, sleep, 
fatigue, disability, anxiety and depression using robust patient-reported measures.  
3.3. Overview and study design 
The present study forms a pilot phase of the larger study entitled 'Trajectories of 
Outcome in Neurological Conditions (TONiC)’. TONiC is a UK based multicentre 
observational study investigating the factors influential to QOL in MS and motor 
neurone disease. Brief descriptions of qualitative, cross-sectional and longitudinal stages 
of the TONiC study are given below. 
3.4. Study phases  
3.4.1. Phase 1 – Qualitative stage  
A total of 78 participants took part in the focus groups and interviews. 8 focus 
group sessions were carried out to identify the main themes underpinning the concepts 
of QOL in MS. Following this, in-depth, semi-structured interviews were conducted by a 
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PhD student (HA) using an inductive approach. In an inductive approach, the themes 
obtained from the interview are data driven, which means that themes are not fitted 
into pre-existing theoretical models, but coded based on the data (Boyatzis, 1998). 43 
participants (mean age 52 yrs (range 20-75 yrs), 16 males (37%), EDSS range 0-9.5, 
illness duration 15 years (range = 5months – 45 years)) took part in this study phase, 
representing 4 different types of MS: 14 RRMS, 13 PPMS, 14 SPMS and 5 REMS. The 
aim of phase 1 was to explore the factors expressed by participants as being influential 
to their QOL. 
In preparation for the qualitative stage of the study, a literature search was 
performed to identify the scales that measure these factors. A preliminary version of the 
questionnaire pack was piloted on 11 participants through a process of cognitive debrief. 
Patients were given 2 weeks to fill out the questionnaires and were contacted by the 
research assistants (NR, CP) to give feedback on the content, layout, appropriateness 
and length. The feedback from the patients led to a number of revisions and the 
finalised pack was produced to be used for phase 3. 
3.4.2. Phase 2 – Documentation of demographic information 
The aim of phase 2 of the study was to record the demographic information of the 
participants. The following parameters were documented:   
1. Age and sex 
2. Date of diagnosis 
3. Type of MS  
 Relapsing-remitting MS 
 Secondary progressive MS 
 Primary progressive MS 
 Rapidly evolving MS – 2 or more disabling relapses in 1 year (if MRI has 
been repeated it should show 1 or more gadolinium enhancing lesions 
on the brain or a significant increase in T2 lesion load as compared with 
previous recent MRI) 
4. Disease-modifying therapy 
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5. Contact preference (email, phone call, post)  
6. Clinician-rated prediction of patient’s QOL over the next year (1-improve, 2-
stay stable, 3-worse, 4 – no opinion) 
7. Patient’s preference for method of completion (postal or online questionnaire). 
 The rationale for recording this information was to identify the factors associated 
with an increased likelihood of withdrawal from the study, thus addressing the problem 
of selection bias.  
3.4.3. Phase 3 – Questionnaire Administration 
The main centre for recruitment was the Walton NHS Foundation Trust. Two other 
sites (Royal Preston Hospital and Salford Royal Hospital) also took part in the pilot of 
phase 3. During this phase, questionnaires were administered to the patients that had 
given phase 2 and 3 consents. The data obtained from the pilot study was used for the 
statistical analysis in this thesis.  
3.4.4. Phase 4 – Longitudinal Phase 
Participants diagnosed with MS <1 year will be invited to participate in phase 4 of 
the study. Patients taking part in the longitudinal phase will receive the questionnaire 
pack at 6 months following the first questionnaire and then yearly for the next 5 years. 
In order to address the burden of a large volume of questionnaires, a shortened version 
of the pack will be administered to the prospective cohort. This will be achieved through 
item reduction of the newly designed scales using Rasch analysis of the data collected 
during the pilot phase. The aim of the longitudinal study is to assess the change of 
various parameters over time and investigate their impact on overall QOL.   
3.5. Ethical approval 
Ethical approval was granted in full by the National Research Ethics Service 
Northwest committee in November 2011 (reference no 11/NW/0743). Local Research 
and Development approval was obtained from the Walton NHS foundation Trust. The 
study was conducted in accordance with the substantial amendment 4, which was 
approved in November 2013 after final modifications were made to the questionnaire 
packs before administration. 
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3.6. Study Population 
Patients with a diagnosis of MS that fulfilled McDonald or Poser diagnostic criteria 
were invited to take part in the study. 
3.6.1. Principal Inclusion Criteria 
1. Diagnosis of MS. 
2. Adults 
3. Capable of answering questionnaires with or without assistance. 
4. Capable of providing informed consent. 
5. Patients diagnosed >1 year ago were included in the cross-sectional phase of 
the study (phase 3). For longitudinal study (phase 4) patients were recruited only if the 
diagnosis was made <1 year. 
3.6.2. Principal Exclusion Criteria: 
1. Patients that have not fulfilled McDonald or Poser diagnostic criteria (e.g. 
clinically isolated syndrome) 
2. Patients with other demyelinating disorders of the CNS (e.g. neuromyelitis 
optica) 
3. Concomitant serious medical or psychiatric condition 
4. Not capable of informed consent 
5. Not capable of answering the questionnaires (severe cognitive impairment, 
language barriers) 
3.7. Patient Recruitment Procedure 
Patient recruitment was commenced in Jan 2012 at the Walton NHS Foundation 
Trust. The patients were approached by a healthcare professional (neurologist, nurse, 
physiotherapist) or one of the members of the TONiC research team (NR, HA, CR, KM) 
in the outpatient clinics. 
As part of the recruitment process, patients were given a short overview of the 
rationale, aims and risks of the study supplemented with a patient information leaflet 
(PIL).  To ensure that the patients do not feel pressured to take part in the study, all 
potential subjects were given a minimum of 15 minutes to decide whether they are 
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willing to participate in the study. The consenting procedure took place in a quiet room 
in the outpatient department or clinical trials unit to ensure patient privacy. The 
recruiting person assisted with any questions or queries that a patient might have. If a 
patient was not able to give written consent, one witness was required to countersign a 
consent form stating that they had witnessed the participant’s non-written consent.  
In instances where a patient was not able to consent for phase 3 (e.g. time 
constraints, needing more information), a recruiting person gave a PIL with the consent 
forms and a pre-paid envelope to take back home. Similarly, if a patient's carer was not 
present at the time of recruitment, a PIL together with the consent forms and a pre-
paid envelope was given to the patient. The researcher offered a 2-week follow-up 
contact by phone, letter, or email according to patient preference, in order to answer 
any queries that the patient or his/her carer might have had. 
 If a patient expressed an interest in taking part in the study either through other 
members of staff or by directly contacting the research team, the consent forms 
together with the pre-paid envelope would be posted to the patient. 
First post-out of the questionnaires was administered to 186 participants in 
December 2013. Out of 250 patients that had been consented during the period 
between 2012 -2013 December, only the patients with the diagnosis >1 year and who 
expressed a preference for postal questionnaire completion received a questionnaire 
pack. Together with the questionnaire pack a cover letter, news letter and Christmas 
greeting were included. Participants who had not consented for phase 3 or whose 
carers had not consented, were posted a phase 3 PIL together with the consent form 
and a carer PIL with the consent form accordingly. 
Four to five weeks after the initial post-out the non-respondents were contacted 
by phone, email or letter (based on the preferred choice of contact on the phase 2 
database) by one of the researchers (KM and HA) to inquire if any assistance was 
needed for completing the questionnaire and if they are still willing to participate. If a 
patient decided to withdraw, a researcher would thank politely, reassure about their 
right to decline, remind them that they are welcome to join the study in the future if 
they change their mind and ask if they mind returning the blank questionnaire in order 
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to minimise the costs of the study. If a patient only partially completed the 
questionnaire, he or she would be asked if the research team could use the incomplete 
questionnaire for some parts of the statistical analysis. The clinical care team would be 
informed not to re-approach patients who have previously declined. 
Following the initial post-out and follow-up of the non-respondents it was 
apparent that some participants were challenged by the large volume of the 
questionnaire. Consequently, during the remaining recruitment period, a consenting 
person would show a paper copy of the questionnaire to a potential participant and 
explain the reasons for the lengthy format. In addition, a patient would be informed 
that, although it is preferred that the entire questionnaire is completed in a single 
attempt or within one day, the questionnaire may also be completed in stages. It was 
agreed within the research team that it was unrealistic to expect the patients to 
complete questionnaires in a single attempt due to the high prevalence of impairments 
in the MS population, such as difficulties with concentration and fatigue. 
In order to meet the target of 250 completed questionnaires by the end of March, 
so that Rasch analysis could reduce the number of items in preparation for the 
longitudinal phase, the recruitment was intensified by inviting all of the consultant 
neurologists, MS nurses and MS therapists to offer an opportunity for the patients to 
take part in the TONiC study. In addition, MS patients attending inpatient day treatment 
ward for natalizumab infusions were invited to take part in the study by the researcher 
(KM). Patients were allowed to complete the questionnaire pack while waiting for the 
clinic appointment or receiving treatment and then return it to the clinical or research 
staff on the same day. 
3.8. Data entry, processing and 10% check 
Demographic data was uploaded online on the phase 2 database. Although an 
analogous phase 3 database was planned to be designed for entry of the questionnaire 
data, due to unforeseen IT problems the completion date for the online phase 3 
database was postponed. An alternative method for entering preliminary data was 
sought using the Filemaker Pro 12 software. A 10% data check was performed before 
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exporting the data in into Excel format. 
3.9. Measures used in the Questionnaire Pack 
The pack contained 31 questionnaires (table 12). The scales consisted of 
previously validated measures and newly developed tools that had not been validated in 
MS.  A detailed description of scales relevant to this thesis is given below. 
 
 
Table 12. Questionnaires used in TONiC 
Relevant to this study Not relevant to this study 
MSSS-88 
NRS spasticity 
Hospital Anxiety and Depression Scale 
Neurological Fatigue Index - MS 
WHOQOL-BREF 
Leeds MS QOL 
Neuropathic Pain Scale 
SF-Qualiveen 
WHO Disability Assessment Schedule 2.0 
 
 
 
MS - Coping  
EuroQol-5D 
Herth Hope Index 
Multiple Sclerosis Vision Questionnaire 
London Handicap Scale 
MS Impact Scale 
Medical Outcome Study Sleep Scale 
MS Self-efficacy Scale 
Social Withdrawal Scale in MS 
COPE scale 
Epworth Sleepiness Scale 
Rosenberg Self-Esteem Scale 
Stigma Scale for Chronic Illness 
General Self-Efficacy Scale 
Peen State Worry Questionnaire 
Multidimensional Health Locus of Control Scale 
MS Work Instability Scale 
MS Intimacy and Sexuality Questionnaire 
Neurological Hopelessness Scale 
Leeds Spasticity Scale 
NRS (pain, coping, disability, QOL, fatigue, 
hopelessness) 
Health Economics Questionnaire  
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3.9.1. Spasticity measures 
Two patient-reported measures were used in the assessment of spasticity: the 
numerical rating scale 11 (NRS11) and MS Spasticity Scale-88 (MSSS-88) (three 
subscales: pain/discomfort, spasms, stiffness). Detailed psychometric characteristics of 
the scales are provided in Chapter 1, under the spasticity section.  
3.9.1.1. Justification for choosing patient-reported measures for spasticity 
Measurement of spasticity has been the subject of intense debate and controversy 
for many years and unfortunately as of today there is no single perfect measure for 
spasticity (Burridge et al., 2005; Pandyan et al., 2005). The reasons for choosing 
patient-reported outcome measures are many. Firstly, as discussed in chapter 1, 
clinician ratings of spasticity poorly correspond to patient reports (Lechner et al., 2006; 
Priebe et al., 1996; Skold et al., 1999). Spasticity may vary throughout the day or week 
and is under the influence of many factors that are often clinically silent (Skold, 2000). 
Hence, single measurement of spasticity performed by a clinician might inadequately 
represent the overall severity of spasticity and can often be undetectable (Lechner et al., 
2006; Skold, 2000). Secondly, although previous similar studies employed the Ashworth 
Scale, there is growing evidence suggesting low reliability and poor validity of this 
measure (Fleuren et al., 2010; Pandyan et al., 1999). Lastly, biomechanical and 
electrophysiological studies were considered to be inappropriate and impractical for use 
in this large scale, population-based study.  
 In contrast, self-assessment of spasticity is much more information-rich, since 
patients themselves experience spasticity. In addition, patient-reported measures for 
spasticity are easy to administer in population surveys, such as the TONiC study. It has 
been increasingly recognised that assessment of a single aspect of spasticity, such as 
tonic or phasic spasticity alone, is not adequate. As a result, three subscales of the 
MSSS-88 assessing stiffness, spasms and pain and discomfort were included in the 
questionnaire pack.  
In addition to MSSS-88, the numerical rating scale for spasticity was used. NRS 
has been shown to be a reliable and valid measure of spasticity in previous studies 
(Arroyo et al., 2013; Barnes et al., 2003; Farrar et al., 2008). In the present study, 
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patients were asked to rate their spasticity over the preceding 2 weeks. Some studies 
used a 24h period, however because of the length of the questionnaire pack and time 
references for other measures, (e.g. fatigue) 2 weeks was felt to be the most 
appropriate time frame (Arroyo et al., 2013; Svensson et al., 2014). Spasticity was 
explained to patients as ‘stiffness, tightness, cramps and spasms in muscles’.  NRS was 
used to stratify the study sample into four groups based on the severity of spasticity: 0 
- none, 1-3 - mild, 4-6 moderate, 7-10 severe (Arroyo et al., 2013; Flachenecker et al., 
2014; Svensson et al., 2014). Lastly, data regarding spasticity obtained using NRS would 
allow standardised comparisons with other neurological conditions, such as MND, in the 
future.  
3.9.2. QOL measures 
Two QOL measures were chosen: a generic tool, WHOQOL-BREF, and an MS-
specific, Leeds Multiple Sclerosis Quality of Life scale (LMSQoL). The measures were 
selected on the basis that they both measure overall QOL, in contrast to previous 
studies, which administered health status measures (Arroyo et al., 2013; Flachenecker 
et al., 2014; Ford, Gerry, Johnson, et al., 2001; Huang et al., 2006; Wu et al., 2007). As 
discussed in chapter 1, QOL assessment is complex and there is lack of agreement on 
which measures are best to use in the MS population. There is a notion that general 
QOL instruments may be less sensitive than disease-specific ones, therefore both 
measures were included in this study. In addition, there is no overall WHOQOL-BREF 
score, while LMSQOL allows calculation of the total QOL score. With the view of future 
studies investigating QOL in other neurological conditions, generic QOL measures would 
enable comparisons to be made across different conditions.  
3.9.2.1. LMSQoL  
LMSQoL is an 8-item instrument that was developed in a community-based sample 
with MS (Ford, Gerry, Tennant, et al., 2001). The developers’ aim was to design an 
instrument that measures overall QoL and not merely the aspects of impairment, 
disability and handicap- a feature of many previous health status or HRQOL measures, 
such as MSQOL-54 and Functional Assessment in Multiple Sclerosis (FAMS) (Cella et al., 
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1996; Vickrey et al., 1995). The eight items of the scale address: tiredness, loneliness, 
energy, worries about health, family relationships, appearance, attitudes of other people, 
and the future. All of the items are rated on the four-point Likert Scale (0-not at all; - 
sometimes; 2-quite often; 3 - most of the time).  
 The scale was shown to meet the requirements of unidimensionality using 
psychometric Rasch analaysis, have high internal consistency (Cronbach’s a=0.86), 
good reliability (test-retest Spearman’s rank=0.85) and good external validity (General 
Well Being Index, Spearman’s rank=0.83). The scale was shown to measure different 
construct to health status, by having low correlation with SF-36 physical functioning 
subscale (rank=0.35).  
Further validation of the LMSQoL scale was undertaken on a sample of 69 Turkish 
patients, which showed the scale to be valid and reliable in the Turkish language 
(Akbiyik et al., 2009). More evidence on the validity and responsiveness of the LMSQoL 
was generated in a post-hoc analysis of the transcutaneous electrical nerve stimulation 
trial for back pain in 100 patients with MS (Nicholl, Hobart, Cramp, & Lowe-Strong, 
2005). The scale was shown to be responsive to treatment (effect size: 0.34) and have 
moderate internal consistency (Cronbach’s a=0.71). Convergent validity was examined 
using MSQOL-54, which showed moderate correlations with emotional health subscales 
(-0.38 to -0.65) and physical health subscales (-0.27 to -0.5), except for physical 
function subscale which was statistically non-significant. The findings are in line with 
the results obtained by Ford et al. in the scale development study described above 
(Ford, Gerry, Tennant, et al., 2001). High responsiveness was also supported in a 
multicentre, observational study (n=197) examining the effects of glatiramer acetate on 
QOL using LMSQOL, which improved significantly after treatment (Jongen et al., 2010).  
3.9.2.2. WHOQOL-BREF 
In the early 1990s, the WHOQOL group recognised a lack of conceptual 
agreement of QOL and its standardised measurement (1995). In particular, it was 
emphasised that the existing ‘QOL’ measures were focused on disability and health 
aspects, and were not measuring QOL per se (1995, 1996). In order to address these 
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problems, an international collaborative initiative, the WHO QOL group, was set up 
which proposed a definition of QOL (described in Chapter 1) and set out to develop a 
QOL instrument, which would reflect the WHO definition of QOL. WHOQOL – 100 
assessment was developed in 15 field centres simultaneously across the globe, covering 
24 facets of QOL (1998b). It was recognised that in some circumstances the lengthy 
format of WHOQOL-100 was not appropriate, and a shortened version, the WHOQOL-
BREF was designed (1998a). The WHOQOL-BREF retained all 24 facets with a single 
item representing each facet and included an additional 2 items addressing overall QOL 
and general health.  
WHOQOL-BREF consists of 4 domains: physical health (7 items), psychological (6 
items), social relationships (3 items) and environment (8 items). Domain scores are 
scaled in a positive direction, i.e. higher scores denote better QOL. The mean score of 
the facets within each domain is used to calculate domain score. In order to make the 
scores comparable with WHOQOL-100, the mean scores are multiplied by 4.   
WHOQOL-BREF was shown to have good internal consistency (Cronbach’s alpha 
range 0.66 to 0.86), excellent discriminative validity between ill and healthy subjects 
and good test-retest reliability (Pearson’s correlation 0.66 to 0.87) (1998a). 
Confirmatory factor analysis showed acceptable fit to the model (0.901 Comparative Fit 
Index) when 4 domain solution was applied. Multiple regression analysis confirmed a 
significant contribution of each of the domains to overall QOL (>60% variance 
explained for each domain) (1998a).  
Despite the large scale of the WHOQOL project and robustness of the WHOQOL-
BREF, comparatively very few papers reported the use of WHOQOL-BREF in studies on 
MS. A literature search (February 2014) using WHOQOL AND multiple sclerosis 
produced only 11 hits on the MEDLINE search engine. Out of 11 studies, only 2 
reported psychometric properties of WHOQOL-BREF in the MS population (Ozakbas, 
Akdede, Kosehasanogullari, Aksan, & Idiman, 2007; Wynia et al., 2008). The study by 
Chopra et al. compared MSQOL-54 and WHOQOL-BREF in 112 patients at two time 
points: at relapse and at 1 month later. MSQOL-54 showed better responsiveness and 
better correlation with EDSS (r=0.54 vs. r= 0.13) (Chopra et al., 2008). The correlation 
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between two instruments was low (r=0.17). The authors suggested that MSQOL-54 
may be more favourable to assess QOL in both remission and relapse. Another study by 
Wynia et al. investigated the effects of MS-related disabilities (Multiple Sclerosis Impact 
Profile) on QOL using two measures: SF-12 and WHOQOL-BREF (Wynia et al., 2008). 
Regression analyses revealed that SF-12 was only sensitive to changes in physical 
disabilities, while WHOQOL-BREF scores were also significantly influenced by 
psychosocial variables. The authors concluded that the WHOQOL-BREF provides a more 
comprehensive assessment of QOL than SF-12.  
In conclusion, the WHOQOL-BREF is a measure of overall QOL that has been 
developed and validated in large populations of people with and without conditions. It 
has been shown to have highly robust psychometric properties, however there has been 
a paucity of application of the WHOQOL-BREF in the MS population and this needs 
further examination.  
3.9.3. Measures for fatigue, pain, depression, anxiety, bladder dysfunction and 
disability 
        Literature search identified a number of impairments that may confound the 
relationship between spasticity and QOL (Arroyo et al., 2013; Oreja-Guevara, 2011; 
Rizzo et al., 2004). These included fatigue, pain, depression, anxiety, bladder 
dysfunction and disability. Although bowel problems can often be seen in patients with 
spasticity, a measure of bowel function was not included for several reasons. Firstly, 
there is no validated measure of bowel dysfunction for MS in the literature. Secondly, 
the qualitative stage (phase 1) of the TONiC study did not identify bowel dysfunction to 
be influential to patients’ QOL in MS. Thirdly, previous similar studies on spasticity, QOL 
and related impairments did not identify correlations between spasticity and bowel 
dysfunction (Arroyo et al., 2013; Oreja-Guevara, 2011; Rizzo et al., 2004). Finally, 
bladder and bowel dysfunction are known to be intimately related, therefore accounting 
for bladder dysfunction in the regression models will provide a proxy assessment of 
bowel dysfunction.  
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3.9.3.1. Fatigue – NFI-MS 
Neurological fatigue index for multiple sclerosis (NFI-MS) is a self-report measure 
for fatigue which was developed and validated in a large sample (n=635) of patients 
with MS (Mills, Young, Pallant, & Tennant, 2010a). The items were derived from 
qualitative work with MS patients, which were then tested against strict assumptions of 
Rasch measurement model.  
NFI-MS consists of 23 items and covers 4 domains: physical (8 items), cognitive (4 
items), diurnal sleep (6 items) and nocturnal sleep (5 items). The summary scale (10 
items) is derived from adding up physical (8 items) and cognitive subscale scores (2 
items). All of the subscales were shown to fit to the Rasch model and met the 
requirement of unidimensionality. Test-retest analysis confirmed good reliability of the 
subscales (Spearman’s correlation 0.796 to 0.864, Wilcoxon Signed Rank <0.05). 
Physical and cognitive scales showed better external validity (assessed by Modified 
Fatigue Impact Scale, VAS Fatigue, Fatigue Severity score (Spearman rank 0.58 to 0.71)) 
than diurnal and nocturnal sleep subscales (0.43 to 0.51).  
The main advantage of NFI-MS compared to the previous scales assessing fatigue, 
such as Modified Fatigue Impact Scale (MFIS) and Fatigue Severity Scale (FSS), is that 
raw scores can be converted to linear measurements. In addition, given fit to the Rasch 
model, summation of raw scores gives sufficient statistic of ordinal level of fatigue, 
hence it can be conveniently administered in clinical practice.  
3.9.3.2. Hospital Anxiety and Depression Scale 
The Hospital Anxiety and Depression Scale (HADS) was developed by Zigmond 
and Snaith in 1983 with the aim to aid rapid detection and quantification of the two 
most common mood disorders: depression and anxiety (Zigmond & Snaith, 1983). 
Somatic manifestations of depression and anxiety were not included in the scale, in 
order to reduce false positives as a result of physical symptoms related to the 
underlying somatic disorder. The HADS contains 14 items with 4 response options (0-3).  
The scale has been shown to have good internal consistency (Cronbach alpha 0.8-
0.93) and high short term (<2 weeks) reliability (r>.80) (Herrmann, 1997). High 
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correlation of both subscales with the observer assessment support external validity of 
the scale (Herrmann, 1997).  
Several studies employed HADS in the assessment of depression and anxiety in 
the MS population (Honarmand & Feinstein, 2009; Janssens, van Doorn, de Boer, 
Kalkers, et al., 2003; Janssens, van Doorn, de Boer, van der Meche, et al., 2003; Jones 
et al., 2012). Honarmand et al. examined psychometric performance of HADS in the MS 
sample (n=140), reporting high sensitivity and specificity of the depression subscale 
(Honarmand & Feinstein, 2009). A score of ≥8 was suggested to be the most optimal 
cut-off point both for anxiety and depression. The anxiety subscale was shown to be a 
reliable measure only in patients diagnosed with generalised anxiety disorder, but not 
with other anxiety-related conditions.  
3.9.3.3. Disability - World Health Organisation Disability Assessment Schedule 2.0  
 
WHODAS 2.0 is a disability assessment instrument which is based on the 
conceptual framework of the International Classification of Functioning, Disability and 
Health (ICF) (WHO, 2001). WHO defines disability as: ‘"a difficulty in functioning at the 
body, person, or societal levels, in one or more life domains, as experienced by an 
individual with a health condition in interaction with contextual factors" (WHO, 1980). 
WHODAS 2.0 contains 36 items rated on the 5-point scale (1-no difficulty, 5-
extreme or cannot do) and measures disability across 6 life domains: understanding 
and communicating (6 items), getting around (5 items), self-care (4 items), getting 
along with others (5 items), life activities (8 items), and participation in society (8 
items) (Üstün, 2010). The instrument allows calculation of the global disability score (0-
no disability, 100-worst disability) and the individual domain scores. SPSS syntax was 
obtained from the WHO website to calculate ‘item-response theory’ based scores for 
global and individual domains.  
 WHODAS 2.0 was developed and validated cross-culturally across 19 countries 
involving large study populations (Garin et al., 2010; Üstün, 2010). The scale has robust 
7-factor structure with good internal consistency across all subscales (Cronbach’s apha 
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0.79-0.96) and excellent retest reliability (r=0.98). External validity was supported by 
high correlation with other measures of disability and health, including SF-12, London 
Handicap Scale, WHOQOL-100 and Functional Independence Measure.  
3.9.3.4. Bladder - SF-Qualiveen  
SF-Qualiveen was developed based on the original 30-item Qualiveen 
questionnaire, which assess a broad range of urinary symptoms in neurological 
disorders, including incontinence, urgency and voiding problems (Bonniaud, Bryant, 
Parratte, Gallien, & Guyatt, 2006; Bonniaud, Bryant, Parratte, & Guyatt, 2008). SF-
Qualiveen contains 8-items rated on 5-point response scale and covers 4 domains (2 
items per domain): bother with limitations, frequency of limitations, fears and feelings. 
The scale was shown to have high correlation with original version of Qualiveen (r=0.7-
0.92), however correlations with clinical history and symptoms was generally low 
(r=0.26=0.65). Internal consistency was high (0.83-0.9).  
3.9.3.5. Neuropathic Pain Scale 
The Neuropathic Pain Scale (NPS) was designed to assess qualitative and 
quantitative aspects of neuropathic pain (Galer & Jensen, 1997). The NPS was originally 
developed in patients with peripheral nerve conditions (diabetes, post-herpetic 
neuralgia), but since then has been validated in central causes of neuropathic pain, 
such as MS (Rog, Nurmikko, Friede, & Young, 2007).  
The NPS consists of 11 items which are rated on a 10-point Likert Scale and 
address a broad range of pain experiences. 8 items interrogate different qualities of 
pain, including ‘‘Sharp,’’ ‘‘Hot,’’ ‘‘Dull,’’ ‘‘Cold,’’ ‘‘Sensitive,’’ ‘‘Itchy,’’ ‘‘Deep,’’ and 
‘‘Surface.’’. The remaining three items assess global severity of pain, temporality of pain 
and unpleasantness.  
The scale has been shown to have acceptable internal consistency (Cronbach’s 
alpha 0.78) and external validity (SF-12 bodily pain r=-0.49, Short Form McGill Pain 
Questionnaire r=0.63) (Rog et al., 2007). Short-term reliability of the scale was 
supported by moderate test-retest correlation (r=0.71).   
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3.10. Data Analysis 
Statistical analysis of the data was carried out using Statistical Package for Social 
Sciences (SPSS) 20.0. Selected item reversal was performed before calculating total and 
domain scores. Missing data analysis at the item level showed less than 5% missing 
data. Conversion and summation of the item scores was performed in accordance with 
the guidance provided by the authors of the scales, i.e. computation of the WHOQOL-
BREF and WHODAS 2.0 scores was done using SPSS syntax obtained from the WHO 
website. Reliability of the measures was assessed using Cronbach’s alpha. A value 
greater than 0.7 was considered to be acceptable (Reynaldo & Santos, 1999).  
 For purposes of descriptive statistics, normally distributed data was presented as 
means, standard deviations and ranges. Frequency counts and percentages were used 
to present the results on categorical data. Assessment of normality of the data 
distribution was based on Q-Q plots, histograms, Kolmogorov-Smirnov test and Shapiro-
Wilkinson test. Medians and interquartile ranges were used to describe not normally 
distributed data.  
Depending on the type of data appropriate tests were used to detect statistically 
significant differences across four severity groups of spasticity. Letters in the brackets 
indicate what test was performed when reporting the results. One-way ANOVA (F) was 
used to assess normally distributed variables across three or more groups. Student t 
test (t) was used to compare two groups with normally distributed variables. The 
remaining comparisons were performed utilising non-parametric tests including Mann-
Whitney U (U) for two groups and Kruskal-Wallis (H) for more than two groups. Chi – 
square test (χ²) was employed to compare the differences across the groups with 
categorical variables. When less than five counts were observed, Fisher’s exact test was 
used instead to determine statistical significance.  
Spearman’s rank correlation was use to describe the associations between 
spasticity and other variables (QOL, disability, fatigue, etc.). Differences in means and 
medians, were deemed statistically significant if p value was <0.05. Spearman’s rank 
values were defined as follows: negligible (r<0.2), weak (r=0.2-0.39), moderate 
(r=0.4-0.59), high (0.6-0.79), very high (≥0.8) (Armitage, 1994). α value of <0.05 was 
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considered to represent statistically significant correlation. Bonferroni correction was 
used for multiple comparisons across the groups. For post-hoc ANOVA analysis, Tukey’s 
HSD test was used to determine statistically significant differences.  
 
3.10.1 Multiple regression analysis 
The contribution of spasticity and other clinical and sociodemographic variables to 
predicting QOL was assessed using multiple regression analysis. Although questionnaire 
data which is based on the Likert-type scales is considered ordinal and not suitable for 
parametric testing, an assumption of linearity may be made with larger sample, multiple 
items and more than 5 point Likert-type response options (Baggaley & Hull, 1983; 
Carifio, 2007). For future studies, ideally the raw scores should be transformed to the 
interval-level data using the Rasch method (Rasch, 1960).  
Several assumptions were sought and tested before accepting the validity of the 
regression models (Field, 2005): 
1. Normal distribution of the dependent variables. The assumptions were tested 
visually using histograms and Q-Q plots, and statistically employing Komogorov-Smirnov 
test and Shapiro-Wilkinson test. However, with larger samples > 50 these are likely to 
be significant, hence these were only considered supplemental to visual plots.  
2. Linear relationship between predictor and outcome variables. The linearity of 
the relationships was explored using scatter plots.  
3. Homoscedasticity of the predictor variables. This implies that that the residuals 
at each level of the predictors should have the same variance. The assumption was 
tested using scatter plots of the standardised residuals.  
4. Normally distributed errors. The residuals of the model are random, therefore 
they should be normally distributed with the mean of 0. This assumption was tested by 
examining distribution of the residuals using histogram.  
5. Independent errors. The regression model assumes that the residuals should be 
uncorrelated. Durbin-Watson test is used to test the assumption. A value of 2 means 
that the residuals are uncorrelated (Field, 2005). Although there is no agreed cut off 
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points, values more than 1 and less than 3 are considered to be acceptable.  
6. Multicollinearity. If more than one predictor is used, there should be no perfect 
correlation between them (Pearson’s correlation >0.8 or >0.9) (Field, 2005). The 
correlations are tested by performing correlation matrix of the predictor variables. In 
addition, variance inflation factor (VIF) and tolerance statistic are used to investigate 
multicollinearity (Field, 2005). The average VIF value should be below 4 and the 
tolerance statistic above 0.2. 
7. Outliers. Unusual cases were identify using ‘case diagnostics’ option on SPSS 
and were subsequently interrogated. It is expected that 5% of cases will be outliers 
which is consistent with 2 standard deviations. None of the regression analyses 
exceeded 5% limit.  
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Chapter 4 - Results 
4.1. Missing data analysis 
Less than 5% of missing data at the item level was detected. Missing values of 
the summary scores are shown in table 13. There were more missing data in the 
WHODAS domains compared to the remaining scales. Specific instructions regarding the 
process of dealing with missing values were followed and are summarised in appendix 
2. There were no significant differences between subjects with and without missing 
values regarding age, sex, disease duration, type of MS and employment status.   
Table 13. Missing data from the total or domain scores 
Measure Number of 
patients 
Percentage  
MSSS-88 stiffness 2 0.4 
MSSS-88 pain and discomfort 2 0.4 
MSSS-88 spasms 2 0.4 
SF- Qualiveen 2 0.8 
NFI-MS  0 0 
HADS-A 3 1.2 
HADS-D 3 1.2 
WHOQOL-Physical 1 0.4 
WHOQOL-Psychological 2 0.8 
WHOQOL-Social relationships  3 1.2 
WHOQOL-Environment 1 0.4 
LMSQOL 8 3.2 
WHODAS-communication 7 2.7 
WHODAS-getting around 10 3.8 
WHODAS-self-care 3 1.2 
WHODAS-getting along 3 1.2 
WHODAS-life activities 8 3.1 
WHODAS-participation 10 3.8 
NPS 3 1.2 
 
4.2. Reliability of the scales 
Cronbach’s alpha was calculated to assess the reliability of the measures. 
Cronbach’s alpha values of the scales and subscales are presented in table 14. Good 
internal consistency was confirmed across all the measures with values higher than 0.7. 
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WHOQOL-BREF social relationships domain had a borderline Cronbach’s alpha (0.7), 
which is consistent with the findings from the previous studies (WHO, 1998a).  
Table 14. Internal consistency of the measures 
Measure Cronbach’s 
alpha 
No of 
items 
MSSS-88 stiffness 0.96 12 
MSSS-88 pain and 
discomfort 
0.95 9 
MSSS-88 spasms 0.96 14 
SF-Qualiveen 0.94 8 
NFI-MS physical 0.94 8 
NFI-MS cognitive 0.87 4 
NFI-MS abnormal sleep 0.81 5 
NFI-MS overall fatigue 0.94 10 
HADS-A 0.87 7 
HADS-D 0.79 7 
WHOQOL-Physical 0.83 7 
WHOQOL-Psychological 0.83 6 
WHOQOL-Social 
relationships  
0.71 3 
WHOQOL-Environment 0.82 8 
LMSQOL 0.80 8 
WHODAS 0.98 36 
NPS 0.94 10 
 
4.3. Response rates 
186 questionnaires were administered during the initial mail out in December 
2013 to the participants who had previously given phase 2 and/or phase 3 consent. 
After having made the follow up calls to the non-responders, a total of 122 (65.6%) 
patients returned completed questionnaires packs.  
During the period between 6 January 2014 and 17 March 2014 190 participants 
were recruited and given the questionnaires packs in the clinics. 103 (54.3%) 
questionnaires were returned following the reminder calls to the non-responders.  A 
total of 225 completed questionnaires were received at the Walton centre (225/376, 
59.8% response rate). Together with 25 questionnaires from Preston and 10 
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questionnaires from Salford, a total of 260 participants were included in the data 
analysis.  
4.4. Sociodemographic characteristics  
Sociodemograpahic information of the sample is summarised in the Table 15. 
Mean age of the participants was 50.8 years (SD 11.8, range 22-76). 178 (63.5%) were 
female, with male to female ratio 1:2.2. Majority of the patients had relapsing-remitting 
MS (122, 46.9%), followed by secondary progressive (66, 25.4%), rapidly evolving (40, 
15.4%) and primary progressive MS (28, 10.8%). Median duration of the disease was 
10 years (range 1-47). Only 32 patients (12.3%) had had a relapse in the preceding 
year. The sample included a broad range of disability levels. 101 (38.8%) patients had 
EDSS score below 4, 122 (46.8%) had EDSS score 4.5-6.5 and the rest of the sample 
(36, 13.8%) were classed as EDSS 7-9.5.  
Only 57 (21.9%) participants were in full time and 36 (13.8%) in part time 
employment. A third of the whole sample were retired due to medical reasons. Majority 
of the subjects were married or cohabiting (185, 71%). Less than a fifth of patients 
were single or separated (42, 16.2%). A small minority were divorced (18, 6.9%) or 
widowed (11, 4.2%).  
 
Table 15. Sociodemographic characteristics of the sample 
Characteristics 
 
 
Total sample n=260 
Age  
      Mean (SD) 
      Range 
 
50.8 (11.8) 
22-76 
Sex (%) 
      Female  
      Male  
      Unknown           
 
178 (68.4) 
81 (31.2) 
1 (0.0) 
MS type (%) 
     Relapsing-remitting  
     Rapidly evolving 
 
122 (46.9) 
40 (15.4) 
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     Secondary progressive  
     Primary progressive  
     Unknown                                                    
66 (25.4) 
28 (10.8) 
4 (0.02) 
Duration of disease (years) 
     Median (IQR) 
     Mean (SD) 
     Range  
 
10 (15) 
13.1 (9.6) 
1-47 
1 or more relapse in the last year (%) 32 (12.3%) 
EDSS score (%) 
    0-4  
    4.5-6.5  
    7.0-7.5 
    8.0-9.5     
    Unknown 
 
101 (38.8) 
122 (46.8) 
12 (4.6) 
24 (9.2) 
1 (0.0) 
Employment status (%) 
     Full time employment 
     Medically retired  
     Unemployed 
     Part-time  
     Retired 
     Not working for other reasons  
     Unknown 
 
57 (21.9) 
76 (29.2) 
17 (6.5) 
36 (13.8) 
47 (18.1) 
23 (8.8) 
4 (0.02) 
Marital Status (%) 
    Single/separated  
    Married/cohabiting  
    Divorced 
    Widowed 
    Unknown 
 
42 (16.2) 
185 (71.2) 
18 (6.9) 
11 (4.2) 
4 (0.02) 
Centre (%) 
   Walton centre  
   Preston  
   Salford 
 
225 (86.5) 
25 (9.6) 
10 (3.8) 
SD: standard deviation, IQR: interquartile range 
4.5. Sociodemographic characteristics of non-responders 
Sociodemographic information of the sample was compared with the non-
responders to identity the sources of selection bias. Table 16 summarises demographic 
characteristics of the non-responders. There were no significant differences between 
the groups regarding sex, disease duration, MS type and EDSS score (p>0.05). The 
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non-responders were younger (mean age 47.6, SD 12.1), which was statistically 
significant (p=0.006). 
 
Table 16. Sociodemographic characteristics of the non-responders 
Characteristic  p value 
 
Sample 
 
Age 
  Mean (SD) 
 
151 
 
 
47.6 (12.1) 
 
 
 
 
p = 0.006 
   
Female, % 
 
66.2 
 
p=0.126 
Duration 
   Mean (SD) 
 
12.0 (10.4) 
 
p = 0.088 
 
MS type, % 
     Relapsing-remitting  
     Rapidly evolving  
     Secondary progressive  
     Primary progressive 
 
 
44.7 
24.7 
20.7 
10.0 
p = 0.146 
EDSS score, % 
    0-4  
    4.5-6.5  
    7.0-7.5  
    8.0-9.5      
 
43.0 
42.2 
6.0 
8.6 
p=0.746 
 
Note: p values <0.05 indicate statistically significant difference 
between responders and non-responders 
 
4.6. Spasticity characteristics  
Spasticity was assessed using NRS and MSSS-88 three physical subscales 
(stiffness, pain and discomfort, spasms). The following values of the NRS spasticity 
were used to categorise patients into 4 groups according to increasing levels of 
severity: none (0), mild (1-3), moderate (4-6), severe (7-10) (Arroyo et al., 2013; 
Flachenecker et al., 2014; Svensson et al., 2014). The mean of the NRS spasticity of the 
overall sample was 4.3 (SD 3.0) (table 17). Majority of the patients had at least some 
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degree of spasticity (219, 84.8%) with nearly a third of patients reporting severe 
spasticity (76, 29.2%).  
 
Table 17. NRS spasticity and MSSS-88 scores 
Spasticity characteristics  
 
NRS spasticity (n=257) 
 
   No (NRS <1) (%) 
   Mild (NRS 1-3) (%) 
   Moderate (4-6) (%) 
   Severe (7-10) (%) 
   NRS total mean (SD) 
 
 
 
41 (15.8) 
70 (26.9) 
70 (26.9) 
76 (29.2) 
4.3 (3.0) 
 
MSSS-88 (n=257) 
   
 Stiffness (median, min-max) 
 Pain and discomfort (median, min-max) 
 Spasms (median, IQR) 
 
 
25 (12-48) 
17 (9-36) 
21 (14-56) 
 
239 patients completed three subscales of MSSS-88. The patients were instructed 
not to complete the questionnaire if they did not experience spasticity in order to 
relieve participant’s burden. However, there was some discrepancy when comparing 
MSSS-88 completion rate with the NRS spasticity results, as 41 patients scored 0 on the 
NRS, while only 21 patients did not complete MSSS-88. This is most probably as a result 
of failure to read the instructions, with patients without spasticity completing the 
questionnaire. Minimal values for each of three MSSS-88 subscales were assigned to 
those 21 persons who did not complete the questionnaire in order to retain these 
subjects in the analysis. The results of MSSS-88 subscales are shown in table 17.  
4.7. Spasticity in relation to sociodemographic and disease parameters 
Several clinical and sociodemographic variables were found to be associated with 
increased severity of spasticity (table 18). Older age was significantly associated with 
higher degrees of spasticity (F (3) = 5.3, p=0.001). Patients with severe spasticity were 
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more likely to have a progressive type of MS (χ² = 33.4, p<0.001). No difference was 
observed between SPMS and PPMS (p=1.0).  Interestingly, duration of MS appeared not 
to have a significant effect on spasticity levels (H (3) = 4.5, p=0.213). Since PPMS 
could have confounded the results, duration of disease was compared after excluding 
PPMS patients, however no statistical significance was observed (H (3) = 4.24, 
p=0.229). Patients diagnosed within 4 years had a similar degree of spasticity (4.1, SD 
2.7) when compared to those with over 20 years of disease activity (4.9, SD 2.8, 
p=0.86).   
Spasticity increased in parallel to worsening disability (χ² =56.3, p<0.001). 
However, less than a third (27.6%) of patients with severe spasticity had EDSS score 
>6.5, with a majority of patients experiencing moderate or severe spasticity at lower 
levels of disability. More patient with severe spasticity had a relapse were in the 
preceding year, however this was not statistically significant (χ² = 1.66, p=0.657). 
Severity of spasticity did not significantly differ between RRMS and REMS (U=2.56, 
0.364). There were no significant differences in sex across the spasticity groups 
(p=0.326). Patients were less likely to be employed as spasticity levels increased, with 
only 21.3% of participants with severe spasticity in full or part time employment.  
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Table 18. Spasticity in relation to sociodemographic and MS characteristics 
 Spasticity  
 None   Mild Moderate Severe  p value 
Age (mean, CI) 45.5  
(42.0-49.3) 
49.9  
(47.1-52.5) 
51.4  
(48.8-54-4) 
54.26 
(51.9-56-7) 
0.001  
Sex (female %) 70.7 72.5 72.9 60.5 0.326  
 
MS type 
(progressive %) 
 
14.6 
 
19.1 
 
44.9 
 
57.3 
 
0.001  
Duration of MS 
(median, IQR) 
9 (11) 9 (14) 10.5 (18) 12.5 (16) 0.216 
 
Relapse in the 
last 12 months 
(%) 
4 (11.4) 10 (18.2) 8 (21.1) 7 (21.9) 0.657 
Disabled 
(EDSS>6.5) (%) 
2.4 5.8 14.3 27.6 <0.001 
In employment 
(%) 
61.0 41.2 31.9 21.3 <0.001 
4.8. Quality of Life profile of the sample 
QOL was assessed by two measures: the LMSQOL and WHOQOL-BREF. Table 19 
summarises QOL scores of an overall sample. The mean score on the LMSQOL scale 
was 10.0 (SD 4.6) with scores ranging from 1 (better QOL) to 22 (worse QOL). The 
WHOQOL-BREF raw scores were transformed on a 4-20 scale. All domain scores are 
scaled in positive direction (higher score indicates better QOL). Mean scores were 13.8 
(SD 3.2) on the physical domain, 14.1 (SD 2.8) on the psychological domain, 14.5 (SD 
3.3) on the social relationships domain and 15.0 (SD 2.5) on the environment domain. 
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Table 19. QOL scores of the sample 
QOL instrument Score 
 
LMSQOL  
    Mean (SD, min-max) 
 
 
10.0 (4.6, 1-22) 
WHOQOL-BREF (SD, min-max) 
 
   Physical 
   Psychological 
   Social relationships 
   Environment  
 
 
 
13.8 (3.2, 6.3-20) 
14.1 (2.8, 5.33-20) 
14.5 (3.3, 4-20) 
15.0 (2.5, 8-20) 
 
 
 Figure 6 shows how patients rated their QOL and health. Majority of the patients 
reported their QOL as good (111, 42.9%), with only 23 participants (8.9%) rating QOL 
as poor or very poor. In contrast, patients rated their health worse, with more than a 
third (88, 34.1%) reporting as being dissatisfied or very dissatisfied with their health. 
Only 11 patients (4.3%) were very satisfied with their health. 
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4.8.1. Quality of life in relation to sociodemographic and disease characteristics 
Several sociodemographic and clinical parameters were examined in relation to 
the LMSQOL scores and four domains of the WHOQOL-BREF (table 20). Age was found 
to be an insignificant factor on both measures, except for physical domain of the 
WHQOL-BREF (F (3) =6.2, p<0.001), with older patients reporting worse physical 
health. There were no significant differences in QOL scores across both sexes, except 
for social relationships domain with females reporting better QOL (t (254) = 2.6, 
p=0.01). Disability, measured by EDSS, was strongly associated with worse QOL across 
all the domains on the WHOQOL-BREF and LMSQOL. However, the relationship 
between disability and QOL was not linear (figure 7). While there was a significant 
difference in LMSQOL scores between mild (EDSS 0-4, median 9.0) and moderate 
disability (EDSS 4.5-6.5, median 11.0) (H (3) = 12.1, p=0.007), no statistical 
significance was observed using pairwise comparisons between mild or moderate 
disability and most disabled group (EDSS 8-9.5) (H (3) = -1.0, p=1.0). Similar 
observations were found in relation to the WHOQOL-BREF domains, except for physical 
domain (patients with higher EDSS grade had consistently lower scores on the physical 
domain).  
Figure 4. WHOQOL-BREF quality of life and health ratings 
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While there was no statistical difference in LMSQOL scores between different MS 
types (p=0.498), QOL was worse across all of the WHOQOL-BREF domains in 
progressive types of MS compared to relapsing remitting or rapidly evolving MS 
(p<0.001). There was no statistical difference between SPMS and PPMS groups 
(p=0.95). Longer duration of MS was associated with only marginally lower QOL scores 
on the both measures, which was not statistically significant (p>0.05). Patients in full or 
part time employment had significantly higher scores compared to unemployed or 
retired (LMSQOL t (247) = 2.134, p=0.33). Marital status was found to be significant 
only in relation to the WHOQOL-BREF Social relationships and Environment domains 
(Social relationships t (251) = 2.89, p=0.004, Environment t (253) = 2.35, p=0.019). 
 
Table 20. QOL in relation to sociodemographic and disease parameters 
 
 
 
 
LMSQOL 
 
 
WHOQOL 
Physical 
 
 
WHOQOL 
Psychological  
 
WHOQOL 
Social 
relationships 
 
 
WHOQOL 
Environment 
 
 
Age (n), mean (SD) 
  22-42 (59) 
  43-51 (63) 
  52-59 (70) 
  over 60 (70) 
 
 
10.2 (5.2) 
9.8 (4.8) 
10.1 (4.5) 
9.6 (3.9) 
 
 
14.1 (3.4)* 
13.7 (3.2)* 
12.8 (3.1)* 
11.9 (2.6)* 
 
 
14.2 (3.2) 
14.3 (2.8) 
13.9 (2.9) 
13.8 (2.3) 
 
 
14.9 (3.4) 
15.0 (3.5) 
14.3 (3.3) 
13.9 (3.1) 
 
 
15.0 (2.6) 
15. 0 (2.8) 
15.1 (2.5) 
14. 9 (2.1) 
Sex (n) 
   Male (81) 
   Female (177) 
 
10 (5.1) 
10 (4.0) 
 
 
13.2 (3.1) 
13.1 (3.2) 
 
14.2 (2.8) 
14.0 (2.8) 
 
13.7 (3.3)* 
14.9 (3.3)* 
 
14.7 (2.6) 
15.1 (2.5) 
EDSS (n), median 
(IQR) 
  0-4 (97) 
  4.5-6.5 (118) 
  7.0-7.5 (12) 
  8-9.5 (22) 
 
 
9.0 (7)*** 
11 (7) *** 
14 (6) *** 
10 (4) *** 
 
 
15.4 (4.3) *** 
12.0 (4.6) *** 
10.5 (4.5) *** 
11.4 (3.5) *** 
 
 
15.3 (3.7) *** 
13.8 (4) *** 
12.6 (5.7) *** 
12.7 (3.0) *** 
 
 
16 (3.3) *** 
14.7 (4.0) *** 
13.3 (4.5) *** 
14.0 (4.7) *** 
 
 
16 (3.1) *** 
15 (4.0) *** 
13 (3.9) *** 
14.5 (2.1) *** 
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MS type 
  RR (122) 
  RE (40) 
  PP (27) 
  SP (66) 
 
9.7 (4.8) 
9.5 (5.2) 
10.3 (4.5) 
10.7 (3.9) 
 
14.0 (3.2)*** 
14.2 (3.2)*** 
11.8 (2.6)*** 
11.5 (2.5)*** 
 
14.7 (4)** 
15.3 (4.3)** 
12.7 (4)** 
13.3 (3.3)** 
 
16 (4)*** 
16 (2.7)*** 
13.3 (4)*** 
13.3 (4.3)*** 
 
16. 0 (4)** 
15.3 (3.4)** 
15.0 (3.5)** 
14.8 (2.5)** 
 
Duration 
  1-4 (54) 
  5-9 (65) 
  10-19 (71) 
  20 plus (67) 
 
 
10.1 (4.8) 
10.5 (4.7) 
9.8 (4.8) 
10.0 (4.2) 
 
 
13.9 (3.3) 
13.3 (3.3) 
13.1 (3.4) 
12.4 (2.8) 
 
 
15.3 (4) 
14.5 (3.3) 
14.7 (4.7) 
13.7 (3.3) 
 
 
14.5 (3.5) 
14.8 (3.0) 
14.6 (3.6) 
14.3 (3.2) 
 
 
15.3 (2.5) 
14.6 (2.5) 
15.1 (2.8) 
15.0 (2.2) 
In Employment 
  Yes (93) 
  No (162) 
  
 
9.2 (4.5)* 
10.5 (4.6)* 
 
15.1 (2.8) *** 
12.0 (2.8) *** 
 
 
15.0 (2.8) *** 
13.6 (2.5) *** 
 
15.2 (2.8)* 
14.2 (3.5)* 
 
15.6 (2.3)** 
14.7 (2.6)** 
Married 
   Yes (185) 
   No  (71) 
 
9.86 (4.4) 
10.47 (5.1) 
 
13.2 (3.1) 
12.9 (3.6) 
 
14.3 (2.8) 
13.6 (2.9) 
 
14.3 (2.7)** 
13.6 (2.9)** 
 
15.2 (2.5)* 
14.4 (2.5)* 
*p <0.05, **p<0.01, ***P <0.001 
4.8.2. Spasticity and QOL  
Table 21 shows the comparisons of QOL scores using one-way ANOVA across four 
spasticity groups. The LMSQOL scores were significantly higher (worse QOL) in patients 
with increasing severity levels of spasticity (F (3) = 7.9, p<0.001). Post-hoc 
Figure 5. LMSQOL scores compared across EDSS groups 
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comparisons using Tukey’s HSD test showed that significant differences were found 
between none or mild spasticity and severe spasticity, but not between other groups.  
Table 21. Spasticity and QOL  
 Spasticity  
 None Mild Moderate Severe p value 
 
LMSQOL 
 (mean, SD) 
 
8.32 (4.3) 
 
8.94 (4.5) 
 
10.13 (4.6) 
 
11.92 (4.2) 
 
<0.001 
WHOQOL – 
BREF (mean, SD) 
 
   Physical 
   Psychological 
   Social  
relationships 
   Environment 
 
 
 
 
 
16.0 (2.7) 
15.4 (2.7) 
15.2 (3.2) 
 
16.6 (2.3) 
  
 
 
 
 
14.4 (2.8) 
15.1 (2.3) 
15.6 (3.0) 
 
15.9 (2.4) 
 
 
 
12.5 (2.7) 
13.7 (2.7) 
14.3 (3.3) 
 
14.6 (2.5) 
 
 
 
11.0 (2.4) 
12.9 (2.7) 
13.5 (3.4) 
 
13.8 (2.0) 
 
 
 
<0.001 
<0.001 
<0.001 
 
<0.001 
 
 
Similar trends were observed on the WHOQOL-BREF domains. Increasing severity 
of spasticity had the most pronounced effect on the Physical domain scores (F (3) 
=41.1, p<0.001). Post-hoc tests revealed that physical domain scores decreased 
significantly (worse QOL) at every stage of advancing spasticity. There were significant 
differences across all groups, except between none or mild spasticity on Psychological 
domain (F (3) =13.0, p<0.001). Social relationships domain scores were significantly 
different between none or mild and severe spasticity (F (3) = 5.9, p=0.001). 
Environment domain scores worsened as spasticity increased (F (3) = 16.3, p<0.001). 
However, post-hoc Tukey’s HSD showed that there appeared to be only a significant 
difference between NRS 0-3 and NRS 4-10 groups on the Environment domain.   
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                Figure 6. WHQOL Physical Health in relation to spasticity 
 
 
 
 
 
 
Spearman’s rank correlations were carried out to investigate the relationship 
between three MSSS-88 subscales and QOL (table 22). Statistically significant 
correlations (p<0.001) were found between all MSSS-88 subscales and the LMSQOL 
and WHOQOL-BREF domains. Pain and discomfort subscale of the MSSS-88 correlated 
particularly strongly with both QOL measures (r = -0.3 - -0.7, p<0.001). Overall, 
spasticity correlated less well with the LMSQOL compared to the WHOQOL-BREF 
domains. Spasticity was found to be strongly associated with physical, psychological 
and environment domains, but less so with social relationships domain.  
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Table 22. Spearman’s rank correlation (r) between spasticity and QOL 
 Stiffness Pain and 
discomfort 
Spasms 
LMSQOL 0.42 0.40 0.36 
 
WHOQOL-BREF 
 
   Physical 
   Psychological 
   Social 
relationships 
   Environment 
 
 
 
-0.64 
-0.48 
-0.31 
 
-0.45 
 
 
 
-0.70 
-0.47 
-0.30 
 
-0.45 
 
 
 
-0.61 
-0.43 
-0.31 
 
-0.44 
p<0.001 
 
Figure 7. Linear relationship between LMSQOL and MSSS-
88 stiffness subscale 
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           4.9. Disability profile of the sample 
Disability was assessed with the WHODAS 2.0. The scores were transformed on 
a 0-100 scale. Higher scores indicating higher degree of disability. Since majority of the 
patients were not in employment, domain scores regarding work were not calculated. 
Table 23 shows the means, standard deviation and ranges of WHODAS domain scores. 
Mean score of overall WHODAS 2.0 was 33.81 (SD 22.2, range 0-89.7). Domains with 
the highest scores were ‘Getting around’ (mean 48.1, SD 31.4) and ‘Life activities’ 
(mean 52.23, SD 33.2). 
 
Table 23. WHODAS 2.0 domain scores of the sample 
n=234 Mean (SD)                            min-max 
Communication 24.42 (23.5)                            0-95 
Getting around 48.71 (31.4)                            0-100 
Self-care 26.20 (29.6)                            0-100 
Getting along with people 22.57 (16.7)                            0-91.7 
Life activities 52.23 (33.2)                            0-100 
Participation in society 33.22 (24.1)                            0-100 
Total disability  33.81 (22.2)                            0-89.7 
4.9.1. Spasticity and Disability 
Spasticity was found to be closely related to disability. Table 24 shows 
comparisons of the total WHODAS 2.0 scores across the spasticity groups. Pairwise 
comparison between the groups showed that disability levels were significantly higher in 
patients with increasing spasticity (H (3) = 84.63, p<0.001). Disability was worse but 
not statistically significantly different between none and mild spasticity (p=0.266).  
Table 24. Disability in relation to spasticity 
 Spasticity  
 None  Mild  Moderate  Severe  p value 
 
Total WHODAS 
2.0 
Score (median, 
IQR) 
 
 
10.87 (17.4) 
 
 
20.1 (25.5) 
 
 
37.37 (26.6) 
 
 
50.51 (30.4) 
 
 
<0.001 
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Moderate to high correlations were observed between spasticity and individual 
domains of WHODAS 2.0 (r=0.43-0.71, p<0.001). As expected, the correlations were 
lower between spasticity and ‘Understanding and Communicating’ and ‘Getting along 
with people’ domains (r=0.43-0.49). Physical domains regarding self care, mobility and 
participation in society showed strongest correlations with spasticity (r=0.54-0.71).  
 
Table 25. Spearman’s rank correlations (r) between spasticity and disability 
 Stiffness Pain and 
discomfort 
Spasms 
WHODAS 2.0 
 
Understanding and 
Communication 
Getting around 
Self-care 
Getting along with people 
Life activities 
Participation in the society 
Overall disability 
 
 
0.43 
 
0.71 
0.61 
0.47 
0.57 
0.60 
0.70 
 
 
0.49 
 
0.66 
0.58 
0.48 
0.54 
0.55 
0.68 
 
 
0.46 
 
0.65 
0.59 
0.45 
0.52 
0.54 
0.68 
p<0.001    
         
4.10. Depression and Anxiety  
Mood disorder was measured using the Hospital Anxiety and Depression Scale 
(HADS). Cut-off point of ≥8 was applied for both anxiety and depression scales 
(Honarmand & Feinstein, 2009). Mean depression score (HADS-D) was 5.6 (SD 3.7). 
Almost a third (74. 28.5%) of the total sample had depression (HADS-D ≥8). Mean 
anxiety score was 7.1 (4.0) and 111 (42.7%) had a score of ≥8 on the HADS-A. 
4.10.1. Depression in relation to sociodemographic and clinical characteristics 
Several demographic and MS related variables were compared between patients 
with (n=74) and without depression (n=182) (table 26). No difference in age of the 
participants was found between the two groups (t (253) = -0.301, p =0.764). Male to 
female ratio was similar in both groups (69.8% vs. 66.2% female, χ² (1) = 0.311, 
p=0.656). Patients with advanced EDSS (>6.5) were more likely to be depressed, 
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however this was not statistically different (χ² (1) =1.34, p=0.247). Progressive disease 
course was found to be significantly associated with depression (χ² (1) = 7.2, 
p=0.008). There was no significant difference in duration of disease between patients 
with and without depression (U = 6771.5, p = 0.809). Significantly smaller proportion 
of patients in the depression group were in employment (20.5%) compared to 
depression-free group (42%) (χ² = (1) = 10.6, p=0.001).   
Table 26. Comparison of sociodemographic and disease characteristics between depressed and 
depression-free groups 
 Depression No depression  p value 
 
Age (mean, SD) 
 
51. 1 (12.0) 
 
50.6 (11.7) 
 
0.764 
Sex (female %) 49 (66.2) 127 (69.8) 0.656 
Progressive (%) 36 (49.5) 57 (31.5) 0.008 
Duration (median, IQR) 11 (14) 10 (15) 0.809 
EDSS >6.5 (%) 13 (17.6) 22 (12.1) 0.247 
In Employment (%) 16 (20.5) 76 (42) 0.001 
 
4.10.2. Anxiety and its relation to sociodemographic and clinical characteristics  
Only younger age was found to be significantly associated with anxiety (t (253) = 
2.05, p=0.046), while no significant differences were found across other clinical and 
sociodemographic parameters including sex (χ² (1)= 0.035, p=0.852), EDDS score (χ² 
(1)=0.004, p=0.949), progressive type (χ² (1)=1.923, p=166), employment (χ² 
(1)=0.093, p=0.76) and disease duration (U = 7252, p=0.215) (table 27).  
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Table 27. Comparison of sociodemographic and disease characteristics between anxiety and 
anxiety-free groups 
 Anxiety No anxiety p value 
 
Age (mean, SD) 
 
49.1 (11.8) 
 
52.1 (11.8) 
 
0.046 
Sex (female %) 77 (69.4) 99 (68.3) 0.852 
Progressive (%) 35 (31.8) 58 (40.3) 0.166 
Duration (median, IQR) 10 (12) 11 (16) 0.215 
EDSS >6.5 (%) 15 (13.5) 20 (13.8) 0.949 
In Employment (%) 40 (37) 51 (35.2) 0.76 
 
4.10.3. Spasticity and its relation to depression and anxiety 
Cases of depression and anxiety were compared across four spasticity groups 
(table 28).  There was a significantly larger proportion of patients with depression at 
more severe levels of spasticity (17.1% in none vs. 45.3% in severe spasticity, χ² (3) = 
19.888, p<0.001). Modest correlations were detected between three MSSS-88 
subscales and HADS-D (r=0.38-0.43, p<0.01) (table 29).  
 
In contrast, only weak correlations were found between MSSS-88 subscales and 
HADS-A (r=0.22-0.25) (table 29). There was no statistical difference in number of 
anxiety cases across spasticity groups, although there was a positive trend between 
increasing spasticity and higher prevalence of anxiety (χ² (3) = 3.754, p = 0.289).  
 
Table 28. Cases of depression and anxiety in spasticity groups 
 Spasticity  
 None Mild Moderate Severe p value 
 
Depression (%) 
 
7 (17.1) 
 
10 (14.5) 
 
21 (30.4) 
 
34 (45.3) 
 
<0.001 
Anxiety (%) 15 (36.6) 28 (40.1) 27 (39.1) 39 (52.0) 0.289 
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Table 29. Spearman’s rank correlation (r) between spasticity and QOL 
 Stiffness Pain and 
discomfort 
Spasms 
 
Depression 
 
0.43 
 
0.42 
 
0.38 
Anxiety 0.22 0.25 0.23 
p<0.01    
 
4.11. Spasticity and Fatigue 
Three subscales of the NFI-MS were used in the assessment of fatigue and 
abnormal sleep. The mean score of the overall fatigue was 19.6 (SD 6.8, range 0-30). 
Table 30 shows the comparisons of fatigue levels across four spasticity groups. There 
was a significant increase in the overall fatigue scores as the levels of spasticity 
increased (H (3) = 52.03, p<0.001). Pairwise comparisons with adjusted p-values 
showed that there was no significant difference between none and mild spasticity 
(p=0.2) as well as moderate and severe spasticity (p=0.942). Similar trend was 
observed in relation to physical fatigue subscale (H (3) = 52.3, p<0.001). One-way 
ANOVA showed that cognitive fatigue was also significantly affected by spasticity (F (3) 
= 116.9, p < 0.001). Post hoc Tukey HSD showed that there was no statistically 
significant difference between none and mild spasticity (p=0.07) and moderate and 
severe spasticity (p=0.789). It appears that presence of spasticity in determining 
fatigue is less significant at mild and extreme levels of spasticity.  
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Table 30. Spasticity and fatigue (NFI-MS) 
 Spasticity  
 None Mild Moderate Severe p value 
 
Overall fatigue (median, 
IQR) 
 
16.0 (9) 
 
17 (9) 
 
21 (9) 
 
23 (7) 
 
<0.001 
Physical (median, IQR) 13 (8) 15 (9) 17 (7) 19 (7) <0.001 
Cognitive fatigue (mean, 
SD) 
4.2 (3.1) 5.6 (3.1) 7.0 (3.1) 7.4 (2.8) <0.001 
Abnormal nocturnal sleep 
(mean, SD) 
7.1 (3.1) 7.9 (3.7) 8.9 (2.9) 9.71 (2.8) <0.001 
Abnormal nocturnal sleep was also found to be affected by increasing levels of 
spasticity (F (3) = 78.88, p<0.001). Post hoc analysis showed slightly different trends in 
comparison to physical and cognitive fatigue. Patients with no spasticity had 
significantly less abnormal nocturnal sleep compared to moderate (p=0.017) and severe 
spasticity (p<0.001), but not mild spasticity (p=0.56). There was no significant 
difference between mild and moderate spasticity, but there was a significant difference 
between mild and severe spasticity (p=0.003).  
Table 31 shows Spearman’s rank correlations between three MSSS-88 subscales 
and the NFI-MS domains. Moderate correlations were found between spasticity and 
overall, physical and cognitive fatigue (p<0.001). Pain and discomfort subscale had 
higher correlations with NFI-MS than other two MSSS-88 subscales. Spasticity was 
found to correlate more closely with physical fatigue (r=0.51-0.61) compared to 
cognitive fatigue (r=0.41-0.5). Weakest correlations were observed between abnormal 
nocturnal sleep and spasticity (r=0.35-0.47).  
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Table 31. Spearman’s rank correlation (r) between spasticity and 
fatigue 
 Stiffness Pain and 
discomfort 
Spasms 
 
NFI – MS - overall 
 
0.51 
 
0.61 
 
0.52 
NFI – MS - physical 0.52 0.61 0.52 
NFI – MS- cognitive 0.41 0.5 0.42 
NFI-MS – abnormal 
nocturnal sleep 
0.35 0.47 0.4 
p<0.01    
        4.12. Spasticity and Pain  
Neuropathic Pain Scale (NPS) was used to assess the severity, type and range of 
pain experiences in patients with MS. Fifty participants reported no pain and were 
instructed not to complete the questionnaire. In order to include these participants in 
the analysis, the score of 0 was assigned to each NPS subscale.  Total mean NPS score 
was 29 (SD 24.8, range 0-100) (table 32). Data on the temporality of pain was available 
only for 160 subjects (a total of 100 patients excluded). 50 patients selected more than 
one option with regards to temporality of pain, which precluded using the data 
according to the instructions. Constant background pain with breakthrough pain was 
the most common type of pain experienced by MS patients (84, 52.5%). More than a 
third experienced occasional pain (59, 36.9%), while 10.6% had constant pain. 
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Table 32. Pain characteristics on NPS scale 
(n=258) Mean SD Range 
Intensity 3.4 3.1 0-10 
Sharp 3.1 3.2 0-10 
Burning 2.6 3.2 0-10 
Dull 3.5 3.1 0-10 
Cold 2.1 2.9 0-10 
Sensitive 2.5 3.1 0-10 
Itchy 1.9 2.9 0-10 
Unpleasant 3.8 3.2 0-10 
Deep 3.6 3.4 0-10 
Surface 3.1 3.1 0-10 
Total 29.7 24.8 0-100 
 
When total NPS scores were compared across four spasticity groups, there was a 
significant trend of increasing pain prevalence in parallel to worsening spasticity (H (3) 
= 52.25, p<0.001) (table 33). Pairwise comparisons showed significant differences in 
pain levels in all groups, except between moderate and severe spasticity (p=0.14) as 
well as moderate and mild spasticity (p=0.125)  
Table 33. Total NPS scores compared across spasticity groups  
 Spasticity  
 None  Mild  Moderate  Severe  p value 
 
NPS total 
(median, IQR) 
 
0 (20) 
 
22 (34) 
 
27 (34) 
 
47 (33) 
 
<0.001 
 
Table 34 shows the Spearman’s rank correlations between different types of pain 
and MSSS-88 spasticity subscales. There was a moderate correlation between spasticity 
and total NPS score (r=0.53-0.6, p<0.001). Highest correlations were observed 
between spasticity and ‘intense’, ‘sharp’, ‘dull’, ‘unpleasant’ and ‘deep’ pain (r=0.41-
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0.62). The correlations were weak to modest between spasticity and superficial or 
allodynic pain (‘burning’, ‘cold’, ‘sensitive’, ‘itchy’ and surface’) (r=0.33-0.45, p<0.001). 
As expected, pain and discomfort subscale correlated better with NPS than stiffness or 
spasms subscales (r=0.6 (pain and discomfort) vs. r=0.53 (stiffness) and r=0.53 
(spasms)).     
Table 34. Spearman rank correlation s between spasticity and 
NPS domains 
n=(256) Stiffness Pain and 
discomfort 
Spasms 
Intensity 0.52 0.60 0.53 
Sharp 0.51 0.57 0.49 
Burning 0.38 0.47 0.38 
Dull 0.44 0.52 0.46 
Cold 0.38 0.39 0.39 
Sensitive 0.38 0.42 0.39 
Itchy 0.33 0.36 0.34 
Unpleasant 0.49 0.57 0.46 
Deep 0.51 0.58 0.51 
Surface 0.41 0.49 0.39 
Total  0.53 0.60 0.53 
p<0.01    
4.13. Spasticity and bladder dysfunction 
Bladder dysfunction and its impact was assessed by the SF-Qualiveen. The mean 
score of the total SF-Qualiveen was 1.25 (IQR 2). Table 35 shows the severity of the 
overall bladder dysfunction in relation to worsening spasticity. It was found that 
patients with more severe spasticity had significantly more bladder problems (higher 
SF-Qualiveen score) (H (3) = 33.23, p < 0.001). Pairwise comparisons with adjusted 
values showed that there was no statistically significant difference between mild 
spasticity and none (p=1.0) or moderate spasticity (p=0.364). In contrast, at more 
severe levels of spasticity the SF-Qualiveen scores were significantly higher in patients 
with severe spasticity compared to moderate spasticity (median 2.38 (IQR 2.1) vs. 
median 1.25 (IQR 1.76), p=0.045).  
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Table 35. Bladder dysfunction and spasticity 
 Spasticity  
 None  Mild  Moderate  Severe  p value 
 
Total Bladder 
(median, IQR) 
 
0.63 (1.25) 
 
0.75 (1.63) 
 
1.25 (1.75) 
 
2.38 (2.1) 
 
<0.001 
 
Correlations between four domains (bother with limitations, fear, feelings and 
frequency limitations) of SF-Qualiveen and MSSS-88 subscales were performed (table 
36). Modest (r=0.35-0.45), but statistically significant (p<0.01) correlations were 
observed across all the domains.  
Table 36. Spearman’s rank correlation between spasticity and bladder 
dysfunction 
 Stiffness Pain and 
discomfort 
Spasms 
Bother with 
limitations 
0.44 0.42 0.39 
Fears 0.38 0.40 0.41 
Feelings 0.42 0.40 0.39 
Frequency 
limitations 
0.39 0.35 0.38 
Overall 0.45 0.44 0.44 
p<0.01    
4.14. Regression Analysis 
The results above show that spasticity is associated with reduced QOL on both 
measures (the LMSQOL and WHQOL-BREF). However, as postulated in the hypothesis 
of this thesis, spasticity was also found to be related to other sociodemographic (age, 
employment) and clinical variables (depression, anxiety, fatigue, pain, bladder 
dysfunction, disability).  These factors may also have influential role to QOL in patients 
with MS. To investigate an independent contribution of spasticity towards QOL, 
hierarchical multiple regression analysis was employed. Before inserting predictors into 
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the final regression models, a series of univariate regression analyses were performed 
to identify any significant predictors of QOL.  
4.14.1. Univariate regression analysis 
 All of the dependent variables were considered to be normally distributed, except 
for WHQOL-BREF psychological health and social relationships domains. Log and square 
transformations were attempted but normality parameters did not improve. Not 
normally distributed data was unlikely to affect the regression analysis due to the large 
sample size (n=260). According to the central limit theorem, the distribution of the 
means of the samples in the population is normal, therefore even if the distribution of 
the given sample is not normal, assumptions of normally distributed data can be made 
if the sample size is >40 (Ghasemi & Zahediasl, 2012).     
Individual sociodemographic variables and clinical parameters were tested using 
univariate regression analysis in predicting QOL. Each set of predictors was analysed in 
relation to five outcome variables: four domains of the WHOQOL-BREF and LMSQOL. 
The results of the univariate analyses regarding adjusted R² values, betas, standard 
errors, and standardised β coefficients are reported in appendix 3. Predictors with p 
value below 0.05 were considered to be significant and were included in the multiple 
regression analysis. All of the independent variables were significant across the both 
measures, except for sociodemographic predictors, which varied depending on the 
measure and domain. Table 37 shows the variables found to be significant in relation to 
the LMSQOL and the individual domains of the WHOQOL-BREF.  
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Table 37. Variables found to be significant predictors of QOL in univariate regression analysis 
 WHOQOL-
BREF 
Physical 
health 
WHOQOL-
BREF 
Psychological 
health 
WHOQOL-
BREF 
Social 
relationships 
 
WHOQOL-
BREF 
Environment 
LMSQOL 
Sociodemographic 
and disease 
parameters 
 
Age 
Sex 
Marital status 
Employment 
Type of MS 
Duration 
 
 
 
 
 
+ 
 
 
+ 
+ 
+ 
 
 
 
 
 
 
 
+ 
+ 
 
 
 
 
+ 
+ 
+ 
+ 
+ 
 
 
 
 
 
 
+ 
+ 
+ 
 
 
 
 
 
 
 
+ 
 
 
Associated 
conditions 
 
Anxiety 
Depression 
Bladder dysfunction 
Fatigue 
Pain 
 
 
 
+ 
+ 
+ 
+ 
+ 
 
 
 
+ 
+ 
+ 
+ 
+ 
 
 
 
+ 
+ 
+ 
+ 
+ 
 
 
 
+ 
+ 
+ 
+ 
+ 
 
 
 
+ 
+ 
+ 
+ 
+ 
Spasticity + + + + + 
Disability + + + + + 
4.14.2. Hierarchical multiple regression analysis 
Predictors of QOL found to be significant in the univariate regression analyses 
were included in the multiple regression models. Independent variables were inserted 
into the models in four steps:  
1. Step 1 - Sociodemographic variables 
2. Step 2 - Associated conditions- depression, anxiety, bladder dysfunction, 
fatigue, pain 
3. Step 3 - Spasticity 
4. Step 4 - Disability  
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At each step of the analysis, the assumptions of the regression model (described 
in the Methodology Chapter) were checked and were deemed to be valid. Since MSSS-
88 subscales had very high intercorrelations (r=0.84-0.89) which would adversely affect 
multicollinearity, only one subscale (MSSS-88 muscle stiffness) was included in the 
analysis. Five multiple regression analyses were carried out, which results are described 
below in relation to the individual domains of the WHOQOL-BREF and LMSQOL.  
 
4.15. Results of multiple regression analysis 
4.15.1 WHOQOL-BREF Physical Health 
The final model (step 4) accounted for 74.3% variance of the WHOQOL-BREF 
Physical Health domain (adjusted R² = 0.743, F (11, 210) = 58.95, p<0.001) (table 
38). Addition of spasticity (step 3) produced a significant change in R² value (R²change 
0.013, p=0.01). Spasticity was a significant predictor of QOL after adjusting for 
sociodemographic variables and associated conditions (β=-0.16, p=0.001). Insertion of 
disability in to the model (step 4) improved the R² value (R² change 0.019, p<0.001), 
however spasticity became an insignificant predictor (β=-0.08, p=0.117). Employment 
(β=0.11, p=0.015), depression (β=-0.15, p=0.006), fatigue (β=-0.29, p<0.001), pain 
(β=-0.18, p<0.001) and disability (β=-0.28, p<0.001) remained significant predictors of 
QOL in the final model. 
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Table 38.  Hierarchical multiple regression analysis with WHOQOL-BREF Physical health as a dependent variable 
 Step 1 Step 2 
 
Step 3 Step 4 
Adjusted 
R² 
0.249*** 
R² change 
0.263*** 
Adjusted 
R² 
0.711*** 
R² change 
0.46*** 
Adjusted 
R² 
0.724*** 
R² change 
0.013** 
Adjusted R² 
0.743*** 
R² change 
0.019*** 
 B SE  β B SE  β B SE  β B SE  β 
Sociodemographic 
and disease 
parameters 
 
Age 
Type (relapsing) 
Duration 
Employment 
 
 
 
 
 
0.001 
1.8 
0.03 
2.68 
 
 
 
 
 
0.02 
0.48 
0.03 
0.44 
 
 
 
 
 
0.01 
0.25*** 
0.09 
0.41*** 
 
 
 
 
-0.02 
 0.54 
-0.01 
 1.03 
 
 
 
 
0.01 
0.31 
0.02 
0.29 
 
 
 
 
 
-0.06 
-0.08 
-0.03 
 0.15*** 
 
 
 
 
 
-0.02 
 0.30 
-0.01 
 0.88  
 
 
 
 
 
0.01 
0.32 
0.02 
0.29 
 
 
 
 
 
-0.07 
 0.04 
-0.03 
 0.13** 
 
 
 
 
 
-0.03 
-0.01 
-0.001 
 0.69 
 
 
 
 
0.01 
0.31 
0.02 
0.28 
 
 
 
 
-0.09 
-0.001 
-0.003 
 0.12* 
 
Associated 
conditions 
 
Anxiety 
Depression 
Bladder dysfunction 
Fatigue 
Pain 
 
   
 
 
 
 
-0.05 
-0.20 
-0.12 
-0.17 
-0.03 
 
 
 
 
0.04 
0.05 
0.13 
0.02 
0.01 
  
 
 
-0.07 
-0.23*** 
-0.04 
-0.37*** 
-0.25*** 
 
 
 
-0.05 
-0.19 
-0.06 
-0.16 
-0.03 
 
 
 
 
0.04 
0.05 
0.12 
0.02 
0.01 
 
 
 
 
-0.07 
-0.22*** 
-0.02 
-0.35*** 
-0.19*** 
 
 
 
 
-0.04 
-0.13 
 -0.06 
 -0.13 
-0.02 
 
 
 
 
0.04 
0.05 
0.12 
0.02 
0.01 
 
 
 
 
-0.05 
-0.15** 
-0.02 
-0.29*** 
-0.18*** 
 
Spasticity       -0.05 0.02 -0.16** -0.03 0.02 
 
-0.08 
Disability          -0.04 0.01 -0.28*** 
p<0.05*, p<0.01**,p< 0.001*** 
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4.15.2. WHOQOL-BREF Psychological Health 
The final model accounted for 66.8% variance of the WHOQOL-BREF 
Psychological Health domain (adjusted R²=0.668, F (9, 219) = 50.49, p<0.001) (Table 
39).  Addition of spasticity (step 3) did not improve the R² value (R² change=0.002, 
p=0.208) and spasticity was not a significant predictor of QOL after adjusting for 
sociodemographic variables and associated conditions (β=-0.02, p=0.208). Addition of 
disability into the final model produced a significant change in R² value (R² change = 
0.011, p=0.008). Anxiety (β=-0.13, p<0.04), depression (β=-0.48, p<0.001), fatigue 
(β=-0.14, p=0.01) and disability (β=-0.21, p=0.008 were predictive of psychological 
health. Sociodemographic variables were only significant at step 1 (R²=0.066, F (2, 19) 
= 9.49, p<0.001).  
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Table 39.  Hierarchical multiple regression analysis with WHOQOL-BREF Psychological health as a dependent variable 
 Step 1 Step 2 
 
Step 3 Step 4 
Adjusted 
R² 
0.066*** 
R² change 
0.073*** 
Adjusted 
R² 
0.632*** 
R² change 
0.567*** 
Adjusted 
R² 
0.633*** 
R² change 
0.002 
Adjusted R² 
0.668*** 
R² change 
0.011** 
 B SE  β B SE  β B SE  β B SE  β 
Sociodemographic 
and disease 
parameters 
 
Type (relapsing) 
Employment 
 
 
 
 
0.77 
1.11 
 
 
 
 
0.38 
0.38 
 
 
 
 
0.13* 
0.19** 
 
 
  
 
 0.02 
-0.08 
 
 
 
 
0.27 
0.26 
 
 
 
 
 0.01 
-0.01 
 
 
 
 
-0.003 
-0.12 
 
 
 
 
 
0.23 
0.26 
 
 
 
 
0.00 
-0.02 
 
 
 
 
-0.22 
-0.25 
 
 
 
 
0.29 
0.27 
 
 
 
 
 
-0.04 
-0.04 
 
Associated 
conditions 
 
Anxiety 
Depression 
Bladder dysfunction 
Fatigue 
Pain 
 
    
 
 
-0.1 
-0.36 
-0.29 
-0.09 
-0.01 
 
 
 
0.04 
0.04 
0.12 
0.02 
0.01 
 
 
 
-0.15** 
-0.47*** 
-0.12* 
-0.21*** 
-0.07 
 
 
 
 
-0.11 
-0.36 
-0.26 
-0.08 
-0.01 
 
 
 
0.04 
0.05 
0.12 
0.02 
0.01 
 
 
 
 
-0.16** 
-0.46*** 
-0.11* 
-0.20*** 
-0.05 
 
 
 
 
-0.08 
-0.36 
-0.13 
-0.06 
-0.004 
 
 
 
 
 
0.04 
0.05 
0.12 
0.02 
0.01 
 
 
 
 
-0.11* 
-0.48*** 
-0.05 
-0.14* 
-0.03 
Spasticity       -0.02 0.02 -0.06 
 
-0.003 
 
0.02 0.01 
Disability          -0.03 0.01 0.21** 
p<0.05*, p<0.01**, p< 0.001*** 
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4.15.3. WHOQOL-BREF Social Relationships 
Step 2 of the analysis produced the most optimal model, however only 35.5% of 
variance of the WHOQOL-BREF Social Relationships domain was explained (adjusted 
R²=0.355, F (10, 209) = 13.08, p<0.001) (table 40). Addition of spasticity or disability 
did not produce a significant change in R² value (Step3 R² change = 0.000, p=0.697, 
step 4 R² change= 0.002, p=0.456). Being married (β=0.15, p=0.005) and having 
relapsing type of MS (β=0.14, p=0.047) were significantly predictive of better QOL. In 
addition, anxiety (β=-0.21, p=0.004), depression (β=-0.29, p<0.001) and pain (β=-
0.14, p=0.016) were consistently predictive of worse QOL.  
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Table 40.  Hierarchical multiple regression analysis with WHOQOL-BREF Social relationships as a dependent variable 
 Step 1 Step 2 
 
Step 3 Step 4 
Adjusted 
R² 
0.084*** 
R² change 
0.103*** 
Adjusted 
R² 
0.355*** 
R² change 
0.249*** 
Adjusted 
R² 
0.353*** 
R² change 
0.000 
Adjusted R² 
0.351*** 
R² change 
0.002 
 B SE  β B SE  β B SE  β B SE  β 
Sociodemographic 
and disease 
parameters 
 
Age 
Sex 
Married 
Type (relapsing) 
Employment 
 
 
 
 
 
-0.01 
0.74 
1.18 
1.26 
0.38 
 
 
 
 
0.02 
0.50 
0.45 
0.50 
0.47 
 
 
 
 
-0.05 
0.10 
0.16* 
0.19* 
0.06 
 
 
 
 
-0.03 
0.73 
1.10 
0.94 
-0.53 
 
 
 
 
0.02 
0.40 
0.40 
0.47 
0.43 
 
 
 
 
-0.09 
0.10 
0.15** 
0.14* 
-0.08 
 
 
 
 
-0.03 
0.80 
1.13 
0.93 
-0.53 
 
 
 
 
0.02 
0.40 
0.40 
0.49 
0.44 
 
 
 
 
 
-0.10 
0.10 
0.16** 
0.14 
-0.08 
 
 
 
 
-0.03 
0.61 
1.30 
0.94 
-0.62 
 
 
 
 
 
0.02 
0.43 
0.41 
0.53 
0.46 
 
 
 
 
-0.10 
0.08 
0.18** 
0.13 
-0.09 
Associated 
conditions 
 
Anxiety 
Depression 
Bladder dysfunction 
Fatigue 
Pain 
 
    
 
 
-0.17 
-0.26 
-0.10 
0.01 
-0.02 
 
 
 
0.06 
0.07 
0.18 
0.03 
0.01 
 
 
 
-0.21** 
-0.29*** 
-0.04 
0.02 
-0.14* 
 
 
 
-0.17 
-0.26 
-0.09 
 0.01 
-0.02 
 
 
 
 
0.06 
0.07 
0.19 
0.03 
0.01 
 
 
 
-0.21** 
-0.30*** 
-0.03 
 0.02 
-0.14* 
 
 
 
-0.13 
-0.31 
0.03 
0.03 
-0.02 
 
 
 
 
0.06 
0.08 
0.20 
0.04 
0.01 
 
 
 
 
-0.16* 
-0.35*** 
0.01 
0.06 
-0.11 
 
Spasticity       0.001 0.02 0.004 -0.002 0.03 
 
-0.01 
 
Disability          -0.01 0.02 -0.08 
p<0.05*, p<0.01**, p< 0.001*** 
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4.15.4. WHOQOL-BREF Environment 
49.8% variance of the WHOQOL-BREF Environment domain was explained by the 
model produced at step 4 (adjusted R²= 0.498, F (10, 210) = 22.71, p<0.001) (table 
41). Spasticity was found to be an insignificant predictor of QOL after adjusting for 
sociodemographic variables and associated conditions (β=-0.129, p<0.067). The 
strongest predictors of QOL were disability (β=-0.36, p<0.001), depression (β=-0.17, 
p=0.024), bladder dysfunction (β=-0.17, p=0.008) and pain (β=-0.12, p=0.044). 
Anxiety (β=-0.13, p=0.04) and fatigue (β=-0.13, p=0.046) and being married (β=0.11, 
p=0.03) were significant predictors before adjusting for disability.   
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Table 41.  Hierarchical multiple regression analysis with WHOQOL-BREF Environment as a dependent variable 
 Step 1 Step 2 
 
Step 3 Step 4 
Adjusted 
R² 
0.061*** 
R² change 
0.073*** 
Adjusted 
R² 
0.448*** 
R² change 
0.391 
Adjusted 
R² 
0.457*** 
R² change 
0.006 
Adjusted R² 
0.498*** 
R² change 
0.033*** 
 B SE  β B SE  β B SE  β B SE  β 
Sociodemographic and 
disease parameters 
 
Married 
Type (relapsing) 
Employment 
 
 
 
 
0.78 
0.70 
0.72 
 
 
 
 
0.34 
0.34 
0.34 
 
 
 
0.14* 
0.14* 
0.14* 
 
 
 
0.67 
0.20 
-0.23 
 
 
 
 
0.27 
0.29 
0.28 
 
 
 
0.12* 
0.004 
-0.05 
 
 
 
0.58 
-0.04 
-0.30 
 
 
 
 
0.27 
0.30 
0.28 
 
 
 
0.11* 
-0.01 
-0.06 
 
 
 
0.58 
-0.34 
-0.54 
 
 
 
 
0.27 
0.31 
0.29 
 
 
 
 
0.11 
-0.07 
-0.11 
Associated conditions 
 
Anxiety 
Depression 
Bladder dysfunction 
Fatigue 
Pain 
 
    
 
-0.08 
-0.16 
-0.56 
-0.05 
-0.02 
 
 
0.04 
0.05 
0.13 
0.02 
0.01 
 
 
-0.13* 
-0.24** 
-0.26*** 
-0.14* 
-0.16** 
 
 
-0.08 
-0.15 
-0.53 
-0.05 
-0.01 
 
 
 
0.04 
0.05 
0.13 
0.02 
0.01 
 
 
 
-0.13* 
-0.22** 
-0.25*** 
-0.13* 
-0.13* 
 
 
-0.07 
-0.11 
-0.35 
-0.01 
-0.01 
 
 
0.04 
0.05 
0.13 
0.02 
0.01 
 
 
 
-0.11 
-0.17* 
-0.17** 
-0.03 
-0.12* 
 
Spasticity       -0.03 0.02 -0.11 -0.01 0.02 -0.02 
Disability          -0.04 0.01 
 
-0.36*** 
p<0.05*, p<0.01**, p< 0.001***  
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4.15.5. LMSQOL  
The model produced at step 2 of the analysis accounted for 57% variance of the 
LMSQOL scores (adjusted R²=0.57, F (6, 233) = 52.79, p<0.005) (table 42). Addition 
of spasticity and disability did not significantly improve model variance parameters (step 
3 R² change =0.002, p=0.267, step 4 R² change = 0.006, p<0.07). Neither spasticity 
(β=0.05, p=0.327), nor disability (β=0.15, p=0.07) were significant predictors after 
adjusting for sociodemographic parameters and associated conditions. Strongest 
predictors of poor QOL (higher LMSQOL score) were depression (β=0.37, 0<0.001) 
followed by anxiety (β=0.24, p<0.001), fatigue (β=0.22, p<0.001) and pain (β=0.12, 
p=0.015).   
 Table 42. Hierarchical multiple regression analysis with LMSQOL as a dependent variable.  
 Step 1 Step 2 
 
Step 3 Step 4 
Adjusted R² 
0.017* 
R² 
change 
0.024* 
Adjusted R² 
0.565*** 
R² change 
0.555*** 
Adjusted R² 
0.578*** 
R² 
change 
0.002 
Adjusted R² 
0.582*** 
R² 
change 
0.006 
 B SE  β B SE  β B SE  β B SE  β 
Sociodemographic 
and disease 
parameters 
 
Employment 
 
 
 
 
 
-1.37 
 
 
 
 
0.60 
 
 
 
 
-0.14* 
 
 
 
 
0.79 
 
 
 
 
0.50 
 
 
 
 
0.08 
 
 
 
 
0.84 
 
 
 
 
0.46 
 
 
 
 
0.09 
 
 
 
 
1.0 
 
 
 
 
0.48 
 
 
 
 
0.10 
Associated 
conditions 
 
Anxiety 
Depression 
Bladder dysfunction 
Fatigue 
Pain 
 
 
 
 
 
   
 
 
0.27 
0.46 
0.27 
0.14 
0.02 
 
 
 
0.06 
0.08 
0.20 
0.04 
0.01 
 
 
 
0.24*** 
0.37*** 
0.07 
0.22*** 
0.12* 
 
 
 
0.27 
0.44 
0.24 
0.14 
0.02 
 
 
 
 
0.06 
0.08 
0.21 
0.04 
0.01 
 
 
 
0.25*** 
0.37*** 
0.06 
0.21*** 
0.10 
 
 
 
 
0.26 
0.42 
0.02 
0.11 
0.02 
 
 
 
0.07 
0.09 
0.23 
0.04 
0.01 
 
 
 
0.23*** 
0.34*** 
0.01 
0.16** 
0.10 
 
Spasticity       0.03 0.03 0.05 0.01 0.03 0.02 
Disability          0.03 0.02 0.15 
p<0.05*, p<0.01**, p< 0.001***  
 
 Chapter 5 - Discussion 
5.1. Overview 
A cross-sectional questionnaire-based study was carried out in the UK to 
investigate the relationship between spasticity, QOL and other neurological impairments 
in MS. Although several studies have been conducted in this field, a number of 
methodological limitations regarding both spasticity and QOL measurement were 
identified. The present study attempted to address these weaknesses to increase the 
validity of the findings. Firstly, to avoid the conceptual confusion regarding QOL, the 
study operated on a definition of QOL proposed by WHO (WHO, 1995). To fulfil the 
requirement of this definition, two instruments, WHOQOL-BREF and LMSQOL, which 
measure overall QOL and not merely health status, were chosen. Secondly, literature 
review found that measurement of spasticity is complex, multidimensional and clinician-
administered measures do not reflect patients’ experience. To address these issues a 
robust multidimensional MS-specific measure for spasticity, MSSS-88, was employed 
alongside NRS. Lastly, the present study acknowledged that many factors may influence 
QOL, therefore the relationship between QOL and spasticity was controlled for other 
neurological impairments and sociodemographic variables. The study findings are 
discussed in the paragraphs below.  
5.2. Prevalence and severity of spasticity 
The study confirmed high prevalence of spasticity in the MS population. As 
many as 84.8% reported some degree of spasticity, with almost a third of patients 
(29.2%) suffering from severe spasticity. Despite the fact that most of the patients 
recruited to the study attended tertiary centres for neurology, which provide specialised 
rehabilitation services for spasticity, prevalence and severity of spasticity was found to 
be similar to previous population surveys in MS (Arroyo et al., 2013; Flachenecker et al., 
2014; Rizzo et al., 2004). This highlights the problematic nature of spasticity and limited 
efficacy of current treatments (Paisley et al., 2002; Shakespeare et al., 2003). This has 
important implications for healthcare costs and the overall burden of MS. Previous 
studies have shown that MS-related spasticity is associated with significant healthcare 
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utilisation (Schapiro, 2014; Svensson et al., 2014; Tyry, Salter, Largent, & Marrie, 
2014). Patients with spasticity were more likely to attend emergency department, be 
hospitalised, require appointments with a neurologist, MS nurse and physiotherapist 
and rely on a professional caregiver support (Schapiro, 2014; Tyry et al., 2014).  
           A significant proportion (29.2%) of MS patients was found to have severe 
spasticity, for which management can be particularly problematic. Arroyo et al. found 
that patients who did not respond to two antispasticity agents progressed to more 
severe degrees of spasticity over the course of 3 years (Arroyo et al., 2011). Up to a 
third of patients became wheelchair bound and less than a fifth were still in 
employment. The findings from this study also show a sharp decline in proportion of 
patients in employment as severity of spasticity increases. 21.3% of patients with 
severe spasticity were in full or part time employment compared to 61% with no 
spasticity. Svensson et al. in a study on 105 patients with MS investigated the costs 
related to spasticity and reported that reduced capacity to work and care giver burden 
were the biggest contributors to societal costs related to MS-associated spasticity 
(Svensson et al., 2014). Hence, maximising mobility and administering adequate 
treatment is imperative to prevent loss of productivity of MS patients. However, in a 
review on spasticity management practices in Europe, Berger emphasised that only 3% 
of overall healthcare costs in MS are related to rehabilitation services and antispasticity 
agents (Berger, 2013). As a result, increasing provision of these services may have a 
significant impact on reducing burden of spasticity in MS.  
5.3. Spasticity and sociodemographic and disease characteristics 
Several important sociodemographic and disease parameters were found to be 
related to severity of spasticity. As expected, patients with higher EDSS were found to 
have more severe spasticity. However, it is important to acknowledge that less than a 
third of patients with severe spasticity had EDSS >6.5, with the majority of patients 
experiencing moderate or severe spasticity at lower levels of disability. This highlights 
the importance of using measures that specifically assess spasticity in MS, and not 
simply disability (Flachenecker et al., 2014). In addition, several studies found that the 
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impact of spasticity on healthcare utilisation is significant even after accounting for 
disability (Schapiro, 2014; Svensson et al., 2014; Tyry et al., 2014). Interestingly, 
although patients with severe spasticity had longer duration of disease, this was not 
found to be statistically significant (p=0.213). This was thought to be confounded by 
PPMS, however no statistical significance was observed even after excluding patients 
with PPMS. This may suggest that location of CNS lesions, rather than duration of 
disease may be more important for development of spasticity. Of note, patients 
diagnosed with MS within 4 years were found to have similar degree of spasticity when 
compared to patients diagnosed >20 years (NRS 4.1 and 4.9 respectively, p=0.89). 
85% of those with recent diagnosis (<4 years) reported some degree of spasticity with 
15.2% of patients having severe spasticity. The findings highlight that even very early 
in the course of MS spasticity is a common impairment and may need early 
intervention.  
Progressive type of MS was associated with significantly higher levels of 
spasticity. However, no difference was observed in spasticity levels between rapidly 
evolving and relapsing remitting MS. This contrasts to the findings from the NARCOMS 
study by Rizzo et al. (Rizzo et al., 2004). Authors reported that a relapse in the last 6 
months and worsening MS (determined by a patient as worse MS symptoms compared 
to a year before) were significantly associated with severe spasticity. In this study, the 
majority of patients diagnosed with rapidly evolving MS were recruited from the day 
treatment unit. It is likely that these patients had well-controlled MS as a result of 
regular infusions of natalizumab, preventing development of spasticity. Similar to the 
findings from the study mentioned above, patients with severe spasticity were more 
likely to have had a relapse in the last 12 months, however because of small numbers 
no statistical significance was detected (p=0.657). 
5.4. Relationship between spasticity and QOL 
The main aim of this study was to determine the relationship between 
spasticity and QOL in MS. Previous studies reported that spasticity is associated with 
worse health status and physical functioning, however effects of spasticity on overall 
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QOL have not been explored so far (Arroyo et al., 2013; Flachenecker et al., 2014; 
Rizzo et al., 2004; Svensson et al., 2014; Wu et al., 2007). In order to achieve this, two 
measures of overall QOL were administered: WHOQOL-BREF and LMSQOL. The above 
QOL measures were selected for three reasons. Firstly, using a generic QOL measure 
such as the WHOQOL-BREF, would allow comparisons about the impact of spasticity on 
QOL across other neurological conditions which are also characterised by spasticity. 
Secondly, the LMSQOL was employed as an MS-specific QOL measure, which might be 
more sensitive to subtle changes in QOL than generic QOL measures (Bandari et al., 
2010; Benito-Leon et al., 2002; D. M. Miller & Allen, 2010). Lastly, since the WHOQOL-
BREF provides scores only for individual domains, the LMSQOL was used for calculating 
a global QOL score.  
The study found a significant linear relationship of worsening QOL as severity 
of spasticity increased, this was true across both measures. The findings support 
previous observations regarding significant negative effects of spasticity on health 
status, physical function and activities of daily living in MS (Arroyo et al., 2013; 
Flachenecker et al., 2014; Rizzo et al., 2004). The study also provides first insight into 
the strong negative relationship between spasticity and overall QOL. The LMSQOL 
scores were significantly higher (worse QOL) in patients with severe spasticity 
compared to no or mild spasticity (p<0.001). In accordance with previous research, the 
physical health domain of the WHOQOL-BREF was particularly strongly related to 
worsening spasticity (rho -0.61--0.7), with significant differences in domain scores 
across all four spasticity groups (p<0.001).  
Spasticity was also found to be associated with significantly worse scores on 
the non-physical domains of the WHOQOL-BREF including psychological health, social 
relationships and environment. This provides important information about broader 
implications of spasticity in MS, which are not simply related to physical disability. The 
psychosocial effects of spasticity in MS have only been previously explored in qualitative 
studies (Bhimani, McAlpine, & Henly, 2012; Morley et al., 2013; Nicolson & Anderson, 
2001). The studies found that spasticity can have deleterious effects on patients’ 
147 
 
psychological health and social roles. Patients reported that spasticity affected their 
relationships, employment and future planning. Anxiety, depression, low self-esteem 
and locus of control were all reported to be affected by spasticity. The present study 
has taken these observations from qualitative to quantitative stages.  The findings 
closely accord with the studies reported by Nicolson et al. and Morley et al. supporting 
wide-ranging effects of spasticity on overall QOL in MS (Morley et al., 2013; Nicolson & 
Anderson, 2001).  
A number of sociodemographic and clinical parameters have been shown to 
affect QOL, which may confound the relationship between spasticity and QOL (Benito-
Leon et al., 2002; Mitchell et al., 2005; Rudick & Miller, 2008). In this study, increasing 
age, disability, progressive type of MS, unemployment and being unmarried were 
shown to be associated with worse QOL. Furthermore, univariate analyses identified 
several MS-associated conditions to be significantly predictive of worse QOL, which 
included fatigue, pain, bladder dysfunction, anxiety and depression. These findings 
confirm previous observations regarding predictors of QOL in MS (Ford, Gerry, Johnson, 
et al., 2001; Janssens, van Doorn, de Boer, van der Meche, et al., 2003; Lobentanz et 
al., 2004; Wynia et al., 2008). The question arises whether QOL is diminished as a 
result of spasticity or other conditions listed above. To address this issue hierarchical 
multiple regression was employed. Five regression models were constructed 
corresponding with five dependent variables: four domains of the WHOQOL-BREF and 
one for LMSQOL.  
Table 43. Summary of multivariable regression analyses 
 Physical Health Psychological Health Social relationships Environment LMSQOL 
Steps 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 
Standardised Beta coefficients β β β β β β β β β β β β β β β β β β β β 
1) Sociodemographic and 
disease parameters
a 
 
Age 
Sex 
Marital status 
Type (relapsing) 
Duration 
Employment 
 
 
 
 
0.01 
 
 
0.25 
0.09 
0.41 
 
 
 
-0.06 
 
 
-0.08 
-0.03 
0.15 
 
 
 
 
-0.07 
 
 
0.04 
-0.03 
0.13 
 
 
 
 
-0.09 
 
 
-0.01 
-0.01 
0.12 
 
 
 
 
 
 
 
0.13 
 
0.19 
 
 
 
 
 
 
0.01 
 
-0.01 
 
 
 
 
 
 
0.01 
 
-0.02 
 
 
 
 
 
 
-0.04 
 
-0.04 
 
 
 
-0.05 
0.10 
0.16 
0.19 
 
0.06 
 
 
 
-0.09 
0.10 
0.15 
0.14 
 
-0.08 
 
 
 
-0.10 
0.10 
0.16 
0.14 
 
-0.08 
 
 
 
-0.10 
0.08 
0.18 
0.13 
 
-0.09 
 
 
 
 
 
0.14 
0.14 
 
0.14 
 
 
 
 
 
0.12 
0.01 
 
-0.05 
 
 
 
 
 
0.11 
-0.01 
 
-0.06 
 
 
 
 
 
0.11 
-0.07 
 
-0.11 
 
 
 
 
 
 
 
 
-0.14 
 
 
 
 
 
 
 
 
0.08 
 
 
 
 
 
 
 
 
0.09 
 
 
 
 
 
 
 
 
0.1 
2) Neurological impairments 
 
Anxiety 
Depression 
Bladder dysfunction 
Fatigue 
Pain 
 
 
 
 
 
-0.07 
-0.23 
-0.04 
-0.37 
-0.25 
 
 
-0.07 
-0.22 
-0.02 
-0.35 
-0.19 
 
 
 
-0.05 
-0.15 
-0.02 
-0.29 
-0.18 
 
 
 
 
 
 
-0.15 
-0.47 
-0.12 
-0.21 
-0.07 
 
 
 
-0.16 
-0.46 
-0.11 
-0.20 
-0.05 
 
 
 
-0.11 
-0.48 
-0.05 
-0.14 
-0.03 
 
  
 
-0.21 
-0.29 
-0.04 
0.02 
-0.14 
 
 
-0.21 
-0.30 
-0.03 
0.02 
-0.14 
 
 
-0.21 
-0.30 
-0.03 
0.02 
-0.14 
 
 
 
 
 
-0.13 
-0.24 
-0.26 
-0.14 
-0.16 
 
 
-0.13 
-0.22 
-0.25 
-0.13 
-0.13 
 
 
-0.11 
-0.17 
-0.17 
-0.03 
-0.12 
 
  
 
0.24 
0.37 
0.07 
0.22 
0.12 
 
 
0.25 
0.37 
0.06 
0.21 
0.10 
 
 
 
0.23 
0.34 
0.01 
0.16 
0.10 
 
3) Spasticity   -0.16 -0.08   -0.06 0.01   -0.01 -0.01   -0.11 0.01   0.01 0.02 
4) Disability    -0.28    -0.21    -0.08    0.36    0.15 
Model performance (adjusted 
R
2
) 
0.249 0.711 0.724 0.743* 0.066 0.632 0.633 0.668* 0.084 0.355* 0.353 0.351 0.061 0.448 0.457 0.498* 0.017 0.565* 0.578 0.582 
R
2
 change 0.263 0.46 0.013 0.019 0.073 0.567 0.002 0.011 0.103 0.249 0.001 0.002 0.073 0.391 0.006 0.033 0.024 0.555 0.002 0.006 
a
Not all of the sociodemographic variables were significant in univariate analyses. Blank rows correspond with those variables that were not entered into the multivariable regression models 
*The model with the most optimal performance 
Note: the bold indicates significant values (p<0.05) 
 
Spasticity was found to be a significant predictor of WHOQOL-BREF physical 
health domain after accounting for sociodemographic variables and associated 
conditions. However, once disability was added to the model spasticity became 
insignificant. It could be hypothesised that spasticity mediates most of its effects on 
physical health via disability, however this needs to be further investigated using more 
advanced statistical techniques such as structural equation modelling (further discussed 
under limitations). For the remaining dependent variables (LMSQOL and WHOQOL-BREF 
psychological health, social relationships, environment domains) spasticity was not 
found to be significantly predictive of worse QOL. This raises a second question: if 
spasticity is not an independent predictor of QOL, could it mediate its effects via other 
conditions? Alternatively, could it be that spasticity is not an important factor in 
determining overall QOL in MS and the previous observations are as a result of 
confounders such as depression, fatigue etc.? Studies investigating QOL in MS have 
previously reported that physical impairments were weaker predictors of QOL compared 
to psychological and social factors (Amato, Ponziani, Rossi, et al., 2001; Ford, Gerry, 
Johnson, et al., 2001; Lobentanz et al., 2004). On the other hand, it is not known how 
spasticity is related to other variables, which are strong predictors of QOL in MS such as 
depression. It maybe that spasticity may affect mood or social relationships, which 
could in turn reduce QOL. To investigate this, the relationships between spasticity and 
fatigue, sleep, pain, bladder dysfunction, anxiety and depression were sought and the 
findings are discussed below.  
5.5. Relationship between spasticity and other neurological impairments 
5.5.1. Depression and anxiety 
There is paucity of research investigating the relationship between spasticity 
and mood disorders, such as depression and anxiety, which are particularly common in 
MS (Chwastiak et al., 2002). Three qualitative studies found that spasticity had 
important implications to emotional and psychological well-being in MS (Bhimani et al., 
2012; Morley et al., 2013; Nicolson & Anderson, 2001). Some patients reported feeling 
depressed as a result of pain and physical limitations related to spasticity, others 
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experience anxiety caused by unpredictability of spasticity-related spasms and 
uncertainty regarding future progression. To date, no quantative studies examined the 
relationship between spasticity and mood disorders using instruments that specifically 
assess depression and anxiety in MS. Two studies reported that spasticity was 
associated with only marginal reductions in mental health components on SF-36 (Arroyo 
et al., 2013; Rizzo et al., 2004). Flachenecker et al. found no difference on EQ-5D 
anxiety and depression subscale scores between mild, moderate and severe spasticity.    
In this study, mood disorder was assessed using HADS, a measure which has 
been previously validated in MS and has high sensitivity and specificity for diagnosis of 
depression and anxiety (Honarmand & Feinstein, 2009). The study found that 
depression was significantly more common (p<0.001) in patients with moderate 
(30.4%) and severe spasticity (45.3%) compared to none (17.1%) or mild spasticity 
(14.5%). In contrast, no statistical significant difference was found in cases of anxiety 
across the groups, although there was a positive trend between anxiety and spasticity. 
The shortcomings of the HADS anxiety subscale might be responsible for failure to find 
a significant relationship between anxiety and spasticity. While the HADS-A has high 
specificity and sensitivity for generalised anxiety disorder, it is a poor measure for other 
anxiety disorders (Honarmand & Feinstein, 2009).  In light of these limitations, it is 
premature to conclude that spasticity is not associated with anxiety since several 
qualitative studies repeatedly found that patients with spasticity often felt anxious 
(Bhimani et al., 2012; Morley et al., 2013; Nicolson & Anderson, 2001). Indeed, in a 
study on SCI patients (n=26) Fleuren et al. found that 25% of patients reported that 
mental stress worsened spasticity, suggesting that anxiety may also be a cause, rather 
than a result of spasticity.   
Literature on the determinants of depression in MS is conflicting. Disability, 
disease duration, relapse rate and MS type have been linked to depression in MS in 
some, but not all studies (Chwastiak et al., 2002; Patten, Lavorato, & Metz, 2005; 
Zabad, Patten, & Metz, 2005).  In this study, patients with depression were significantly 
more likely to have progressive disease (49.5% vs. 31.5%, p=0.008) and be 
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unemployed (42.5% vs. 42%, p=0.001). Patients with depression were more likely to 
have EDSS >6.5%, however this was not statistically significant (17.6% in depression 
groups vs. 12.1% in depression free, p=0.247). It is difficult to ascertain what role 
spasticity plays in depression in MS due to multiple confounders such as fatigue and 
pain, which may be related to both depression and spasticity. However, understanding 
the factors that drive depression in MS is of particular importance, since depression is 
one of the strongest predictors of poor QOL in MS (Amato, Ponziani, Rossi, et al., 2001; 
Janssens, van Doorn, de Boer, van der Meche, et al., 2003; Lobentanz et al., 2004). 
The findings of this study also support this. In all five regression models depression 
remained a significant predictor of QOL. Further study is required to determine the 
independent contribution of spasticity to depressive disorder in order to better 
understand its effects on QOL.  
 The findings also have some important clinical implications. Particular attention 
should be paid to depressive symptoms when treating MS patients with spasticity. In 
addition, it may be relevant to assess depressive symptoms in studies investigating 
antispasticity therapies in MS. Equally, assessment of spasticity during treatment of 
depression in MS may also be important. Stolp-Smith et al. reported a case of increased 
spasticity in a patient with SCI as a result of commencement of selective serotonin 
receptor inhibitor (fluoxetine) and suggested that increased motor neurone reflex 
activity and denervation supersenstivity could be responsible (Stolp-Smith & Wainberg, 
1999). The effect of antidepressants on spasticity was not analysed in this study. 
Information obtained from interventional studies would give further insight into causal 
relationships between spasticity and depression.  
5.5.2. Fatigue and sleep  
Fatigue has been reported to affect more than 90% of patients with MS and is 
often rated as one of the most debilitating symptoms (Hemmett et al., 2004). Although 
a number of studies have examined the relationship between fatigue and disability, 
depression and sleep, none of the quantative studies specifically examined the 
relationship between spasticity and fatigue (Bakshi et al., 2000; Kroencke, Lynch, & 
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Denney, 2000; Mills & Young, 2011). The possibility of a significant relationship 
between fatigue and spasticity was reported in several qualitative studies in patients 
with MS and SCI (Fleuren et al., 2009; Nicolson & Anderson, 2001).  Nicolson et al. in a 
qualitative study with 18 patients with MS-related spasticity reported that spasticity and 
spasms in particular contributed to tiredness and lack of energy (Nicolson & Anderson, 
2001). Similarly, Fleuren et al. and Mahoney et al. found that a proportion of patients 
with SCI reported that fatigue worsened spasticity (Fleuren et al., 2009; Mahoney et al., 
2007).   
 To determine the relationship between fatigue and spasticity, three subscales 
(physical, cognitive fatigue and abnormal nocturnal sleep) of the NFI-MS were 
employed. NFI-MS is a rigorously developed measure, which meets robust standards of 
measurement unlike other measures of fatigue such as the Fatigue Severity Scale and 
the MS Fatigue Impact Scale (Mills, Young, Nicholas, Pallant, & Tennant, 2009; Mills et 
al., 2010a; Mills, Young, Pallant, & Tennant, 2010b). Using NFI-MS as a measure of 
fatigue, this study found that spasticity was significantly associated with overall fatigue 
and abnormal nocturnal sleep. Physical fatigue correlated more closely with spasticity (r 
= 0.52 - 0.61) than cognitive fatigue (r = 0.41 - 0.5) or abnormal nocturnal sleep 
(r=0.35 - 0.47).  
Again, no causal relationships can be drawn from these observations. In fact, 
the relationship between fatigue could also be bidirectional, i.e. higher levels of fatigue 
may cause more spasticity. Since the pathophysiology of fatigue is poorly understood, it 
is difficult to explain the association between spasticity and fatigue. A number of studies 
that used brain MRI to investigate central causes of fatigue found only weak or absent 
correlations between fatigue and structural changes of the brain, such as brain atrophy 
or lesion load (Bakshi et al., 1999; Codella et al., 2002; van der Werf et al., 1998). 
However, studies using functional MRI (magnetic or diffusion transfer MRI and PET-
FDG) identified significant functional changes in the frontal cortex, thalamus and basal 
ganglia (Inglese et al., 2007; Mainero et al., 1999; Tellez et al., 2008). It could be 
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hypothesised that CNS changes seen in MS-related fatigue also affect the pathways 
responsible for the development of spasticity.  
Significant positive correlation between spasticity and cognitive fatigue 
observed in this study supports the idea that spasticity is related to central causes of 
fatigue.  Gandevia et al. investigated the origin of central fatigue by stimulating motor 
cortex and motor point in healthy subjects during voluntary isometric contractions 
(Gandevia, Allen, Butler, & Taylor, 1996). The authors demonstrated suboptimal cortical 
output during fatigue and suggested that the motor cortex is the most likely site for 
generation of central fatigue. However, not all of the studies support this. In a study of 
14 patients with MS Morris et al. assessed walking and fatigue (measured by VAS) in 
the morning and afternoon on the same day (Morris, Cantwell, Vowels, & Dodd, 2002). 
While fatigue levels increased significantly, walking patterns remained constant. The 
authors suggested that mechanisms controlling locomotion may be different to the ones 
responsible for fatigue. However, as spasticity was not assessed, conclusions regarding 
the relationship between spasticity and fatigue cannot be drawn.    
   There is also some evidence to suggest that some interventions can 
simultaneously improve both spasticity and fatigue. Mori et al. in a pseudorandomised 
control trial investigated the effects of exercise training (ET) and intermittent 
transcranial magnetic theta burst stimulation (iTBS) on spasticity, fatigue and disability 
in 30 patients with MS (Mori et al., 2011). The rationale for using ET and iTBS is based 
on the idea that repetitive motor tasks cause plastic changes of intracortical neurones. 
The study found significant improvements in spasticity (measured by the Modified 
Ashworth Scale) and fatigue (measured by FSS), but not disability after combining ET 
and iTBS together. iTBS alone improved spasticity, but not fatigue. The study suggests 
that there may be common as well as distinct mechanisms underlying both spasticity 
and fatigue. 
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 It is also possible that antispasticity medication, particularly baclofen, could 
have accounted for increased fatigue levels in patients with more severe levels of 
spasticity. Again, no data regarding spasticity medication was available for analysis. 
Literature regarding fatigue and QOL in MS has consistently shown strong 
inverse correlation between the two constructs (Amato, Ponziani, Rossi, et al., 2001; 
Goksel Karatepe et al., 2011; Hemmett et al., 2004; Lobentanz et al., 2004).  Similar 
findings were reproduced in this study. Fatigue was found to be a significant predictor 
in all multiple regression models, except for WHOQOL-BREF social relationships and 
environment domains. Lack of the effect of fatigue on these domains has also been 
reported in a study of 530 patients with MS in Poland (Wynia et al., 2008).  Wynia et al. 
investigated  effects of multiple disabilities (measured by MS Impact Scale) on QOL and 
found that fatigue was not a significant predictor for any of the four domains of 
WHOQOL-BREF, but significant for physical functioning domain of SF-36 (Wynia et al., 
2008). The authors postulated that fatigue might have a more direct effect on physical 
aspects of QOL, while mental components of QOL might be mediated by fatigue 
through other factors such as disability or depression. Similar finding was reported in a 
study of 504 patients with MS by Lobentanz et al., in which fatigue was found to be 
predictive of physical subscales of Quality of Life Index, but not mental (Lobentanz et 
al., 2004).  
In conclusion, the findings of this study provide the first insight into a positive 
relationship between spasticity and fatigue. Future studies investigating both therapies 
for fatigue and spasticity will provide a better understanding regarding the relationship 
between these two impairments in MS. 
5.5.3. Pain  
Mechanisms of pain in spasticity have been poorly researched and are not well 
understood (Ward & Kadies, 2002). Spasticity may cause pain in several ways. 
Biomechanical changes may occur in hypertonic muscles, which may lead to muscle 
shortening and contractures (Ward & Kadies, 2002). Reduced mobility and 
misalignment of the joints causes poor posture and musculoskeletal pain. Frozen 
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shoulder is a typical example of the consequences of spasticity.  Spasms associated 
with spasticity may directly cause pain. Although the pathophysiology of spasticity-
related pain is unknown, one hypothesis suggests that pain might be caused by muscle 
ischaemia (Mense, 1993; Travell & Rinzler, 1952). Prolonged muscle contraction or tonic 
activation causes compression of the muscle vasculature leading to reduced oxygen 
delivery. Ischaemic contractions cause release of nociceptive substance, such as 
prostaglandins (PGE2) and potassium ions, which trigger pain and further muscle 
contraction, initiating a vicious cycle.  
Pain affects around 60% of patients with MS and may occur independently 
from spasticity (Osterberg, Boivie, & Thuomas, 2005). By definition, spasticity is a 
sensori-motor disorder, therefore any afferent input such as a nociceptive stimulus may 
have a role in driving spasticity. Unfortunately, evidence on the relationship between 
pain and spasticity in clinical studies is limited. A systematic review by Phadke et al. on 
physiological and psychological triggers of spasticity found no studies reporting pain as 
a cause of worsening spasticity (Phadke et al., 2013). The present study found a strong 
association between spasticity and pain. Patients with more severe spasticity 
experienced significantly more pain (p<0.001). Indeed, in a group of patients with no 
spasticity NPS total median score was 0 (IQR 20), which increased sharply as spasticity 
levels increased (NPS median score 47 in severe spasticity). Similar findings were 
reported in a pilot study of 19 patients with spinal cord injury by Voerman et al. 
(Voerman, Erren-Wolters, Fleuren, Hermens, & Geurts, 2010). The investigators found 
significant correlation (r=0.43) between pain and spasticity (both measured by NRS). In 
the present study, relationships between spasticity and specific types of pain were 
sought too. There was a trend for spasticity to correlate most strongly with deep 
somatic pain (r=0.41-0.62, p<0.01). This supports the theory that spasticity causes 
musculoskeletal type pain, possibly as a result of biomechanical changes in the muscles. 
Weaker, but statistically significant correlations were observed between spasticity and 
dysesthetic or allodynic type pain (r=0.33-0.45, p<0.01). These findings suggest that 
spasticity might also be influenced by afferent noxious stimuli. This is also supported by 
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studies that administered analgesic medications, such as morphine, to patients with 
severe spasticity and found improvement in muscle tone (Erickson, Blacklock, 
Michaelson, Sperling, & Lo, 1985; Sadiq & Poopatana, 2007). Cannabinoids have been 
used to treat both spasticity and pain in MS with some but not all studies reporting 
favourable results (Wade et al., 2010; Zajicek et al., 2003; Zajicek, Hobart, Slade, 
Barnes, & Mattison, 2012). Stimulation of CB1 receptors in the basal ganglia has been 
suggested to reduce painful muscle spasms (Hohmann & Herkenham, 1999). In 
addition, CB1 are largely populated in the pain pathway, which explains effects of 
cannabinoids on pain in MS, however whether it is implicated in reducing spasticity is 
unknown (Pertwee, 2001). 
In conclusion, there is a complex interaction between pain and spasticity in MS. 
It is well established that spasticity produces pain, possibly through mechanical changes 
in muscles and joints as well as muscle ischaemia. Noxious stimulation, such as 
neuropathic pain in MS, is a likely source of aggravation of spasticity, however the 
pathophysiological mechanisms remain to be elucidated.  
5.5.4. Bladder dysfunction 
Bladder problems are present in 33%-90% of patients with MS (Giannantoni et 
al., 1998; Goldstein, Siroky, Sax, & Krane, 1982; Nortvedt et al., 2007). Neural 
pathways responsible for micturition descend from the cerebral cortex and pons to the 
sacral spinal cord and are particularly vulnerable to lesions affecting the spinal cord 
(Nicholas, Young, & Friede, 2010). As a result, concomitant occurrence of pyramidal 
dysfunction and bladder problems in MS may be expected. Several studies reported that 
EDSS pyramidal scale scores and extensor plantar reflexes significantly correlated with 
bladder dysfunction (Betts, D'Mellow, & Fowler, 1993; Giannantoni et al., 1999). In a 
study of 2029 patients with MS, urinary dysfunction was found in 70.4% of patients 
with spasticity compared to 29.2% without spasticity (p<0.001) (Oreja-Guevara, 2011). 
Patients with spasticity were also more likely to have disturbed sleep as a result of 
urinary urgency. The findings of the present study support these observations. There 
was a significant linear relationship between severity of spasticity and bladder 
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dysfunction (p<0.001). However only modest correlations were found between MSSS-
88 subscales and SF-Qualiveen total and individual domain scores (r=0.35-0.45). One 
possible explanation is that SF-Qualiveen measures the impact of bladder problems to a 
patient’s life, rather than individual symptoms of bladder dysfunction. According to 
Ferrans QOL model, a number of factors mediate the impact of biological symptoms on 
a patient’s life, which might explain only modest correlations between spasticity and SF-
Qualiveen (Ferrans et al., 2005).    
Spasticity and bladder dysfunction most likely represent different 
manifestations of the same underlying pathology, i.e. damage to the descending tracts 
in the spinal cord. However, it would be of clinical importance to know whether one 
might aggravate another. It was postulated above that noxious stimuli from the 
periphery might increase spasticity. In the same vein, it could be hypothesised that 
sensory input originating in the bladder may affect spinal neural networks that control 
muscle tone. Several studies in spinal cord injury reported that bladder distension, 
infection and incomplete emptying caused an increase in spasticity (Fleuren et al., 
2009; Meng et al., 2010; Ronco et al., 2011). A study by Laesoe et al. (n=9) found 
significant reductions (p<0.01) in spasms and the Modified Ashworth Scale score after 
penile vibratory stimulation suggesting that there might be a common pathway from 
bladder, bowels and organs of reproduction which connects to the neurones controlling 
muscle tone (Laessoe, Nielsen, Biering-Sorensen, & Sonksen, 2004). Future studies will 
confirm whether similar interactions exist between bladder dysfunction and spasticity in 
MS, as all of the previous studies were performed in the SCI population. Although this is 
likely, it should not be assumed due to the distinct nature of these conditions.  
Two studies reported by Nortvedt et al. showed that bladder dysfunction was 
significantly associated with worse HRQOL (measured by SF-36 and MSQOL-54) 
(Nortvedt et al., 2007; Nortvedt et al., 2001). However, both studies did not control for 
confounding factors. In the present study, although bladder dysfunction was found to 
be a significant predictor of WHOQOL-BREF and LMSQOL in univariate analyses 
(p<0.001), it remained significant only in predicting the WHOQOL-BREF environment 
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domain after accounting for other factors (p<0.01).  In addition, bladder dysfunction 
was also found to be a significant predictor of the WHOQOL-BREF psychological domain 
after accounting for associated conditions, but not disability (p<0.05). The study 
suggests that bladder problems are particularly important for psychological well-being 
of MS patients and adversely affects their interaction with the environment. It is unclear 
though how bladder dysfunction affects other domains of QOL.  
5.6. Limitations of the study 
There are a number of limitations in the present study. The most notable 
limitation is the cross-sectional design of the study. As a result, only associations, but 
not causations between spasticity and other variables could be made. Because self-
reported measures for spasticity were used, it is possible that patients with lower QOL 
rate their spasticity worse. Although patient-reported measures are always at risk of 
such bias, it is possible to minimise this by applying Rasch measurement model. For this 
purpose, MSSS-88 was chosen to measure spasticity in the present study. Hobart et al. 
reported that MSSS-88 was free of differential item functioning (DIF) with reference to 
person’s disability levels (Hobart et al., 2006). In other words, given the same level of 
spasticity, patients with different levels of disability rate the severity of spasticity the 
same. As a result, it is hoped that the present study addressed this issue by employing 
MSSS-88.  
Secondly, the scales used in this study were ordinal, although the assumptions 
of interval-level scales were made when performing regression analyses. Although 
ordinal scales are widely used by researchers in the field of healthcare and psychology, 
differences between two scores may not be equal and technically do not meet 
requirements of interval scales (Knapp, 1990).  
Multiple regression analysis is also not without limitations. While it allows 
examination of predictive values of multiple factors with regards to QOL, multiple 
regression does not take into account interaction between independent variables. This 
is particularly important in MS since many of the neurological impairments are related 
to each other and may mediate their effects on QOL indirectly. Hence, although some 
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factors may appear as non-significant predictors in the final models, it should not be 
inferred that they are not important in determining QOL.   
It should be noted that multiple comparisons, especially multiple correlations, 
were performed, increasing the likelihood of committing type I error. While Benferroni 
adjustments were made for calculations of the Kruskal-Wallis statistic, these were not 
performed for bivariate correlations. The reason for is that Benferroni adjustments 
deflate α and increase the chance of type II error (Perneger, 1998). There is also a 
body of evidence to suggest that Benferroni adjustments should not be used at all 
(Gelman, Hill, & Yajima, 2009; Perneger, 1998).   
Several issues regarding recruitment should be considered too. Firstly, patients 
were recruited from specialised neuroscience centres, which might not reflect standard 
care of the patients in the general population. It is possible that patients were receiving 
optimised care and felt confident about management of their MS. The alternative could 
also be true. Patients with more aggressive MS or difficult complications could have 
been referred to the tertiary centre for specialist input. However, demographics, EDSS 
and spasticity prevalence and severity was found to be similar to other population 
surveys (Arroyo et al., 2013; Flachenecker et al., 2014; Rizzo et al., 2004). There is also 
a risk of selection bias since a convenience sample was used. Patients that declined 
invitation to participate or were deemed unsuitable to be recruited often had emotional 
and social issues precluding their involvement in the study. Failure to include these 
patients in the study could have overestimated QOL of the sample. However, a previous 
study of 245 patients with MS by Wynia et al. found very similar WHOQOL-BREF scores 
(Wynia et al., 2012). Lastly, a proportion of patients were recruited over a year before 
completing questionnaires. This could have caused some discrepancy between clinical 
information (e.g. EDSS score) obtained from the case notes and questionnaire data.   
Another possible limitation of the study is the lengthy format of the 
questionnaire. Several patients expressed difficulties completing the questionnaire due 
to its length. Although patients were instructed to aim to complete the questionnaire in 
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the shortest possible time, ideally during one day, in practice many took longer than 
one week to complete it. This could have affected correlation results, since spasticity 
can vary greatly over time (Skold, 2000). However, a 2 week time reference for 
spasticity was given on purpose to minimise these discrepancies.  
The study acknowledges that QOL is a complex and multidimensional 
construct, which is under the influence of many factors. Although a number of factors 
were accounted for in the regression models, it is likely that many other variables (e.g. 
coping, hopelessness, personality traits, social support, self-efficacy etc.) could have 
important contributions. This is also reflected by a relatively small adjusted R² values 
for WHOQOL-BREF social relationships (0.35) and environment domains (0.49).   
Finally, failure to establish an online questionnaire platform was an important 
setback for this pilot study. Having an online option would have increased the number 
of completed questionnaires as a proportion of patients were not able to complete the 
questionnaire because they expressed online preference. It would have also provided 
important information regarding feasibility and acceptability of an online version 
necessary for future progress of the study. In addition, study costs and work load of the 
research team could be reduced greatly once an online questionnaire becomes 
available.   
5.7. Strengths of the study 
Despite the limitations listed above, this study has several strengths. The 
sample included a broad range of severities of spasticity. In addition, all types of MS 
and disability levels (measured by EDSS) were included and were representative of the 
general MS population (Compston & Coles, 2008). Responder’s bias was addressed in 
this study. Sociodemographic and clinical information of non-responders was similar to 
responders, except for age.  
Spasticity assessment is complex and multidimensional. Previous similar studies 
investigating spasticity and QOL in neurological disorders used the Ashworth scale, 
which is considered a poor measure of spasticity, hence limiting the validity of their 
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results (Arroyo et al., 2013; Urban et al., 2010; Wissel et al., 2010). Other studies did 
not report any specific measure for spasticity and simply dichotomised patients into 
spasticity and no spasticity groups (Noonan et al., 2008; Post et al., 1998; Westgren & 
Levi, 1998). Dichotomisation of spasticity is also not appropriate, since there is a wide 
spectrum of severity of spasticity, which is also reflected in the findings of the present 
study. In addition to NRS, this study also employed three most clinically relevant 
subscales of MSSS-88. MSSS-88 has been derived from patients’ experience of spasticity 
and has been shown to have robust psychometric properties (Hobart et al., 2006). 
Consequently, it is hoped that the present study achieved accurate and comprehensive 
assessment of spasticity. In addition, the relationships between different aspects of 
spasticity and QOL were examined.  
Previous studies repeatedly failed to account for multiple factors that could 
confound the relationship between spasticity and QOL (Arroyo et al., 2013; 
Flachenecker et al., 2014; Rizzo et al., 2004; Wu et al., 2007). The present study for 
the first time controlled for these factors using the hierarchical multiple regression 
model. In addition, clear distinction was made between overall QOL and HRQOL. Unlike 
previous studies, the present study investigated the relationship between overall QOL 
and not HRQOL (Arroyo et al., 2013; Flachenecker et al., 2014; Rizzo et al., 2004; Wu 
et al., 2007). Administering both MS-specific and generic QOL measures enabled more 
comprehensive assessment of QOL and its relationship with spasticity.  
Lastly, some important information regarding feasibility of the study was 
obtained. There were concerns about the lengthy format of the questionnaire, which 
might adversely affect response rate. However, 59.8% of patients returned completed 
questionnaires, which is not dissimilar from previous studies using shorter 
questionnaires in the MS population (Mills & Young, 2011; Mills et al., 2010b). Despite 
IT failures, data entry using Filemaker proved to be efficient and will be used before an 
online version becomes available.   
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5.8. Future research 
The present study serves as a pilot study for future phases of TONiC. Data 
collected from other sites in the UK will provide additional sample of MS patients. Larger 
number of subjects will enable a more comprehensive assessment of both QOL and 
spasticity in MS. In order to address the current limitations, several improvements to 
the data analysis could be made. 
 Firstly, the scales should be transformed from ordinal to interval level using 
the Rasch method (Rasch, 1960). This will provide legitimate data for structural 
equation modelling (SEM). Using SEM the relationships between spasticity, QOL and 
other associated features could be interrogated in more detail. Ultimately, SEM would 
help to understand how spasticity influences QOL.  
Secondly, larger sample size and validation of the new scales (coping, 
hopelessness, social withdrawal) will enable the addition of more factors to the QOL 
model. Relationships between spasticity and coping, hopelessness and social-withdrawal 
have not been explored to date in MS. A pilot study of 19 patients with spinal cord 
injury by Voerman et al. found that reassuring thoughts and low levels of hopelessness 
are associated with less severe spasticity (Voerman et al., 2010). Detailed investigation 
of the relationships between spasticity and the factors mentioned above using robust 
measures and advanced statistical techniques (e.g. SEM) would provide important 
information in understanding how spasticity mediates its effects on QOL in MS.  
Data obtained from the longitudinal phase of this study will most certainly 
provide invaluable information regarding the relationship between spasticity and QOL. 
The present study found that spasticity is common even in patients with recent 
diagnosis of MS. It would be of clinical interest to know how spasticity evolves during 
the first 5 years of MS and how this relates to QOL trajectory. 
Literature review in Chapter 2 indicated that there is paucity of research 
regarding spasticity and QOL in other chronic neurological conditions such as motor 
neurone disease and traumatic brain injury. It is hoped that data generated by TONiC 
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will fill this gap in literature. Qualitative interviews with MND patients on their 
experience of spasticity have already been completed and collection of quantative data 
is underway. Standardised measures for spasticity (NRS) and QOL (WHOQOL-BREF) 
used in the questionnaire packs will enable investigation of the relationship between 
spasticity and QOL, not only in one disease, but in a number of neurological conditions 
simultaneously.  
5.9. Conclusions 
Spasticity is a very common impairment in MS. Due to low efficacy of current 
antispastic therapies, spasticity is often severe and disabling. Previous research has 
shown that spasticity adversely affects physical functioning and health status, however 
its effects on QOL were largely unknown. The present study builds upon the findings of 
qualitative studies, which reported wide-ranging effects of spasticity on patients’ lives. 
It was found that spasticity is associated with significantly worse overall QOL as 
measured by two robust QOL instruments. Due to the limitations of the study design 
and statistical methods, exact mechanisms explaining how spasticity affects QOL could 
not be determined. 
In addition to determining the relationship between spasticity and QOL, 
significant associations between spasticity and fatigue, depression, pain and bladder 
dysfunction were found. Literature investigating these relationships is limited, hence the 
findings of the present study serve as a stepping stone for future studies. Although 
causal relationships were postulated, this needs further confirmation using experimental 
methods. Determining these relationships will help to understand how spasticity affects 
QOL and will ultimately inform clinicians about how to improve the lives of patients with 
MS.  
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Appendix  
Appendix 1 - Literature Search Strategy  
1. MEDLINE; exp MUSCLE SPASTICITY/; 6697 results. 
2. MEDLINE; spast*.ti,ab; 18778 results. 
3. MEDLINE; 1 OR 2; 20675 results. 
4. MEDLINE; exp QUALITY OF LIFE/; 120720 results. 
5. MEDLINE; "quality of life".ti,ab; 153125 results. 
6. MEDLINE; 4 OR 5; 197029 results. 
7. MEDLINE; 3 AND 6; 565 results. 
8. MEDLINE; 7 [Limit to: English Language and Humans and (Age Groups All Adult 19 
plus years)]; 199 results. 
9. EMBASE; spastcity.ti,ab; 1 results. 
10. EMBASE; exp SPASTICITY/; 14152 results. 
11. EMBASE; spast*.ti,ab; 22999 results. 
12. EMBASE; 10 OR 11; 27164 results. 
13. EMBASE; exp QUALITY OF LIFE/; 254068 results. 
14. EMBASE; (""quality of life" AND ").ti,ab; 205382 results. 
15. EMBASE; 13 OR 14; 297888 results. 
16. EMBASE; 12 AND 15; 1078 results. 
17. EMBASE; 16 [Limit to: Human and English Language and (Human Age Groups Adult 
18 to 64 years)]; 257 results. 
18. PsycINFO; exp MUSCLE SPASMS/; 233 results. 
19. PsycINFO; spast*.ti,ab; 2609 results. 
20. PsycINFO; 18 OR 19; 2743 results. 
21. PsycINFO; exp QUALITY OF LIFE/ [Limit to: Human and English Language]; 23643 
results. 
22. PsycINFO; 20 AND 21 [Limit to: Human and English Language]; 35 results. 
23. CINAHL; exp MUSCLE SPASTICITY/; 2270 results. 
24. CINAHL; spast*.ti,ab; 3096 results. 
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25. CINAHL; 23 OR 24; 3837 results. 
26. CINAHL; exp QUALITY OF LIFE/; 43493 results. 
27. CINAHL; 25 OR 26; 47207 results. 
28. CINAHL; 25 AND 26; 123 results. 
29. CINAHL; 28 [Limit to: (Language English) and (Age Groups All Adult)]; 60 results. 
 
 
Appendix 2 - Dealing with missing data 
 
 
Measure Steps in dealing with missing 
data 
MSSS-88  Subscale score computed if <20% 
data missing. 
Mean of the subscale score is used 
to replace missing item  
SF-Qualiveen Subscale score computed if <20% 
data missing. 
Mean of the subscale score is used 
to replace missing item 
NFI-MS  Subscale score computed if <20% 
data missing. 
Mean of the subscale score is used 
to replace missing item 
HADS Subscale score computed if <20% 
data missing. 
Mean of the subscale score is used 
to replace missing item 
WHOQOL Case should be discarded if >20% 
data missing 
Mean of the subscale score is used 
to replace missing item 
If >2 items missing from the 
domain, score should not be 
calculated, except for social 
relationships domain for which 
score should not be calculated if 1 
item is missing 
LMSQOL Subscale score computed if <20% 
data missing. 
Mean of the subscale score is used 
to replace missing item 
WHODAS If <3 items missing from the 
domain, mean score is substituted 
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for missing item.  
Working domain was not 
calculated since majority of 
patients were unemployed (65%) 
NPS Subscale score computed if <20% 
data missing. 
Mean of the subscale score is used 
to replace missing item 
 
Appendix 3 - Results of univariate analyses 
 
WHOQOL-BREF – Physical domain   
Demographic 
and disease 
parameters 
adjusted R2 B  SE B Standardised β p value 
age 0.06 -0.07 0.02 -0.253 <0.0005 
sex (female) 0.004 -0.05  0.43 -0.007 0.908 
Married 0.002 0.32 0.45 0.04 0.482 
Employment 0.213 3.08  0.37 0.47 <0.0005 
Type 
(Relapsing) 
0.129 2.41  0.39 0.36 <0.0005 
Duration 0.03 -0.063  0.02 -0.19 0.002 
 
Associated 
conditions 
adjusted R2 B  SE B Standardised β p value 
Fatigue 0.496 -0.328 0.02 -0.71 <0.0005 
Depression 0.389 -0.54  0.04 -0.63 <0.0005 
Anxiety 0.165 -0.32  0.05 -0.41 <0.0005 
Pain 0.273 -0.07  0.01 -0.53 <0.0005 
Bladder 0.261 -1.401 0.15 -0.51 <0.0005 
 
 adjusted R2 B (CI) SE B Standardised β p value 
Spasticity 0.413 -0.195 0.01 -0.65 <0.0005 
 
 adjusted R2 B (CI) SE B Standardised β p value 
Disability  0.611 -0.112 0.01 -0.78 <0.0005 
 
 
WHOQOL- BREF Psychological domain 
Demographic 
and disease 
adjusted R2 B  SE B Standardised β p value 
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parameters 
age 0.001 -0.02 0.02 -0.07 0.252 
sex (female) 0.003 -0.22 0.34 -0.04 0.545 
Married 0.007 0.65 0.39 0.10 0.099 
Employment 0.055 1.41 0.35 0.24 <0.001 
Type 
(Relapsing) 
0.042 1.24 0.36 0.21 0.001 
Duration 0.002 -0.01 0.02 -0.043 0.489 
 
Associated 
conditions 
adjusted R2 B  SE B Standardised β p value 
Fatigue 0.335 -0.24 0.02 -0.58 <0.001 
Depression 0.535 -0.56 0.03 -0.73 <0.001 
Anxiety 0.315 -0.39 0.04 -0.56 <0.001 
Pain 0.120 -0.04 0.01 -0.35 <0.001 
Bladder 0.233 -1.16 0.13 -0.49 <0.001 
 
 adjusted R2 B  SE B Standardised β p value 
Spasticity 0.225 -0.13 0.02 -0.49 <0.001 
 
 adjusted R2 B  SE B Standardised β p value 
Disability  0.456 -0.09 0.01 -0.68 <0.001 
 
WHOQOL- BREF Social relationships 
Demographic 
and disease 
parameters 
adjusted R2 B  SE B Standardised β p value 
age 0.011 -0.04 0.02 -0.12 0.049 
sex (female) 0.022 1.17 0.45 0.16 0.01 
Married 0.028 1.33 0.46 0.18 0.004 
Employment 0.019 1.04 0.43 0.15 0.016 
Type 
(Relapsing) 
0.069 1.86 0.42 0.27 <0.001 
Duration 0.002 -0.013 0.02 -0.04 0.541 
 
Associated 
conditions 
adjusted R2 B  SE B Standardised β p value 
Fatigue 0.079 -0.14 0.03 -0.29 <0.001 
Depression 0.242 -0.45 0.05 -0.50 <0.001 
Anxiety 0.139 -0.31 0.05 -0.38 <0.001 
Pain 0.063 -0.04 0.01 -0.26 <0.001 
Bladder 0.102 -0.93 0.17 -0.33 <0.001 
 
 adjusted R2 B  SE B Standardised β p value 
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Spasticity 0.105 -0.10 0.02 -0.33 <0.001 
 
 adjusted R2 B  SE B Standardised β p value 
Disability  0.177 -0.06 0.01 -0.42 <0.001 
 
 
 
WHOQOL- BREF Environment 
 
Demographic 
and disease 
parameters 
adjusted R2 B  SE B Standardised β p value 
age 0.003 0.01 0.01 0.03 0.68 
sex (female) 0.003 0.43 0.34 0.08 0.20 
Married 0.18 0.82 0.35 0.15 0.019 
Employment 0.025 0.87 0.32 0.17 0.006 
Type 
(Relapsing) 
0.041 1.09 0.32 0.21 0.001 
Duration 0.000 0.001 0.02 0.002 0.96 
 
Associated 
conditions 
adjusted R2 B  SE B Standardised β p value 
Fatigue 0.212 -0.17 0.02 -0.46 <0.001 
Depression 0.296 -0.37 0.04 -0.55 <0.001 
Anxiety 0.179 -0.26 0.04 -0.43 <0.001 
Pain 0.136 -0.04 0.01 -0.37 <0.001 
Bladder 0.225 -1.03 0.12 -0.48 <0.001 
 
 adjusted R2 B  SE B Standardised β p value 
Spasticity 0.207 -0.10 0.01 -0.46 <0.001 
 
 adjusted R2 B  SE B Standardised β p value 
Disability  0.398 -0.70 0.01 -0.63 <0.001 
 
LMSQOL  
Demographic 
and disease 
parameters 
adjusted R2 B  SE B Standardised β p value 
age 0.004 -0.01 0.02 -0.01 0.835 
sex (female) 0.004 0.03 0.63 0.003 0.966 
Married 0.000 -0.65 0.66 -0.06 0.324 
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Employment 0.014 -1.37 0.60 -0.14 0.024 
Type 
(Relapsing) 
0.005 -0.90 0.60 -0.09 0.142 
Duration 0.003 -0.02 0.03 -0.03 0.608 
 
Associated 
conditions 
adjusted R2 B  SE B Standardised β p value 
Fatigue 0.284 0.36 0.04 0.54 <0.001 
Depression 0.422 0.80 0.06 0.65 <0.001 
Anxiety 0.326 0.64 0.06 0.56 <0.001 
Pain 0.143 0.07 0.01 0.38 <0.001 
Bladder 0.161 1.60 0.23 0.41 <0.001 
 
 adjusted R2 B  SE B Standardised β p value 
Spasticity 0.197 0.19 0.03 0.45 <0.001 
 
 adjusted R2 B  SE B Standardised β p value 
Disability  0.340 0.12 0.01 0.59 <0.001 
 
 
 
